| Excerpt | Reference |
|---|
| "Complicated migraine is regarded as a cerebrovascular syndrome of functional character." | ( Ullrich, J, 1975) |
| "Basilar artery migraine is distinctive disorder characterized by symptoms referable to dysfunction of brainstem structures in conjunction with more typical migrainous phenomena." | ( Swanson, JW; Vick, NA, 1978) |
| "Migraine is one of the most common disorders seen in paediatric neurological practice." | ( Brown, JK, 1977) |
| "Depression and migraine are related, but other psychological correlates are controversial." | ( Ziegler, DK, 1992) |
| "The biochemistry of migraine is complex." | ( Ferrari, MD, 1992) |
| "Migraine headache is thought to be associated with a dilatation of cranial blood vessels, particularly those in the dura mater, and an accompanying localized sterile inflammatory response." | ( Connor, HE; Feniuk, W; Humphrey, PP; Perren, MJ; Whalley, ET, 1991) |
| "Migraine is a common clinical diagnosis, occurring in 4-10% of school age children." | ( Elser, JM; Woody, RC, 1990) |
| "Migraine is associated with a lowered level of platelet serotonin that is thought to reflect monoamine depletion in brainstem nuclei." | ( Lance, JW, 1989) |
| "Migraine is a psychobiological disorder in which a recurrent failure of opioid and adrenergic systems might occur, as plasma and CSF studies suggest." | ( Facchinetti, F; Genazzani, AR; Martignoni, E; Nappi, G; Rossi, F; Sances, G, 1989) |
| "The perspectives on migraine are changing rapidly." | ( Saper, JR, 1989) |
| "Moreover migraine headache is precipitated by intramuscular injection of reserpine, which releases 5-HT from body stores, is relieved by the intravenous infusion of serotonin, and is prevented by the regular administration of medications that act on 5-HT receptors." | ( Goadsby, PJ; Lambert, GA; Lance, JW; Zagami, AS, 1989) |
| "The proposal that migraine is a blood disorder and caused by a primary abnormality of platelet behaviour was first put forward in 1978." | ( Hanington, E, 1989) |
| "Classical migraine is associated with two distinct phases; an initial vasoconstriction followed by vasodilatation." | ( Burnstock, G, 1989) |
| "As many menstrual migraine headaches are refractory to abortive therapy, prophylactic therapy is often needed." | ( Gallagher, RM, 1989) |
| "Migraine is considered to be a primarily neurogenic disease." | ( Drubba, S; Kufner, G; Pfaffenrath, V; Pöllmann, W, 1985) |
| "Migraine is associated with increased platelet activity and an incidence of cerebrovascular ischemic events." | ( Clifford Rose, F; Joseph, R; Schultz, LU; Steiner, TJ, 1988) |
| "A prophylaxis of migraine is indicated if a migraineur suffers from at least 2 attacks per month or if a migraine attack lasts longer than 4 days." | ( Pfaffenrath, V; Reiter, M, 1988) |
| "We propose that migraine is associated with a lowered threshold for stimulus response in both platelets and serotonergic neurons and that the alterations in platelet function reflect central serotonergic disturbances." | ( Hasselmark, L; Malmgren, R, 1988) |
| "Migraine is considered to be a functional neurological disorder." | ( Böttger, I; Brune, G; Grotemeyer, KH; Husstedt, IW; Schlake, HP, 1987) |
| "Migraine is a common hereditary disorder manifested by episodic headache, irritability, and gastrointestinal upset." | ( Diamond, S; Freitag, FG; Millstein, E; Solomon, GD, 1987) |
| "Migraine is then often of the ophthalmic type." | ( d'Athis, P; Dumas, R; Giroud, M; Guard, O, 1986) |
| "For one, migraines are often accompanied by other symptoms, such as nausea and vomiting." | ( MacDonald, JT, 1986) |
| "Migraine is a hereditary disorder afflicting 5 per cent of school-age children." | ( Fenichel, GM, 1985) |
| "Migraine is among the most common disorders seen in office practice." | ( Gunderson, CH, 1986) |
| "The hypothesis that migraine is caused by a primary abnormality of platelet behaviour was investigated in a total of 77 migraine patients and control subjects." | ( Amess, JA; Hanington, E; Jones, RJ; Wachowicz, B, 1981) |
| "Migraine is a chronic neurological disorder, characterized by attacks of severe, usually unilateral and throbbing headache accompanied by nausea, vomiting, and photophobia and photophobia." | ( Ferrari, MD; Haan, J, 1995) |
| "Although migraine is inextricably bound up with 5-hydroxytryptamine and its many receptors, its precise mechanisms continue to elude us and there is still no clear evidence supporting either a vascular or neurogenic hypothesis unequivocally." | ( Sandler, M, 1995) |
| "Migraine is a paroxysmal disorder characterized by recurrent attacks of headache, with or without associated visual and gastrointestinal disturbances." | ( Vapaatalo, H, 1994) |
| "We suggest that migraine is associated with a generalized disorder of mitochondrial oxidative phosphorylation and that this may constitute a threshold for the triggering of migraine attacks." | ( Barbiroli, B; Cortelli, P; Montagna, P, 1994) |
| "Migraine headaches are common in children and adolescents, and stricter diagnostic criteria have been developed." | ( Singer, HS, 1994) |
| "The aura phase of migraine is associated with focal blood flow changes, but it has been largely unknown whether these changes are correlated to changes in the cerebral metabolism." | ( Friberg, L; Karle, A; Lassen, NA; Olesen, J; Olsen, TS, 1994) |
| "Migraine is a common and debilitating disorder of uncertain pathogenesis." | ( Solomon, GD, 1993) |
| "However, because migraine is a recurrent disorder which may persist throughout adult life, sustained efficacy and tolerability are essential if sumatriptan is to be of value in clinical practice." | ( Martin, PM; Pilgrim, AJ; Tansey, MJ, 1993) |
| "Although classical migraine is known to produce lateralized sensory disturbances (e." | ( Boles, DB, 1993) |
| "Migraine is a neurovascular reaction to sudden changes in the internal or external environment." | ( Lance, JW, 1993) |
| "Migraine is associated with stimulus hypersensitivity, increased evoked cortical responses, and abnormal 5-HT levels in peripheral blood." | ( Schoenen, J; Timsit-Berthier, M; Wang, W, 1996) |
| "Migraine is a common and debilitating condition." | ( Goadsby, PJ; Hoskin, KL, 1996) |
| "Migraine is a subjective complaint and no laboratory test has until now been of value." | ( Heinig, JH; Lassen, LH; Oestergaard, S; Olesen, J, 1996) |
| "Migraine is a common, complex neurophysiologic headache disorder." | ( Saper, JR, 1997) |
| "The common migraine is defined in neurology as a unilateral, pulsating headache, which may be associated with nausea and vomiting, and lasts one or several days." | ( Szirmai, A, 1997) |
| "Migraine is caused by intermittent brain dysfunction." | ( Diener, HC, 1997) |
| "In many women, migraine headaches are clearly linked to estrogen levels: the incidence rises at the menarche; attacks may be precipitated by falling estrogen levels before menses; and symptoms usually improve during pregnancy when there are noncyclic high levels of estrogen." | ( Fettes, I, 1997) |
| "Basilar artery migraine is a rare headache characterized by attacks preceded and/or accompanied by transitory focal neurologic symptoms that point to dysfunction in the region irrigated by the basilar artery and its branches." | ( Díez-Tejedor, E; Moreno, MS, 1997) |
| "Migraine headaches are often disabling but usually responsive to treatment." | ( Lipton, RB; Simon, D; Stewart, WF, 1998) |
| "Migraine is a highly prevalent episodic headache disorder." | ( Silberstein, SD, 1998) |
| "Migraine is considered to be a functional neurological disorder." | ( Erdoğan, F; Köseoğlu, E; Kula, M; Mirza, M; Silov, G; Tomar, A; Tutuş, A, 1998) |
| "Migraine is a paroxysmal disorder with attacks of headache, nausea, vomiting, photo- and phonophobia and malaise." | ( Diener, HC; Kaube, H; Limmroth, V, 1998) |
| "Migraine is an idiopathic, recurrent neurovascular headache disorder characterised by attacks of debilitating pain associated with photophobia, phonophobia, nausea and vomiting." | ( Dahlöf, CG, 1998) |
| "Migraine is a headache condition found in significant frequency in the general population." | ( Kunsman, GW; Levine, B; Smith, ML, 1998) |
| "Abdominal migraine is a syndrome characterized by recurrent stereotypic episodes of paroxysmal abdominal pain and nausea and/or vomiting with wellness between episodes." | ( Lichtman, SN; Rhoads, JM; Ulshen, MH; Worawattanakul, M, 1999) |
| "Migraine is a common disorder that causes significant morbidity in those afflicted." | ( Forrest, A; Fullerton, T; Gengo, FM; Komorowski-Swiatek, D, 1999) |
| "Cataracts and migraine are either increased or decreased by hormone therapy." | ( Barrett-Connor, E, 1999) |
| "Migraine is a common illness characterised by severe, often throbbing and/or unilateral headache, which may be accompanied by sensitivity to light or noise." | ( Coukell, AJ; Lamb, HM, 1997) |
| "Migraine is a paroxysmal disorder characterized by attacks of headache, nausea, vomiting, photophobia, phonophobia, and malaise." | ( Diener, HC; Kaube, H; Limmroth, V, 1999) |
| "Migraine is a paroxysmal disorder characterized by attacks of headache, nausea, vomiting, photophobia and phonophobia, and malaise." | ( Diener, HC; Limmroth, V, 1999) |
| "Migraine is a chronic disease that significantly reduces quality of life between, as well as during, attacks." | ( Edvinsson, L; Geraud, G; Korczyn, A; Mauskop, A; Pfaffenrath, V; Tuchman, M, 1999) |
| "Transformed migraine is probably a common cause of chronic daily headache." | ( Bøe, MG; Monstad, P, 1999) |
| "Migraines are a common and often undiagnosed and undertreated problem in children of all ages." | ( Turk, WR, 2000) |
| "Although migraine is the main chronic headache in childhood and adolescence, it remains extensively misdiagnosed." | ( Annequin, D; Dumas, C; Tourniaire, B, 2000) |
| "Migraine headaches are a common medical problem that physicians frequently encounter in their practice." | ( Weintraub, JR, 2000) |
| "Migraine is an expensive disorder in terms of lost productivity and its deleterious impact on health-related quality of life (QOL)." | ( Santanello, N; Solomon, GD, 2000) |
| "Migraine headache is proposed to be mediated by nitric oxide (NO)." | ( Hirst, WD; Parsons, AA; Read, SJ; Upton, N, 2001) |
| "Migraine is a paroxysmal neurological disorder affecting up to 12% of males and 24% of females in the general population." | ( Ferrari, MD; Frants, RR; Ophoff, RA; Roon, KI; van den Maagdenberg, AM, 2001) |
| "Migraine is a common and debilitating condition routinely managed in primary care." | ( Ball, K; Dowson, A; Haworth, D, 2000) |
| "Migraine is a common disorder characterized by recurrent pain attacks of mild-severe intensity associated with autonomic and occasionally neurological symptoms." | ( Del Zompo, M, 2000) |
| "Migraine is a common disorder in which not only the pain but also the accompanying symptoms such as nausea and vomiting reduce activity and productivity of sufferers." | ( Demirkaya, S; Dora, B; Topçuoğlu, MA; Vural, O, 2001) |
| "Migraine is among the most common neurologic disorders encountered in clinical practice." | ( Dandapani, BK; Hanson, MR, 1998) |
| "Although migraine is more common among women than men, the only two large, randomized trials of low-dose aspirin for migraine prophylaxis have been conducted in men." | ( Benseñor, IM; Buring, JE; Chown, MJ; Cook, NR; Hennekens, CH; Lee, IM, 2001) |
| "Migraine is one of the most common neurological disorders, involving periodical attacks of headache and nausea as well as a plethora of other symptoms." | ( Doods, H, 2001) |
| "Abdominal migraine is rare, but not unknown, in adults." | ( Abu-Arafeh, I; Russell, G; Symon, DN, 2002) |
| "Migraine is a primary central nervous system disorder characterized by triggered or spontaneous episodes of activation of trigemino-vascular complex, neurogenic inflammation around vessels and meninges, and stimulation of the peripheral and central pain pathways of the trigemino-cervical complex." | ( Gupta, A; Rothner, AD, 2001) |
| "Migraine is a significant women's health concern." | ( Martin, VT; Penzien, DB; Rains, JC, 2002) |
| "Migraine is a recurrent clinical syndrome characterised by combinations of neurological, gastrointestinal and autonomic manifestations." | ( Diamond, S; Wenzel, R, 2002) |
| "After puberty migraine is more prevalent in women." | ( Malgrange, B; Multon, S; Parducz, A; Pardutz, A; Schoenen, J; Vecsei, L, 2002) |
| "Migraine is a common disorder with a prevalence of 9-10% in Hungary." | ( Csiba, L; Ficzere, A, 2002) |
| "These migraines are often refractory to treatment." | ( Burke, BE; Cusack, BJ; Olson, RD, 2002) |
| "Migraines are known to be linked to hormonal factors." | ( Lebuisson, DA; Malek, N, 1992) |
| "Migraine is characteristically accompanied by a throbbing quality of head pain thought to involve trigeminovascular afferents." | ( Akerman, S; Goadsby, PJ; Kaube, H; Williamson, DJ, 2002) |
| "Migraine is a significant problem for many children." | ( Hershey, AD; Kabbouche, M; LeCates, S; Powers, SW; Vockell, AL, 2002) |
| "Migraine is a cause of recurrent headache in childhood." | ( Erermis, S; Erhan, E; Oksel, F; Serdaroglu, G; Tekgul, H; Tutuncuoglu, S; Uyar, M, 2002) |
| "Menstrual migraines are a treatment challenge for both the migraineur and the health care professional." | ( Chavanu, KJ; O'Donnell, DC, 2002) |
| "Migraine is a common disorder with a serious impact on quality of life." | ( Balbisi, EA, 2002) |
| "Migraine is considered a neurovascular disease involving dilatation of cerebral arteries." | ( Birk, S; Kruuse, C; Olesen, J; Thomsen, LL, 2003) |
| "Migraine headache is common and has multiple etiologies." | ( Hershey, AD; Kabbouche, MA; LeCates, SL; Powers, SW; Vockell, AL, 2003) |
| "Migraine is more prevalent in women than men." | ( Mannix, LK, 2003) |
| "Migraine is a common neurovascular disorder characterized by recurrent episodes of disabling headache, autonomic nervous system dysfunction, and, in some patients, neurological aura symptoms." | ( Gray, RN; McCrory, DC, 2003) |
| "Migraine is a common, chronic, often disabling neurologic condition that is underdiagnosed and undertreated." | ( Cano Orgaz, A; Ceballos Hernansanz, MA; López-Gil, A; Sanchez Roy, R, 2003) |
| "Migraine is a common, frequently incapacitating, headache disorder that imposes a substantial burden on both the individual patient and society." | ( Gawel, M; Gladstone, JP, 2003) |
| "Migraine is an episodic pain disorder whose pathophysiology is related to deficiency of serotonin signaling and abnormal function of the P/Q-type calcium channel, CACNA1A." | ( Cowie, RH; Estevez, AO; Estevez, M; Gardner, KL, 2004) |
| "Migraine is a common disorder that costs US employers billions of dollars each year in missed workdays and reduced productivity." | ( Reeder, CE; Williams, P, 2003) |
| "Migraine headaches are a frequently encountered neurologic problem in children." | ( Kring, D; Pakalnis, A; Paolicchi, J, 2003) |
| "Migraine is an episodic syndrome consisting of a variety of clinical features that result from dysfunction of the sympathetic nervous system." | ( Peroutka, SJ, 2004) |
| "Migraine is most similar to pure autonomic failure in terms of reduced supine plasma norepinephrine levels, peripheral adrenergic receptor supersensitivity, and clinical symptomatology directly related to sympathetic nervous system dysfunction." | ( Peroutka, SJ, 2004) |
| "Migraine is the headache most commonly encountered in primary care practice." | ( Edmeads, J; Pringsheim, T, 2004) |
| "Migraine is the most common cause of severe recurrent headache in children." | ( , 2004) |
| "Migraine is a typical "women's disease": the fluctuations of sex hormones, in particular estrogens, during woman's reproductive life show a direct and major influence on migraine course." | ( Airola, G; Allais, G; Benedetto, C; Bosio, A; Ciochetto, D; De Lorenzo, C; Mana, O; Quirico, PE; Terzi, MG, 2003) |
| "Menstrual migraine is commonly encountered in women who are experiencing attacks of migraine without aura." | ( Martin, VT, 2004) |
| "Migraine is a very common disorder." | ( Araki, N, 2003) |
| "Migraine is a neurovascular syndrome characterized by recurrent headache associated with other symptoms, eventually preceded by aura." | ( Bernardini, R; Bianchi, A; Caraci, F; D'Amato, CC; Pizza, V; Salomone, S, 2004) |
| "Studying attacks of migraine is considerably hampered by its fundamentally episodic nature." | ( Afridi, KS; Goadsby, JP; Kaube, H, 2004) |
| "Migraine is a common medical condition affecting more than 10% of population in Poland." | ( Kozubski, W; Stepień, A, 2004) |
| "Chronic migraine is comorbid with several conditions." | ( Alonso, EO; Faulhaber, MH; Peres, MF; Santos, BF; Senne Soares, CA; Zukerman, E, 2004) |
| "Migraine is a common neurological disorder that is associated with an increase in plasma calcitonin gene-related peptide (CGRP) levels." | ( Arulmani, U; Maassenvandenbrink, A; Saxena, PR; Villalón, CM, 2004) |
| "Migraine is a highly prevalent chronic neurologic disorder." | ( Krymchantowski, A; Tavares, C, 2004) |
| "Migraine is associated with a significant productivity loss to employers, who may benefit from making a migraine intervention available to their employees." | ( Burke, TA; Laínez, MJ; Vicente-Herrero, T, 2004) |
| "Lower-half facial migraine is a condition difficult to classify; according to the international classifications it could not be found as an individual entity." | ( Bagán, JV; Bandrés, A; Peñarrocha, M, 2004) |
| "Migraine is a common, debilitating condition affecting up to 15% of the population." | ( Goadsby, PJ; Shields, KG, 2005) |
| "The hypothesis that migraine is the result of a condition of neuronal hyperexcitability and the quest for drugs that are able to limit the number of crises justifies the attempt to utilise the new antiepileptic drugs in the prophylaxis of this pathology, which is so important due to its high prevalence and due to the high disability it causes." | ( Capuano, A; Di Trapani, G; Evangelista, M; Ferraro, D; Mei, D; Tonali, P; Vollono, C, 2004) |
| "Migraine is a common cause of vertigo." | ( Bisdorff, AR, 2004) |
| "Migraine is a common, disabling condition that has a significant impact on patients and relatives, and is a considerable economic burden on society." | ( Brandes, J; Dodick, D; Elkind, A; Mathew, N; Rodichok, L, 2005) |
| "Migraine is a common disorder in Latin American urban communities imposing significant burden on individuals, families, and communities." | ( Alarcon, F; Aranaga, N; Aulet, S; Chapman, E; Conterno, L; Estevez, E; Garcia-Pedroza, F; Garrido, J; Macias-Islas, M; Monzillo, P; Morillo, LE; Nunez, L; Plascencia, N; Rodriguez, C; Takeuchi, Y, 2005) |
| "Migraine is a common disease of as yet unknown etiology." | ( Freitag, CM; Lesch, KP; Marziniak, M; Meyer, J; Mössner, R; Sommer, C; Weichselbaum, A, 2005) |
| "Migraine is a common disabling condition likely to be associated with dysfunction of brain pathways involved in pain and other sensory modalities." | ( Afridi, SK; Frackowiak, RS; Friston, KJ; Goadsby, PJ; Kaube, H; Lee, L; Matharu, MS, 2005) |
| "Migraine is a common disorder that is disproportionately prevalent in women, especially during the reproductive years." | ( Geweke, LO; Recober, A, 2005) |
| "Migraine is a common medical condition affecting nearly 10% of population in Poland." | ( Kozubski, W; Stepień, A, 2004) |
| "Migraine is a common, disabling problem with three phases: premonitory, main headache attack, and postdrome." | ( Akerman, S; Goadsby, PJ, 2005) |
| "Ophthalmoplegic migraine is a rare syndrome in which headache is associated with ophthalmoplegia and third, fourth or sixth cranial nerves palsy." | ( Borges, PC; Castro, MA; Farage, L; Freitas, LO; Macedo, TA; Souza, LP, 2005) |
| "Migraine headache is a highly prevalent chronic, episodic condition." | ( Lofland, JH; Nash, DB, 2005) |
| "Migraine is one of the commonest of headache disorders presenting to neurologists the world over." | ( Panda, S; Tripathi, M, 2005) |
| "Migraine is a highly prevalent, chronic and disabling illness in which the gap between practice guideline recommendations and actual clinical practice remains wide." | ( Diener, HC, 2005) |
| "Migraine is a highly prevalent primary headache." | ( Bigal, ME; Krymchantowski, AV, 2005) |
| "Menstrual migraines are particularly difficult-totreat." | ( Allais, G; Benedetto, C; Bussone, G; D'Amico, D; Grazzi, L; Moschiano, F; Roncolato, M; Usai, S, 2005) |
| "Migraine headache is now emerging as a previously under-recognized side effect of interferon-beta, the most commonly used therapy for relapsing multiple sclerosis (MS)." | ( Fast, A; Khromov, A; Nissinoff, J; Segal, M, 2005) |
| "Migraine is a common, chronic, neurovascular disorder, generally characterised by attacks of severe headache and autonomic nervous system dysfunction." | ( Desjardins, B; Ferko, N; Gawel, M; Grima, D; Thompson, M, 2005) |
| "Patients whose migraines are frequent, cause disruptions of daily routines, or are unresponsive to acute treatment are primary candidates for preventive migraine therapy." | ( Brown, JS; Friedman, M; Menzin, J; Miller, JD; Neumann, PJ; Papadopoulos, G, 2005) |
| "Migraine is a genetically determined recurrent pain syndrome accompanied by neurological and gastrointestinal features, involving interaction of external triggers and internal pathophysiology and the cause of considerable disability to sufferers." | ( Joubert, J, 2005) |
| "Migraine is a chronic disorder that can be debilitating, especially when the attacks are severe and frequent." | ( Kabbouche, MA; Linder, SL, 2005) |
| "The prevalence of migraine is high, affecting a significant proportion of the adult population during their most productive years of life and promoting impairment of their normal daily activities." | ( Bigal, ME; Krymchantowski, AV, 2005) |
| "Migraine headache is more severe, disabling, and frequent during the menstrual intervals of the female reproductive cycle than during mid-luteal or mid-cycle intervals." | ( Bean, J; Kao, L; Liu, J; Mandell, K; Martin, VT; Ramadan, N; Rebar, R; Wernke, S; Zoma, W, 2005) |
| "Migraine is characterized by the peripheral and central sensitization of pain perceptive neural systems, and neurogenic inflammation is a key step in the development of migraine headache." | ( Araki, H; Fukuhara, Y; Ishizaki, K; Kusumi, M; Nakashima, K; Nakaso, K; Takeshima, T, 2005) |
| "Migraine is a common debilitating primary headache disorder with significant mental, physical and social health implications." | ( Griffiths, LR; Johnson, MP, 2005) |
| "Migraine is much more common in women (18%) than in men (6%)." | ( Andersen, OK; Arendt-Nielsen, L; Gazerani, P, 2005) |
| "Abdominal migraine is a rarely recognized functional intestinal disorder, manifesting as recurrent paroxysmal abdominal pain of neurogenic origin." | ( Karczewska, K; Kasner, J; Kwiecień, J; Piasecki, L, 2005) |
| "Migraine is a complex patholophysiology in which both central and peripheral components of the trigeminal pain pathway probably play a significant role, both in the symptoms and signs of the attack and in the mechanisms of action of antimigraine compounds, such as triptans, which constitute the most important therapy for aborting migraine pain and possess several mechanisms on 5-HT receptor-mediated actions." | ( Buzzi, MG; Moskowitz, MA, 2005) |
| "Although migraine is more common in women than men and often linked to the menstrual cycle, few studies have investigated the biological basis of hormonal influences on the trigeminovascular system." | ( Berman, NE; Klein, RM; Macgregor, RR; Mathur, S; Puri, S; Puri, V; Svojanovsky, SR; Welch, KM, 2006) |
| "Migraine is a common disabling neurological disorder, associated with headache, nausea, and on occasions vomiting." | ( Goadsby, PJ; Yates, R, 2006) |
| "Migraine is a costly, recurrent condition that affects 28 million individuals in the United States yet remains underdiagnosed and undertreated." | ( Padiyara, RS; Schwarz, K; Wenzel, RG, 2006) |
| "Migraine is hypothesized to be a neurovascular coupling disorder where the cerebral vascular reactivity is malfunctioning and measuring hemodynamic changes during migraine without causing more disturbance has always been a challenge." | ( Akin, A; Bilensoy, D; Bolay, H; Candansayar, S; Emir, UE; Gülsoy, M, 2006) |
| "Migraine is a common episodic headache that predominantly affects young adults, particularly women in their most productive years." | ( Bovim, G; Schrader, H; Stovner, LJ; Tronvik, E, 2006) |
| "Migraine headache is strongly influenced by reproductive events that occur throughout the lifespan of women." | ( Behbehani, M; Martin, VT, 2006) |
| "Although migraine is a neurovascular disorder, both scalp tenderness and referred pain have been observed in migraine patients." | ( Calandre, EP; García-Leiva, JM; Hidalgo, J; Rico-Villademoros, F, 2006) |
| "Menstrual migraines are usually more resistant to treatment, generally not associated with aura, of longer duration, and associated with more functional disability compared with attacks at other times of the month." | ( Brandes, JL, 2006) |
| "Chronic migraine is frequently associated with an overuse of symptomatic medications." | ( Arvat, E; Ferrero, M; Ghigo, E; Giordano, R; Limone, P; Pellegrino, M; Pinessi, L; Rainero, I; Rubino, E; Valfrè, W, 2006) |
| "The pathogenesis of migraine is still unclear, but much evidence suggests a role of inflammation in pain generation." | ( Ferrarese, C; Longoni, M, 2006) |
| "Migraine is a distressing disorder that is often triggered by stress and poor sleep." | ( Cameron, LD; Lawler, SP, 2006) |
| "Migraine is a chronic neurologic disorder with heterogeneous characteristics resulting in a range of symptom profiles, burden, and disability." | ( Bigal, ME; Krymchantowski, AV, 2006) |
| "Migraine is 2-3 times more prevalent in women than in men and attacks are often timed with the menstrual cycle, suggesting a mechanistic link with ovarian steroids." | ( Berman, NE; Chandrala, S; Klein, RM; Liverman, CS; Macgregor, R; Puri, S; Puri, V, 2006) |
| "Migraine is a common and disabling neurological disorder that involves activation or the perception of activation of the trigeminovascular system." | ( Akerman, S; Goadsby, PJ; Holland, PR, 2007) |
| "Migraine headache is more common in females and, for many women, the onset of this condition occurs at menarche." | ( Zacur, HA, 2006) |
| "Common triggers of migraine are well established but 'hair wash or head bath' as a trigger for migraine has so far not been reported." | ( Ravishankar, K, 2006) |
| "(1) Migraines are characterized by recurrent headaches generally lasting between 4 and 72 hours and disappearing without complication." | ( , 2006) |
| "Migraine is one of the most common neurological disorder affecting up to 14% of the population." | ( Párdutz, A; Schoenen, J; Tajti, J; Varga, H; Vécsei, L, 2006) |
| "Migraine is one of the commonest diseases of clinical practice." | ( Costa, MS; Fernandes Filho, SM; Fernandes, MT; Foerster, MV, 2006) |
| "The prevalence of migraine is 2 to 3-fold higher in females than in males, and it is intricately related to the levels of female sex hormones." | ( de Vries, R; Garrelds, IM; Gupta, S; MaassenVanDenbrink, A; Mehrotra, S; Saxena, PR; Villalón, CM, 2007) |
| "The prevalence of migraine is higher in women than in men, and changes in 17beta-estradiol levels seem to affect the frequency of attacks in female migraineurs." | ( Boomsma, F; Gupta, S; MaassenVanDenbrink, A; Mehrotra, S; Saxena, PR; Villalón, CM, 2007) |
| "Migraine is common in the pediatric population." | ( Kring, D; Meier, L; Pakalnis, A, 2007) |
| "Migraine is often associated with health consequences including impaired quality of life, and the cost of treating migraine headaches places a significant financial burden on patients who suffer from migraines." | ( Diener, HC; Lampl, C; Voelker, M, 2007) |
| "Chronic migraine is a common form of disabling headache presenting in headache subspecialty practice." | ( Bussone, G; Diener, HC; Goadsby, PJ; Lahaye, M; Schwalen, S; Van Oene, JC, 2007) |
| "The prevalence of migraine is much greater in female than male individuals." | ( Arnold, AP; Brennan, KC; Charles, AC; López Valdés, HE; Romero Reyes, M, 2007) |
| "Migraine is a prevalent neurological disorder that can be alleviated by specific treatment for acute headaches, in particular, the triptans, including naratriptan." | ( Allaert, FA; Druais, PL; El Hasnaoui, A; Lanteri-Minet, M; Nachit-Ouinekh, F, 2007) |
| "Migraine is associated with a variety of electroencephalographic (EEG) changes." | ( Dhachayani, S; Raymond, AA; Rizal, AM; Suganthi, C; Tan, HJ, 2007) |
| "Hemiplegic migraine is an unusual variant of migraine, characterised by a temporary hemiparesis or hemiplegia associated with headache." | ( Kapur, S; Willson, J, 2007) |
| "Migraine is a common disabling condition that results in considerable socioeconomic loss." | ( Loo, CY; Raymond, AA; Tan, HJ; Teh, HS, 2007) |
| "Migraine is a common disorder with a relatively high burden of disease from the perspective of both society and the individual patient." | ( Ergun, H; Gulmez, SE; Tulunay, FC, 2007) |
| "Migraine headaches are common and among the most disabling nonfatal conditions of humankind." | ( Jung, S, 2007) |
| "Migraine is 3 times more common in postpubertal women than in men." | ( Herzog, AG, 2007) |
| "The annual cost of migraine is euro27 billion in Europe, $US1." | ( Steiner, TJ; Tfelt-Hansen, P, 2007) |
| "This chronic migraine is frequently the result of an overuse of triptans." | ( Dewarrat, A; Regli, F, 2007) |
| "Migraine is a complex, debilitating neurovascular disorder." | ( Arndt, K; Doods, H; Just, S; Rudolf, K, 2007) |
| "Migraine is the most frequent neurological disorder in the adult population worldwide, affecting up to 12% of the general population and more frequent in women ( approximately 25%)." | ( Hamel, E, 2007) |
| "Menstrual migraine is generally severe, lasts longer, recurs more frequently, results in greater disability and is more resistant to therapy than nonmenstrual migraine." | ( Goldberg, J; Silberstein, SD, 2007) |
| "Migraine is a common disabling brain disorder that--considering its clinical and economic impact--is understudied and in need of additional management options." | ( Goadsby, PJ, 2007) |
| "Migraine is a chronic, often inherited condition involving brain hypersensitivity and a lowered threshold for trigeminal-vascular activation." | ( Mueller, LL, 2007) |
| "Migraine is a common, often disabling, neurovascular disease that has been shown to be associated with abnormal serotonergic activity." | ( Peterlin, BL; Rapoport, AM, 2007) |
| "Migraine headache is a common presentation in the emergency department (ED)." | ( Blitz, S; Colman, I; Edmonds, ML; Rowe, BH; Walker, A; Wiens, S, 2008) |
| "Migraine is a common disorder associated with considerable individual and economic burden." | ( Láinez, MJ, 2007) |
| "The prevalence of migraine is 8% in men and 12-15% in women." | ( Diener, HC; Katsarava, Z; Limmroth, V, 2008) |
| "Migraine is a periodic disorder with a worldwide prevalence of 5-19%." | ( Liu, JM; Wang, XP; Zhao, YB, 2008) |
| "Pediatric migraine is a disabling condition, which can cause a significant impact on quality of life." | ( Di Trapani, G; Ferraro, D, 2008) |
| "Menstrual migraine is prevalent but it is only recently that research has specifically addressed the pathophysiology and management of this disabling condition." | ( MacGregor, EA, 2008) |
| "Migraine headache is widely believed to be associated with cerebral or meningeal vasodilatation." | ( Ferrari, MD; Kortmann, C; Schoonman, GG; Terwindt, GM; van der Geest, RJ; van der Grond, J, 2008) |
| "Chronic migraine is a subtype of chronic daily headache." | ( Ascher, S; Biondi, D; Bussone, G; Diener, HC; Dodick, D; Freitag, F; Goadsby, P; Greenberg, S; Hulihan, J; Lipton, R; Morein, J; Schwalen, S; Silberstein, S, 2008) |
| "Migraine is a complex neurological disorder in which genetic and environmental factors interact." | ( Farinelli, I; Martelletti, P; Missori, S, 2008) |
| "Drug prevention of migraine is recommended if more than three attacks occur per month, acute drug treatment is insufficient, or very severe attacks with aura are the main problem." | ( Evers, S, 2008) |
| "Migraine is a chronic neurological disease with several trigger factors, including dietary, hormonal and environmental factors." | ( Fukui, PT; Gonçalves, TR; Lucchino, NM; Masruha, MR; Matos, FC; Mercante, JP; Peres, MF; Santos, JP; Strabelli, CG; Vieira, DS; Zukerman, E; Zukerman-Guendler, V, 2008) |
| "Migraine is a prevalent neurological disorder." | ( Jevoux, C; Krymchantowski, AV, 2008) |
| "Episodic migraine is a disabling painful disease that can affect the normal function of daily routine activities such as performance at work and school, and home and social relationships." | ( Rapoport, AM, 2008) |
| "Migraine is twice as prevalent in women than men." | ( Russell, MB; Vetvik, KG, 2008) |
| "Migraine is a common disorder in which changes in cortical excitability, neuroinflammation and dysfunction of the vascular wall contribute to its pathophysiology." | ( Hamed, SA, 2009) |
| "Migraine is an episodic headache disorder affecting as many as 10% of people worldwide." | ( Nedergaard, M; Takano, T, 2009) |
| "Migraine headache is associated with reduced early absorption of GW273629 and excess NO production." | ( de Hoon, JN; Depré, M; Guillard, F; Laurijssens, BE; Lunnon, MW; Palmer, J; Van der Schueren, BJ; Van Hecken, A; Vanmolkot, FH, 2009) |
| "Acute confusional migraine is a rare migraine variant primarily seen in childhood that lacks standardized diagnostic criteria." | ( Hershey, AD; Khatri, R; Wong, B, 2009) |
| "Migraine is a common disabling brain disorder." | ( Conti, R; Fabbro, A; Ferrari, MD; Pietrobon, D; Santello, M; Shapovalova, M; Tottene, A; van den Maagdenberg, AM; Vecchia, D, 2009) |
| "Migraine is a complex neurological disease with a genetic background." | ( Messlinger, K, 2009) |
| "Migraine is a prevalent and debilitating disease that may, in part, arise because of disruption in neurovascular endothelia caused by elevated homocysteine." | ( Colson, N; Griffiths, L; Lea, R; Macmillan, J; Quinlan, S, 2009) |
| "Migraine is characterized by similar metabolic and psychological anomalies suggesting that a possible relationship exists between the two pathological conditions." | ( Bolner, A; Colavito, D; D'Andrea, G; d'Onofrio, F; Francesconi, F; Musco, F; Ostuzzi, R, 2009) |
| "Migraine is a common and disabling neurological disorder." | ( Andreou, AP; Goadsby, PJ, 2009) |
| "Migraine is an episodic headache disorder characterized by a combination of neurological, gastrointestinal, and autonomic symptoms." | ( Du, W; Marbury, T; O'Neill, C; Pierce, M; Sebree, T; Siegel, S, 2009) |
| "Migraine is a complex neurological disorder that affects a significant proportion of the adult population worldwide." | ( Nieber, K, 2009) |
| "Migraine is a very common neurological disorder worldwide." | ( Adjien, C; Adoukonou, T; Avode, DG; Houinato, D; Ntsiba, F; Preux, PM, 2010) |
| "Migraine is associated with increased risk of cardiovascular disease, but the mechanisms are unclear." | ( Affuso, F; Carrieri, PB; Cittadini, A; D'Anna, C; Guardasole, V; Matarazzo, M; Napoli, R; Saccà, F; Saccà, L; Zarra, E, 2009) |
| "Patients with migraine are characterized by a distinct vascular smooth muscle cell dysfunction, revealed by impaired cyclic guanosine monophosphate and hemodynamic response to nitric oxide." | ( Affuso, F; Carrieri, PB; Cittadini, A; D'Anna, C; Guardasole, V; Matarazzo, M; Napoli, R; Saccà, F; Saccà, L; Zarra, E, 2009) |
| "Migraine is a common disorder in childhood and adolescence." | ( Arbizzani, A; Condò, M; Parmeggiani, A; Posar, A, 2009) |
| "Migraine is a complex, chronic, painful, neurovascular disorder characterized by episodic activation of the trigeminal system." | ( Capuano, A; De Corato, A; Dello Russo, C; Lisi, L; Navarra, P; Tringali, G, 2009) |
| "Migraine headache is a particularly prevalent condition associated with major reductions in patients' quality of life." | ( Láinez, MJ, 2009) |
| "Migraine is a neurovascular disorder characterized by recurrent episodic headaches, and is caused by abnormal processing of sensory information due to peripheral and/or central sensitization." | ( Durham, PL; Garrett, FG, 2009) |
| "Migraine is a common, recurrent, primary headache disorder associated with significant morbidity as well as high direct and indirect costs." | ( Silberstein, SD, 2009) |
| "Migraine is a common and often disabling neurovascular disorder." | ( Calhoun, AH; Katsnelson, MJ; Peterlin, BL, 2009) |
| "Migraine is a highly prevalent neurovascular disorder that can be provoked by infusion of calcitonin gene-related peptide (CGRP)." | ( Olesen, J; Villalón, CM, 2009) |
| "Migraine is a chronic disease with episodic attacks and a variable prognosis." | ( Bigal, M, 2009) |
| "Migraine is a neurovascular disorder that induces debilitating headaches associated with multiple symptoms including facial allodynia, characterized by heightened responsivity to normally innocuous mechanical stimuli." | ( Brown, K; Ellis, A; Mahoney, J; Maier, SF; McFadden, A; Rezvani, N; Sprunger, D; Watkins, LR; Wieseler, J, 2010) |
| "Migraine is Europe and North America's most frequent neurological illness." | ( Supiot, F, 2009) |
| "Migraine is a common, disabling, neurological problem whose acute management would benefit from the development of purely neurally acting therapies." | ( Goadsby, PJ; Immke, DC; Storer, RJ, 2009) |
| "Migraine is often a chronic and disabling disorder." | ( Bosnar-Puretić, M; Demarin, V; Lovrencić-Huzjan, A; Vuković, V, 2009) |
| "Migraine is a multifactorial chronic central nervous system disorder, characterized by recurrent disabling attacks of moderate-to-severe headache." | ( Nappi, G; Perrotta, A; Sandrini, G; Tassorelli, C, 2009) |
| "Migraine is a debilitating headache disorder which affects approximately 12% of the general population and is the cause of significant loss of productivity (i." | ( Paone, DV; Staas, DD, 2009) |
| "Migraine is like any other chronic illness." | ( Meyer, H, 2009) |
| "Migraine is a prevalent neurological disorder." | ( Jevoux, C; Krymchantowski, AV; Moreira, PF, 2010) |
| "Patients with migraine headaches are frequently prescribed topiramate to treat their condition." | ( Aronwald, RM; Cole, KL; Wang, EE, 2012) |
| "Migraine is a common neurological disease affecting about 12% of the population in Western Europe and North America, and causing a considerable burden both to migraineurs and to society." | ( Rapoport, AM; Vikelis, M, 2010) |
| "Abdominal migraine is a commonly described migraine variant in children and young adults, but associations with Alice in Wonderland syndrome and lilliputian hallucinations are exceptional." | ( Hamed, SA, 2010) |
| "Many patients with migraine are poorly responsive to conventional preventive therapies." | ( Maizels, M, 2010) |
| "Migraine is among the most prevalent headache disorders and results from dysfunctions within the trigeminovascular system (TVS)." | ( Meents, JE; Neeb, L; Reuter, U, 2010) |
| "Migraine is a common, disabling condition and a burden for the individual, health services and society." | ( Derry, S; Kirthi, V; McQuay, HJ; Moore, RA, 2010) |
| "Patients with migraine are usually undertreated, as treatment guidelines are frequently not followed and, therefore, resulting treatment satisfaction is low." | ( Allaf, B; Becker, H; Donnet, A; Lantéri-Minet, M, 2010) |
| "Migraine is linked with various co-morbid conditions, the most prominent being motion sickness." | ( Cuomo-Granston, A; Drummond, PD, 2010) |
| "Migraine is a common, multisymptom disorder that can severely impact the daily activities of migraineurs." | ( Pierce, MW, 2010) |
| "Migraine is a debilitating disorder of the CNS." | ( Meents, J; Neeb, L; Reuter, U, 2010) |
| "Chronic migraine is a common cause of chronic daily headache, which is often refractory to standard treatment." | ( Lovell, BV; Marmura, MJ, 2010) |
| "Abdominal migraine is one subcategory of migraine-related syndromes." | ( Haginoya, K; Kakisaka, Y; Tsuchiya, S; Uematsu, M; Wakusawa, K, 2010) |
| "Chronic migraine is an important public health problem." | ( D'Amico, D, 2010) |
| "Migraine is a highly prevalent disabling condition, and the current treatment options are not satisfactory." | ( Fischer, MJ, 2010) |
| "Migraine is the most common of the paroxysmal disorders to affect the brain in the pediatric population." | ( Bidabadi, E; Mashouf, M, 2010) |
| "Migraine is a common neurological disorder often treated with triptans." | ( Andrews, JS; Chichorro, J; De Felice, M; Dodick, D; Dussor, G; Lai, J; Maddaford, S; Meng, ID; Ossipov, MH; Porreca, F; Rakhit, S; Wang, R, 2010) |
| "Because such migraines are often predictable, they provide a suitable target for treatment in the mild pain phase." | ( Acuto, G; Allais, G; Allais, R; Benedetto, C; Bussone, G; D'Andrea, G; d'Onofrio, F; Grazzi, L; Manzoni, GC; Moschiano, F; Valguarnera, F, 2011) |
| "Pathomechanism of migraine is not fully understood." | ( Grzybek, M; Kułaga, A; Szczudlik, A; Trabka-Janik, E; Urbanik, A, 2010) |
| "Migraine is a very common disorder characterized by the combination of typical headache with associated autonomic symptoms and ranked by the WHO as number 19 among all diseases worldwide causing disability." | ( Nagy, F, 2010) |
| "Migraine is a common problem affecting 10 - 20% of adolescents." | ( Lewis, DW, 2010) |
| "Migraine is a prevalent headache disorder affecting three times more women than men during the reproductive years." | ( MacGregor, EA, 2010) |
| "Migraine is a common, disabling condition and a burden for the individual, health services and society." | ( Derry, S; McQuay, HJ; Moore, RA; Rabbie, R, 2010) |
| "Migraine is a disabling, painful primary headache disorder that is associated with various combinations of neurological, gastrointestinal, autonomic and pain symptoms." | ( Freitag, F; Pearlman, SH; Rapoport, AM, 2010) |
| "Migraine is a common, debilitating, chronic neurovascular disorder." | ( Ames, PR; Barra, S; Gaeta, G; Lanero, S; Madrid, A; Materazzi, C; Vitagliano, G, 2010) |
| "Migraine is a common, disabling condition and a burden for the individual, health services and society." | ( Derry, S; McQuay, HJ; Moore, RA, 2010) |
| "Chronic migraine is defined in different ways." | ( Diener, HC; Dodick, D; Holle, D, 2011) |
| "Migraine headache is common in women with chronic pelvic pain, regardless of endometriosis, and contributes to disability in those with both conditions." | ( Karp, BI; Nieman, LK; Silberstein, SD; Sinaii, N; Stratton, P, 2011) |
| "Migraine is a risk factor for ischemic stroke." | ( Arslan, H; Horasanli, B; Turan, H; Ugur, M, 2011) |
| "Migraine is a common, paroxysmal, highly disabling primary headache disorder with a genetic background." | ( Bohár, Z; Fejes, A; Kuris, A; Párdutz, A; Tajti, J; Toldi, J; Tuka, B; Vámos, E; Vécsei, L, 2011) |
| "Migraine is a neurological disorder that is associated with increased levels of calcitonin gene-related peptide (CGRP) in plasma." | ( Buteri, J; Griffiths, LR; Haupt, LM; Lea, RA; Macmillan, JC; Menon, S; Murrell, M; Quinlan, S; Roy, B, 2011) |
| "Migraine is usually managed by medication, but some patients do not tolerate migraine medication due to side effects or prefer to avoid medication for other reasons." | ( Chaibi, A; Russell, MB; Tuchin, PJ, 2011) |
| "Migraine is one of the most prevalent neurological disorders in Europe, severely affecting ability to work and quality of life." | ( Beck, M; Bergmann, A; Burmeister, U; Liebnitzky, J; Sihvonen-Riemenschneider, H; Voigt, K; Voigt, R, 2011) |
| "Migraine is a common neurological disorder with a genetically complex background." | ( Amin, N; Aulchenko, YS; Boomsma, DI; Breteler, M; de Geus, EJ; de Moor, MH; de Vries, B; Ferrari, MD; Gudnason, V; Hofman, A; Hottenga, JJ; Ikram, MA; Janssens, AC; Kattenberg, VM; Koelewijn, SC; Launer, LJ; Ligthart, L; Montgomery, GW; Nyholt, DR; Oostra, BA; Penninx, BW; Smit, JH; Smith, AV; Terwindt, GM; Uitterlinden, AG; van den Maagdenberg, AM; van Duijn, CM; Willemsen, G; Zitman, FG, 2011) |
| "Migraine is a common neurological disorder and epidemiological studies have documented its high social and economic impact." | ( Ciuffoli, A; Pizzolato, R; Prosperini, L; Sette, G; Villani, V, 2011) |
| "Migraine is a neurovascular disorder, and although the pathophysiology of migraine has not been fully delineated, much has been learned in the past 50 years." | ( Gupta, S; Nahas, SJ; Peterlin, BL, 2011) |
| "Migraine is one of the risk factor for ischemic stroke." | ( Iizuka, R; Ishii, M; Kiuchi, Y; Mori, Y; Shimizu, S, 2011) |
| "Migraine is a widespread disorder." | ( Ferrari, A; Neri, L; Sternieri, E; Tiraferri, I, 2011) |
| "Migraine is a severe episodic headache disorder affecting one in five people." | ( Lafrenière, RG; Rouleau, GA, 2011) |
| "The Babinskís migraine is a certain well entity and must be recovered for the clinic." | ( García-Albea, E, 2012) |
| "Migraine is the most common painful neurological disorder, affecting 13% of the general population." | ( Casolla, B; Lala, N; Lionetto, L; Martelletti, P; Negro, A; Simmaco, M, 2011) |
| "Although migraine is classified as a headache disorder, a key part of migraine pathophysiology is a heightened excitability of visual cortices in between headache events." | ( Chapman, C; Chung, J; Handy, TC; Hayward, J; Mickleborough, MJ, 2011) |
| "Migraine is affected by fluctuating estrogen levels so it is not surprising that the perimenopause is a time of peak rate of change of migraine prevalence in women." | ( MacGregor, EA, 2012) |
| "Menstrual-related migraine is a particularly disabling presentation of migraine often deserving of specific prevention." | ( Calhoun, A, 2012) |
| "Migraine is a complex neurological disorder with a clear neurogenic inflammatory component apparently including enhanced nitric oxide (NO) formation." | ( Dach, F; de O S Mansur, T; Gonçalves, FM; Lacchini, R; Martins-Oliveira, A; Speciali, JG; Tanus-Santos, JE, 2012) |
| "Opioid use for migraine is associated with more severe headache-related disability, symptomology, comorbidities (depression, anxiety, and cardiovascular disease and events), and greater HRU for headache." | ( Buse, DC; Lipton, RB; Ng-Mak, DS; Pearlman, SH; Reed, ML; Serrano, D, 2012) |
| "Migraine headache is one of the most common neurological disorders, but the pathophysiology contributing to migraine is poorly understood." | ( Dussor, G; Melemedjian, OK; Price, TJ; Yan, J, 2012) |
| "Migraine is a very common headache disorder." | ( Cengizlier, MR; Ercan Sarıçoban, H; Mutlu, N; Ozen, AO, 2011) |
| "Migraine is a common neurovascular disorder characterized by recurrent episodes of disabling headache, autonomic nervous system dysfunction, and, in some patients, neurological aura symptoms." | ( Gray, RN; McCrory, DC, 2012) |
| "Migraine is a highly disabling condition for the individual and also has wide-reaching implications for society, healthcare services, and the economy." | ( Derry, CJ; Derry, S; Moore, RA, 2012) |
| "Migraine is a common, disabling condition and a burden for the individual, health services and society." | ( Derry, S; Moore, RA; Rabbie, R, 2012) |
| "Migraine is a highly disabling condition for the individual and also has wide-reaching implications for society, healthcare services, and the economy." | ( Derry, CJ; Derry, S; Moore, RA, 2012) |
| "Migraine is a highly disabling condition for the individual and also has wide-reaching implications for society, healthcare services, and the economy." | ( Derry, CJ; Derry, S; Moore, RA, 2012) |
| "Migraine is a highly disabling condition for the individual and also has wide-reaching implications for society, healthcare services, and the economy." | ( Derry, CJ; Derry, S; Moore, RA, 2012) |
| "Migraine is one of the primary headaches and may occur with or without aura." | ( Goddard, SL; Zagami, AS, 2012) |
| "Migraine is one of the most common neurological disorders that affects young people, causing a considerable degree of disability in the active population, with an enormous consequent socio-economic impact." | ( Pardutz, A; Vecsei, L, 2012) |
| "Migraine headaches are common in children." | ( Asa, S; Ashrafi, MR; Mahvelati, F; Malamiri, RA; Rashidi-Ranjbar, N; Togha, M, 2012) |
| "Migraine is common in children, but few specific drugs are available." | ( Carotenuto, M; Esposito, M; Pascotto, A; Ruberto, M, 2012) |
| "Acute treatment of migraine is actually based on the use of triptans, class drug which presents a clear limitation due to its cardiovascular side effects." | ( Lionetto, L; Martelletti, P; Negro, A; Simmaco, M, 2012) |
| "Chronic migraine is the most frequent complication of migraine." | ( Láinez-Andrés, JM, 2012) |
| "Migraine is a primary headache disorder with an unknown pathophysiology." | ( Samsam, M, 2012) |
| "Use of opioids in migraine is pennywise and pound foolish." | ( Tepper, SJ, 2012) |
| "Migraine is characterized by similar metabolic and psychological anomalies suggesting that a possible relationship exists between the two pathological conditions." | ( Bolner, A; Colavito, D; D'Andrea, G; Leon, A; Ostuzzi, R, 2012) |
| "Migraine is a chronic neurological disorder with episodic manifestations, progressive in some individuals." | ( Casucci, G; Cologno, D; D'Onofrio, F; Villani, V, 2012) |
| "Migraine is highly prevalent in women, particularly in the reproductive years when contraception may be needed." | ( Casey, PM; Faubion, SS; Shuster, LT, 2012) |
| "Patients with migraine headaches are commonly encountered by clinicians both in the clinic and in the emergency department." | ( Chua, M; Giuliano, C; Mitchon, G; Smalligan, RD, 2012) |
| "Migraine is a multifactorial neurovascular disorder characterized by recurrent episodes of disabling pain attacks, accompanied with gastrointestinal, neurological systems dysfunction." | ( Casolla, B; D'Alonzo, L; Lionetto, L; Martelletti, P; Mastropietri, F; Negro, A; Simmaco, M, 2012) |
| "Migraine is a debilitating neurological disorder characterized by mild to severe headache that is often accompanied by aura and other neurological symptoms." | ( Braas, KM; Koide, M; May, V; Syed, AU; Wellman, GC, 2012) |
| "Prevalence of migraines is greater in the Romany living in Spain than in the general Spanish population." | ( Alonso-Blanco, C; Carrasco-Garrido, P; Fernández-de-las-Peñas, C; Hernández-Barrera, V; Jiménez-García, R; Jiménez-Sánchez, S; Palacios-Ceña, D, 2013) |
| "The frequency of migraine headaches is higher in women than in men and in susceptible women attacks are related to changes in ovarian hormone levels." | ( Boes, T; Levy, D, 2012) |
| "Migraine is a neurovascular disorder characterized by recurrent unilateral headaches accompanied by nausea, vomiting, photophobia and phonophobia." | ( Edvinsson, L; MaassenVanDenBrink, A; Villalón, CM, 2012) |
| "Chronic migraine is a common disabling condition." | ( Carmona-Abellán, M; Irimia, P; Martínez-Vila, E, 2012) |
| "Migraine is a common neurovascular disorder characterized by recurrent episodes of disabling headache, autonomic nervous system dysfunction, and in some patients, neurological aura symptoms." | ( Casolla, B; Lionetto, L; Martelletti, P; Negro, A; Simmaco, M, 2012) |
| "Migraine is a common neurological disorder characterised by debilitating head pain and an assortment of additional symptoms which can include nausea, emesis, photophobia, phonophobia and occasionally visual sensory disturbances." | ( Griffiths, LR; Stuart, S, 2012) |
| "Migraine is a widespread, relapsing, remittent syndrome." | ( Fox, AW, 2012) |
| "Although migraine is a common, paroxysmal, highly disabling disorder, the primary cause and the pathomechanism of migraine attacks are enigmatic." | ( Csáti, A; Kuris, A; Lukács, M; Majláth, Z; Szok, D; Tajti, J; Tuka, B; Vécsei, L, 2012) |
| "Migraine is a common disabling brain disorder whose key manifestations are recurrent attacks of unilateral headache that may be preceded by transient neurological aura symptoms." | ( Pietrobon, D, 2013) |
| "Migraine is a common neurovascular brain disorder characterised by recurrent attacks of severe headache that may be accompanied by various neurological symptoms." | ( Buteri, J; Griffiths, LR; Haupt, LM; Lea, RA; Macgregor, EA; Menon, S; Sutherland, HG, 2013) |
| "Acute migraine headaches are common emergency department presentations, and despite evidence for various treatments, there is conflicting evidence regarding the use of KET." | ( Campbell, S; Doran, S; Kokotillo, A; Rowe, BH; Taggart, E; Villa-Roel, C, 2013) |
| "Migraine is a debilitating illness that has no exact bio molecule to explain its pathology." | ( Rathnasiri Bandara, SM, 2013) |
| "Migraine headaches are often accompanied by systemic platelet activation and a brief but intense platelet oxidative burst which raises extracellular H2O2 levels to the point where H2O2 diffusing passively across lymphocyte cell membranes can raise intracellular H2O2 sufficiently to turn off regulatory T cell function via the CD28 signaling cascade." | ( Eggers, AE, 2013) |
| "Catamenial migraine is a headache disorder occurring in reproductive-aged women relevant to menstrual cycles." | ( Dun, EC; Luo, JJ; Mathew, PG, 2013) |
| "Migraine is a complex disorder with many different manifestations." | ( Cherian, N, 2013) |
| "Chronic migraine is a relatively common disorder in neurological terms that causes very significant disability at a high cost." | ( Goadsby, PJ; Maniyar, FH, 2013) |
| "Migraine is a multifactorial neurovascular disorder characterized by recurrent episodes of disabling pain attacks, accompanied with gastrointestinal, neurological systems dysfunction." | ( Casolla, B; D'Alonzo, L; Lionetto, L; Marsibilio, F; Martelletti, P; Negro, A; Simmaco, M; Vignaroli, G, 2013) |
| "Migraine is one of the most common health problems for children and adolescents." | ( Chamberlin, LA; Coffey, CS; Eklund, DD; Hershey, AD; Korbee, LL; Powers, SW, 2013) |
| "Migraine is a common, disabling condition and a burden for the individual, health services and society." | ( Derry, S; Moore, RA; Rabbie, R, 2013) |
| "Migraine is a common, disabling condition and a burden for the individual, health services and society." | ( Derry, S; Moore, RA, 2013) |
| "Migraine is a common, disabling condition and a burden for the individual, health services and society." | ( Derry, S; Kirthi, V; Moore, RA, 2013) |
| "Migraine is a common, disabling condition and a burden for the individual, health services and society." | ( Derry, S; Moore, RA; Rabbie, R, 2013) |
| "Migraine is a common disabling disorder with a significant genetic component, characterized by severe headache and often accompanied by nausea, vomiting, and light sensitivity." | ( Bates, EA; Brennan, KC; Charles, AC; Fu, YH; Hallows, WC; Huang, Y; Jones, CR; Lee, HY; Ptáček, LJ; Shapiro, RE; Zyuzin, J, 2013) |
| "Chronic migraine is a common and debilitating headache syndrome." | ( Grazzi, L, 2013) |
| "Migraine is a neurologic disorder characterized by disabling attacks of throbbing headache with specific features and associated symptoms." | ( Conte, F; Russo, A; Salemi, F; Tedeschi, G; Tessitore, A, 2013) |
| "Chronic migraine is a highly disabling condition." | ( Finocchi, C; Viani, E, 2013) |
| "Migraine is the most prevalent of the neurological disorders and can affect the patient throughout the lifetime." | ( Edvinsson, L; Warfvinge, K, 2013) |
| "Migraine is a common illness and migraine-related dizziness occurs in up to 3% of the population." | ( Sargent, EW, 2013) |
| "Migraine is a highly prevalent episodic and chronic neurological disorder that impacts otherwise healthy men and women in their most productive years." | ( Engel, ER; Kudrow, D; Rapoport, AM, 2014) |
| "Migraine is a neurovascular disease that has classically been attributed to multifactorial aetiologies, with genetic components and environmental interactions considered the main influence." | ( Gan, SH; Kamal, MA; Shaik, MM; Tan, HL, 2014) |
| "Chronic migraine is a disabling condition that affects hundreds of millions of individuals worldwide." | ( Charles, A; Evans, CJ; McGuire, B; Pradhan, AA; Smith, ML; Tarash, I, 2014) |
| "Migraine is a common, disabling condition and a burden for the individual, health services, and society." | ( Derry, S; Law, S; Moore, RA, 2013) |
| "Migraine is a common disabling condition and a burden for the individual, health services, and society." | ( Derry, S; Law, S; Moore, RA, 2013) |
| "Migraine is a chronic, disabling disorder with an estimated worldwide prevalence of 10% in adults imposing substantial social and economic impact." | ( Amini, A; Asadollahi, S; Forouzanfar, MM; Heidari, K; Shahrami, A; Vafaee, R, 2014) |
| "Migraine is a common and debilitating neurological disorder suffered worldwide." | ( Berman, NE; Gregory, E; McCarson, KE; Vermeer, LM; Winter, MK, 2014) |
| "Menstrual-related migraine is a common form of migraine affecting >50% of female migraineurs." | ( Guo, J; Liu, HL; Shi, GX; Wang, LP; Yang, Y; Zeng, L; Zhang, L; Zhang, T; Zhang, XZ, 2013) |
| "Migraine is a multifactorial and disabling syndrome often in comorbidity with psychiatric illnesses." | ( Lionetto, L; Martelletti, P; Napoletano, F, 2014) |
| "Migraine is number seven in WHO's list of all diseases causing disability and the third most costly neurological disorder in Europe." | ( Jansen-Olesen, I; Olesen, J; Tfelt-Hansen, P, 2013) |
| "Chronic migraine is common in pediatrics and generally disabling." | ( Gelfand, AA; Goadsby, PJ; Reider, AC, 2014) |
| "Chronic migraine is defined as headache on 15 and more days a month over more than 3 months and headache on 8 days or more fulfils the criteria for migraine or were triptan/ergot-responsive when thought to be migrainous in early stages of the attack." | ( Diener, HC; Holle, D; Müller, D; Nägel, S; Rabe, K, 2013) |
| "Migraine is a common form of headache that is a major burden for patients who often seek emergency care." | ( Akdag, Ö; Eken, C; Elicabuk, H; Kiray, C; Serinken, M; Turkcuer, I; Uyan, E; Yilmaz, A, 2014) |
| "Migraine is an extremely common incapacitating neurovascular disorder and has co morbidity with many psychiatric illnesses which are caused by neurotransmitter imbalance, neurodegenerative changes and genetic predisposition." | ( Rathnasiri Bandara, SM, 2014) |
| "Migraine is a disabling disease that can significantly affect a person's quality of life." | ( Maggioni, F; Mainardi, F; Pezzola, D; Zanchin, G; Zava, D, 2014) |
| "Migraine headaches are a significant problem for American women with many of them suffering from headaches around the time of their menstrual cycle." | ( Clark, JW; Coffee, AL; Hansen, DJ; Hill, AJ; Kuehl, TJ; Sulak, PJ, 2014) |
| "Migraine is an extraordinarily common brain disorder for which treatment options continue to be limited." | ( Charles, A; Pradhan, AA; Smith, ML; Zyuzin, J, 2014) |
| "Migraine headache is a common presenting condition to the pediatric emergency department (PED)." | ( Kanis, JM; Timm, NL, 2014) |
| "Chronic migraine is a frequent, severely disabling headache that often evolves from EM." | ( Cady, RK, 2014) |
| "Migraine is a cyclic disorder, in which functional and morphological brain changes fluctuate over time, culminating periodically in an attack." | ( Ambrosini, A; Brighina, F; Coppola, G; de Tommaso, M; Marinazzo, D; Perrotta, A; Pierelli, F; Sandrini, G; Schoenen, J; Stramaglia, S; Valeriani, M, 2014) |
| "Because migraine is a very common condition in childhood and adolescence, often contributing to substantial burden of illness, there is increased interest in alternatives to traditional pharmacologic prevention." | ( Goldman, RD; Sherwood, M, 2014) |
| "Migraine is a common disabling headache disorder that is conventionally classified according to the presence or absence of aura." | ( Cervellin, G; Lippi, G; Mattiuzzi, C, 2014) |
| "Migraine is a debilitating neurological disorder with grave consequences for both the individual and society." | ( Cahill, CM; Cook, C; Pickens, S, 2014) |
| "Migraine is a common illness in children associated with a negative impact on the quality of life." | ( de Coo, IF; de Jong, G; van den Berg, JS; Zielman, R, 2014) |
| "Obesity and migraine are both highly prevalent disorders in the general population, influenced by genetic and environmental risk factors." | ( Ravid, S, 2014) |
| "Migraine is a chronic trigeminal pain condition that affects the daily lives of a large part of our population." | ( DaSilva, AF; DosSantos, MF; Nascimento, TD; Zubieta, JK, 2014) |
| "Migraine is a common, disabling condition and a burden for the individual, health services, and society." | ( Bird, S; Derry, S; Moore, RA, 2014) |
| "Migraine is a highly disabling condition for the individual and also has wide-reaching implications for society, healthcare services, and the economy." | ( Derry, CJ; Derry, S; Moore, RA, 2014) |
| "Migraine is a neurovascular disorder that is associated with severe headache and neurologic symptoms." | ( Chan, K; MaassenVanDenBrink, A, 2014) |
| "Migraine is a painful neurological disorder that affects over 10% of the general population." | ( Egan, CG; Mogavero, S; Savi, L, 2014) |
| "Migraine is a very common medical disorder characterized by attacks of moderate-severe headache, nausea and disability." | ( Marmura, MJ, 2014) |
| "Migraine is a chronic recurring headache for which no complete treatment has been found yet." | ( Borhani-Haghighi, A; Daneshamouz, S; Faridi, P; Kordafshari, G; Mohagheghzadeh, A; Zargaran, A, 2014) |
| "Migraine is one of the most common neurological disorders, leading to more than 1% of total disability reported and over 68 million visits to emergency rooms or physician's offices each year in the United States." | ( Berman, NE; Gregory, E; McCarson, KE; Vermeer, LM; Winter, MK, 2015) |
| "Early treatment of migraine headaches is associated with improved outcome, but medication absorption after oral delivery may be delayed in migraineurs because of reduced gastric motility." | ( Cady, RK; Carothers, J; Djupesland, PG; Mahmoud, RA; McAllister, PJ; Messina, J; Spierings, EL, 2015) |
| "Trauma triggered migraine is seen more frequently in children, adolescents and young adults." | ( Borggreve, AG; Haan, J; Lansink, JG; van Oosterhout, WP, 2014) |
| "Migraine headaches are considered to be associated with increased mitochondrial energy metabolism." | ( Bütün, A; Çelik, Ö; Nazıroğlu, M; Uğuz, AC, 2015) |
| "Migraine is an incompletely understood, debilitating disorder that lacks a universally effective treatment." | ( Boes, CJ; Teigen, L, 2015) |
| "Migraine is one of the most common causes of headache presentations to emergency departments (EDs)." | ( Eken, C, 2015) |
| "Migraine is a highly disabling disease affecting a significant proportion of the Australian population." | ( Griffiths, LR; Haupt, LM; Ingle, S; Lea, RA; Menon, S; Palmer, M; Sutherland, M; Wee, S, 2015) |
| "Migraine is common in society and is one of the primary causes of chronic headache with episodes." | ( Atescelik, M; Gurbuz, S; Gurger, M; Yildiz, M; Yilmaz, M, 2015) |
| "Migraine headache is a common pediatric complaint among emergency department (ED) patients." | ( Bachur, RG; Monuteaux, MC; Neuman, MI, 2015) |
| "The symptoms of migraine are non-specific and can be present in many other primary and secondary headache disorders, which are reviewed." | ( Evans, RW, 2015) |
| "Migraine is a chronic disorder characterized by significant headache and various associated symptoms which worsen with exertion." | ( Garg, T; Goyal, AK; Kumar, A; Rath, G; Sarma, GS, 2015) |
| "Migraine is a complex and multifactorial brain disorder affecting approximately 18% of women and 5% of men in the United States, costing billions of dollars annually in direct and indirect healthcare costs and school and work absenteeism and presenteeism." | ( Da Silva, AN, 2015) |
| "Headaches or migraines are common adverse effects associated with the administration of IVIG." | ( Brown, DA; Henneman, A; Thornby, KA, 2015) |
| "Migraine is an expensive condition impacting on the economically active sector of the population." | ( Truter, I, 2015) |
| "Migraine is the most common form of headache disorder globally." | ( Gan, SH; Shaik, MM, 2015) |
| "Although migraine is a common neurological condition, the pathomechanism is not yet fully understood." | ( Chen, J; Dong, X; Hu, Y; Jing, L, 2015) |
| "Migraine is a common neurological problem, which accounts for large morbidity and disability." | ( Kushwah, A; Tomar, A, 2014) |
| "Migraine is a leading headache etiology that frequently presents to the emergency department (ED)." | ( Akyol, KC; Bozdemir, MN; Celik, A; Eken, C; Gungor, F; Karaca, A; Kesapli, M, 2016) |
| "Migraine headache is a neurological disorder affecting millions worldwide." | ( Ahn, DD; Bischoff, C; Burgos-Vega, CC; Dussor, G; Gavva, N; Horne, D; Wang, J; Wang, W, 2016) |
| "Migraine is a common disabling neurovascular primary headache disorder." | ( Csáti, A; Majláth, Z; Szok, D; Tajti, J; Tuka, B; Vécsei, L, 2015) |
| "Chronic migraine is a disease that affects 0." | ( Pozo-Rosich, P; Torres-Ferrus, M, 2015) |
| "The pathogenesis of migraine is not well understood." | ( Akerman, S; Goadsby, PJ, 2015) |
| "Migraine is a paroxysmal, disabling primary headache that affects 16 % of the adult population." | ( Edvinsson, L; Grände, G; Haanes, KA; Lundblad, C, 2015) |
| "Though migraine is disabling and affects 12%-15% of the population, there are few drugs that have been developed specifically for migraine prevention." | ( Bates, EA; Bialer, M; Brennan, KC; Kaufmann, D; Saunders, GH; White, HS; Wilcox, K; Yagen, B, 2016) |
| "Migraine is a common and incapacitating neurologic disorder manifesting with episodic moderate to a severe headache and other symptoms such as photophobia, phonophobia, nausea, and vomiting." | ( Ghaderibarmi, F; Tavakkoli, N; Togha, M, 2015) |
| "Migraine is a highly disabling neurological condition affecting around 15% of the population worldwide." | ( Bohár, Z; Párdutz, Á; Vécsei, L, 2016) |
| "Migraine is a highly prevalent neurovascular disorder in the brain." | ( Chen, C; Du, JR; Long, FY; Mao, XN; Wan, JY; Wang, PH; Zhang, L; Zhang, S; Zhao, LX, 2016) |
| "Migraine is one of the most common pain symptoms in children." | ( Bruno, A; Russo, A; Tedeschi, G; Tessitore, A; Trojsi, F, 2016) |
| "Migraine is a unilateral and pulsating headache associated with nausea, photophobia, vomiting, and sensitivity to light." | ( Heshmati, J; Namazi, N; Tarighat-Esfanjani, A, 2015) |
| "Migraine is a common form of headache that affects patients quality of life negatively." | ( Divsalar, K; Esmaili, Z; Rafiei, H; Safizadeh, H; Tajadini, H; Zangiabadi, N, 2017) |
| "Migraine headache is a common disorder; patients attending Emergency Departments (ED) for migraine symptoms internationally account for 1-3% of total ED annual attendances." | ( Barleycorn, D, 2016) |
| "Background Migraine is one of the most common and disabling of all medical conditions, affecting 16% of the general population, causing huge socioeconomic costs globally." | ( Ashina, M; Christensen, CE; Deen, M; Hansen, HD; Hougaard, A; Knudsen, GM, 2017) |
| "Migraine is a painful neurologic disorder with premonitory symptomatology that can include disturbed appetite." | ( Akerman, S; Goadsby, PJ; Oliveira, MM; Tavares, I, 2016) |
| "Migraine is a common and debilitating condition affecting approximately nearly one in four women in the USA and Europe." | ( Chaudhry, H; Cohen, SP, 2016) |
| "Migraine headaches are common in the pediatric emergency department." | ( Fu, R; Hansen, ML; Laurie, A; Ma, OJ; Meckler, GD; Pacheco, S; Sheridan, DC, 2018) |
| "Migraine is a risk factor for thiamine deficiency and Wernicke's encephalopathy (WE)." | ( Kumar Singh, A; Prakash, S; Rathore, C, 2016) |
| "Background/Aim Migraine is a risk factor for the formation of silent brain white matter lesions (WMLs) that are possibly ischemic in nature." | ( Bosnyák, E; Deli, G; Erdélyi-Bótor, S; Illes, Z; Kamson, DO; Kéki, S; Komáromy, H; Kovács, N; Molnár, T; Nagy, L; Orsi, G; Perlaki, G; Pfund, Z; Trauninger, A, 2017) |
| "Migraine is common in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) but its treatment responses are not well described, and its relationship to stroke risk unknown." | ( Markus, HS; Tan, RY, 2016) |
| "Migraine is prevalent and disabling yet is poorly understood." | ( Aguila, MR; Brennan, PC; Hübscher, M; Lagopoulos, J; Leaver, AM; Rebbeck, T; Refshauge, KM, 2016) |
| "Migraine is a commonly seen neurovascular disorder during childhood." | ( Arslan, A; Poyrazoglu, HG; Uytun, S; Vurdem, UE, 2016) |
| "Migraine is associated with enhanced motion sickness susceptibility and can cause episodic vertigo [vestibular migraine (VM)], but the mechanisms relating migraine to these vestibular symptoms remain uncertain." | ( Lewis, RF; Wang, J, 2016) |
| "Migraine is a complex polygenic disorder that continues to be a great source of morbidity in the developed world with a prevalence of 12% in the Caucasian population." | ( Gasparini, CF; Griffiths, LR; Smith, RA, 2016) |
| "Migraine is a highly prevalent neurovascular disorder." | ( VanDenBrink, AM; Villalón, CM, 2017) |
| "Introduction Migraine headache is a neurological disorder whose attacks are associated with nausea, vomiting, photophobia and phonophobia." | ( Bhambri, R; Chan, K; Donnet, A; Druyts, E; Goadsby, PJ; Ramos, E; Stark, R; Thorlund, K; Toor, K; Wu, P, 2017) |
| "Among them migraine is the most common disabling cause of primary headache." | ( Ahmed, S; Akhter, S; Bayes, F; Rahman, MM; Rahman, SM; Roy, S; Tabassum, S, 2016) |
| "BACKGROUND Migraine is a chronic disease that interferes with life quality and work productivity." | ( Chen, N; Li, R; Liu, Y; Song, G; Zhang, Y; Zhang, Z, 2016) |
| "Migraine is highly prevalent among women of fertile age." | ( Amble, NM; Amundsen, S; Nordeng, H; Poole, AC; Øvrebø, TG, 2016) |
| "Chronic migraine is one of the most debilitating and challenging headache disorders with no available biomarker." | ( Bolay, H; Cengiz, B; Coskun, O; Evren Boran, H; Vuralli, D, 2016) |
| "Background Migraine is much more common in females than in males, and occurrence is associated with changes in female sex hormones." | ( Buntinx, L; de Hoon, J; Draulans, C; Frederiks, P; Geldhof, V; Ibrahimi, K; Lesaffre, E; MaassenVanDenBrink, A; Vermeersch, S, 2017) |
| "Migraine is a common neurovascular disorder, affecting millions of people worldwide." | ( Allais, G; Benedetto, C, 2016) |
| "Refractory migraine is a challenging condition with great impact on health related quality of life." | ( Ashina, S; Lauritsen, C; Lipton, RB; Mazuera, S, 2016) |
| "Chronic migraine is a debilitating disorder that has a significant impact on patients and society." | ( Alipour, MR; Babri, S; Bughchechi, R; Farajdokht, F; Karimi, P; Mohaddes, G, 2017) |
| "Migraine is a neurological disorder resulting in large socioeconomic burden." | ( Han, W; Li, M; Wang, J; Xu, H, 2016) |
| "Migraine is one of the most common diseases in the world, with high economical and subjective burden." | ( Borro, M; Capi, M; Cipolla, F; Curto, M; de Andrés, F; Gentile, G; Lionetto, L; Martelletti, P; Negro, A, 2017) |
| "Migraine is a common, disabling headache disorder, which is influenced by multiple genes and environmental triggers." | ( Champion, M; Frith, A; Griffiths, LR; Haupt, LM; MacGregor, EA; Plays, A; Stuart, S; Sutherland, HG, 2017) |
| "Migraine is a disabling headache disorder, which affects up to 17% of the female population." | ( Dubey, R; Gantenbein, AR; Imthurn, B; Merki-Feld, GS; Sándor, PS, 2017) |
| "Migraine is a common recurrent neurological disorder combining nausea, vomiting, and hypersensitivities to visual, auditory, olfactory and somatosensory stimuli." | ( Du, X; Hou, TY; Li, GF; Li, J; Liu, FD; Liu, JR; Liu, YS; Lu, H; Qiao, Y; Shi, YH; Su, J; Wang, M; Wu, YL; Yao, Q; Zhang, H; Zhang, J; Zhang, QT; Zhao, R; Zhao, Y; Zhuang, MT, 2017) |
| "Migraine is a brain disorder characterized by a piercing headache which affects one side of the head, located mainly at the temples and in the area around the eye." | ( Gasparini, CF; Griffiths, LR; Smith, RA, 2017) |
| "Migraine is a highly disabling neurovascular primary headache disorder, with its exact pathomechanism being still unrevealed." | ( Nagy-Grocz, G; Petrovics-Balog, A; Szok, D; Tajti, J; Toldi, J; Tuka, B; Vecsei, L, 2017) |
| "Vestibular migraine is a process with significant impact on the quality of life for those afflicted with the disease, with attacks of spontaneous or positional vertigo and migraine symptoms lasting several minutes to 72h." | ( Isildak, H; O'Connell Ferster, AP; Priesol, AJ, 2017) |
| "Vestibular migraine is a challenging disease process to both diagnose and treat." | ( Isildak, H; O'Connell Ferster, AP; Priesol, AJ, 2017) |
| "Migraine is a debilitating neurological disorder where trigeminovascular activation plays a key role." | ( Edvinsson, L; Fülöp, F; Lukács, M; Tajti, J; Toldi, J; Vécsei, L; Warfvinge, K, 2017) |
| "Migraine is a complex nervous system disease characterized by typical throbbing and unilateral headache, which causes severe healthy and social issues worldwide." | ( Bao, Y; Dong, CL; Guo, CR; Hu, WL; Sun, YY; Wang, CZ; Yuan, CS; Zhang, CF; Zhang, WJ; Zhang, XF, 2017) |
| "Migraine is not curable, but preventive treatments are usually used to decrease the intensity and frequency of headache attacks." | ( Ghadikolaei, HS; Kashipazha, D; Siavashi, M, 2017) |
| "Chronic migraine is a common debilitating disease with limited treatment options." | ( Akçali, D; Babacan, A; Belen, AD; Bolay, H, 2017) |
| "Migraine is a recurrent, disabling, complex and highly prevalent neurological disorder." | ( Gunaseelan, V; Lakshmanan, M; Xavier, AS, 2017) |
| "Migraine is a destabilizing neuroinflammatory disorder characterized by recurrent headache attacks." | ( Abdolahi, M; Djalali, M; Eshraghian, MR; Mohammadzadeh Honarvar, N; Okhovat, AA; Sedighiyan, M; Siassi, F; Tafakhori, A; Togha, M, 2017) |
| "Migraine headache is a relatively common, debilitating condition that costs our healthcare system over 78 billion dollars per year." | ( Saluja, HS; Thompson, DF, 2017) |
| "Migraine is a common neurological disorder with a serious impact on quality of life." | ( Cui, CL; Dong, CL; Du, WJ; Hu, WL; Ji, J; Li, F; Sun, YY; Wang, CZ; Wang, L; Wang, X; Yuan, CS; Zhang, CF; Zhang, WJ; Zhang, XF, 2017) |
| "Migraine is included in the top-ten disabling diseases and conditions among the Western populations." | ( Dermitzakis, EV; Kararizou, E; Spingos, KC; Vasiliadis, GG; Vikelis, M; Vlachos, GS, 2017) |
| "Migraine is one of the most common types of pain associated with sterile inflammatory conditions." | ( Kutlu, G; Sirin, B; Yılmaz, M; Yılmaz, N; Yılmaztekin, S, 2017) |
| "Background Migraine is highly prevalent in women (18%)." | ( Bateson, D; Brew, BJ; Garrick, R; McGeechan, K; Merki-Feld, GS; Rofe, CJ; Tomlinson, SE; Warhurst, S, 2018) |
| "Migraine is a common, disabling disorder, and many patients remain dissatisfied with existing treatments." | ( Silberstein, S, 2017) |
| "Migraine is a debilitating condition that affects hundreds of millions of people worldwide." | ( Moye, LS; Pradhan, AAA, 2017) |
| "Migraine is a primary headache disorder." | ( Edvinsson, L; Fulop, F; Lukacs, M; Tajti, J; Toldi, J; Vecsei, L, 2017) |
| "Migraine is among the most disabling disorders worldwide, with a significant therapeutic need." | ( Israel, H; Neeb, L; Raffaelli, B; Reuter, U, 2017) |
| "Background Migraine is a highly prevalent and disabling disorder of the brain with limited therapeutic options, particularly for preventive treatment." | ( Akerman, S; Goadsby, PJ; Martins-Oliveira, M; Zhao, Y, 2018) |
| "Migraine is a common disease with a high morbidity." | ( Chen, N; Song, G; Wang, C; Wu, Q; Yi, L; Zhang, Z; Zou, Q, 2018) |
| "Migraine is the sixth most common cause of disability in the world." | ( Hebestreit, JM; May, A, 2017) |
| "Migraine is affected by fluctuating estrogen levels with evidence to support estrogen 'withdrawal' as a trigger of menstrual attacks of migraine without aura, while high estrogen levels can trigger migraine aura." | ( MacGregor, EA, 2018) |
| "Migraine is a highly prevalent and disabling disorder." | ( Lippi, G; Mattiuzzi, C, 2017) |
| "Migraine is a widespread neurological disease with negative effects on quality of life and productivity." | ( Banga, AK; Eangoor, P; Joyce, JC; Knaack, JS; Nguyen, HX; Prausnitz, MR; Tas, C, 2017) |
| "Migraine is two to three times more prevalent in women than in men, but the mechanisms involved in this gender disparity are still poorly understood." | ( Labastida-Ramírez, A; MaassenVanDenBrink, A; Rubio-Beltrán, E; Villalón, CM, 2019) |
| "Migraine is one of the most common neurological disorders in the general population." | ( Allais, G; Benedetto, C; Chiarle, G; Sinigaglia, S, 2018) |
| "Migraine is a common and disabling primary headache disorder with a significant socioeconomic burden." | ( De Felice, M; Ong, JJY, 2018) |
| "Migraine is an episodic headache, which is an endothelial disorder with neurological inflammation." | ( Abdolahi, M; Djalali, M; Hatami, M; Honarvar, NM; Sarraf, P; Soveyd, N; Tafakhori, A, 2018) |
| "Migraine is a highly disabling primary headache associated with a high socioeconomic burden and a generally high prevalence." | ( Liang, H; Liu, J; Ma, B; Ren, C; Sun, Y; Wang, Y; Yin, Y; Zhou, J, 2018) |
| "The incidence of migraine is higher in women than in men." | ( Chen, C; Diao, X; Li, C; Li, W; Li, Y; Zhang, Y, 2018) |
| "Migraine is prevalent everywhere, and disabling." | ( Herberhold, J; Katsarava, Z; Lampl, C; Mania, M; Steiner, TJ, 2018) |
| "Migraine is a prevalent, disabling type of primary headache disorder associated with a high socioeconomic burden." | ( Liang, H; Liu, J; Ma, B; Ren, C; Sun, Y; Wang, Y; Yin, Y; Zhou, J, 2018) |
| "Migraine is a prevalent neurological disorder, affecting over 16% of adult women and 7% of adult men in the U." | ( Barrow, DA; Faurot, KR; Gaylord, SA; Hibbeln, JR; Johnston, A; Lynch, C; MacIntosh, B; Maiden, K; Mann, JD; Palsson, OS; Ramsden, CE; Suchindran, CM, 2018) |
| "Migraine headaches are a common reason for pediatric emergency department (ED) visits." | ( Fu, R; Hansen, ML; Lin, AL; Meckler, GD; Sheridan, DC, 2018) |
| "Migraine is the third most common disease worldwide; however, the mechanisms underlying migraine headache are still not fully understood." | ( Liu, S; Shu, H; Tang, Y; Tao, F; Xing, Y, 2018) |
| "Menstrual-related migraine is very prevalent, very disabling, yet very easy to manage given a good understanding of its cause." | ( Calhoun, AH, 2018) |
| "Migraine is a common multifactorial and polygenic neurological disabling disorder characterized by a genetic background and associated to environmental, hormonal and food stimulations." | ( Barbanti, P; De Marchis, ML; Della-Morte, D; Ferroni, P; Guadagni, F; Lovero, D; Palmirotta, R; Silvestris, E, 2019) |
| "Migraine is a common, disabling and incapacitating headache disorder that may be triggered by many factors, such as hormones especially during the perimenopausal period, where large alterations in estradiol levels can occur." | ( Gompel, A; Hipolito Rodrigues, MA; Maitrot-Mantelet, L; Plu-Bureau, G, 2018) |
| "Migraine is a disabling and prevalent condition that affects the pediatric and adolescent population." | ( Patterson-Gentile, C; Szperka, CL, 2018) |
| "Migraine is a primary headache disorder characterized by recurrent attacks." | ( Mayans, L; Walling, A, 2018) |
| "Migraine is a common and costly neurological disorder that affects approximately 1 of every 7 people annually." | ( Brown, JN; Gee, ME; Watkins, AK, 2018) |
| "Migraine is highly prevalent in women and, in addition to the pain component, can be associated with significant disability and loss of productivity." | ( Pavlović, JM, 2018) |
| "Migraine is one of the most disabling neurological conditions and associated with high socio-economic costs." | ( Edvinsson, L; Fülöp, F; Lukács, M; Tajti, J; Toldi, J; Vécsei, L, 2019) |
| "Hemiplegic migraine is a rare subtype of migraine that is associated with reversible motor weakness in the aura phase." | ( Bajzik, G; Balogh, G; Csorba, E; Lajtai, A; Nagy, C; Nagy, F; Skobrák, A; Vajda, Z, 2017) |
| "Migraine is the most common neurological disorder and the second most disabling human condition, whose pathogenesis is favored by a combination of genetic, epigenetic, and environmental factors." | ( Aurilia, C; Barbanti, P; Egeo, G; Ferroni, P; Fofi, L; Fratangeli, F; Guadagni, F; Spila, A, 2019) |
| "Migraine is a common disabling neurological disorder which is characterised by a recurring headache associated with a variety of sensory and autonomic symptoms." | ( Cevoli, S; Cortelli, P; Favoni, V, 2019) |
| "Migraine is a disabling neuroinflammatory condition characterized by increasing the levels of interleukin (IL)-6, a proinflammatory cytokine and C-reactive protein (CRP) which considered as a vascular inflammatory mediator, disrupting the integrity of blood-brain barrier and contributing to neurogenic inflammation, and disease progression." | ( Abdolahi, M; Djalali, M; Hatami, M; Honarvar, NM; Jafarieh, A; Javanbakht, MH; Masoudian, Y; Sarraf, P; Sedighiyan, M; Soveyd, N; Tafakhori, A, 2018) |
| "Retinal migraine is an important differential diagnosis of recurrent transient monocular blindness accompanied by headache when other etiologies are excluded." | ( Cha, J; Chung, CS; Kim, ST; Lee, MJ; Park, JH; Park, KA, 2019) |
| "Migraine is a common and burdensome neurological condition which affects mainly female patients during their childbearing years." | ( Dogne, JM; Garcia Burgos, J; Girard, T; Martelletti, P; Straus, S; Vatzaki, E, 2018) |
| "Migraine is a disabling primary headache disorder with unknown exact pathomechanism." | ( Nyári, A; Szok, D; Tajti, J; Vécsei, L, 2018) |
| "Migraine is a highly prevalent neurological pain syndrome, and its management is limited due to side effects posed by current preventive therapies." | ( Jain, S; Silberstein, SD; Spare, N; Yuan, H, 2018) |
| "Migraine is a common disabling neurological condition that is associated with several premonitory symptoms that can occur days before the headache onset." | ( Goadsby, PJ; Holland, PR; Kefel, M; Strother, LC; Vila-Pueyo, M, 2019) |
| "Migraine headache is an enormous health care burden resulting in billions of dollars in workforce revenue lost and millions of lost workdays per year." | ( Cook, CL; Shedd, GC, 2018) |
| "Patients with migraine are more likely to have depression than the general population." | ( Cook, CL; Shedd, GC, 2018) |
| "Migraine is a common problem in pregnancy; however, migraine treatment is challenging in pregnant women for fears of medication teratogenicity and lack of data in this population." | ( Hamilton, KT; Robbins, MS, 2019) |
| "Migraine is a common neurovascular disorder classified by the World Health Organization as one of the most debilitating diseases." | ( Gai, A; Govone, F; Rainero, I; Roveta, F; Rubino, E; Vacca, A, 2019) |
| "Migraine is a common and highly disabling neurological disorder whose acute treatment remains problematic and unsatisfactory in a high percentage of cases." | ( Giamberardino, MA; Martelletti, P, 2019) |
| "Migraine is increasingly recognized as an extremely burdensome and disabling disorder in both children and adolescents." | ( Barbanti, P; Egeo, G; Grazzi, L, 2019) |
| "Migraine is a disabling neurovascular disorder with few targeted, tolerable and effective treatments." | ( Davenport, WJ; Rajapakse, T, 2019) |
| "Migraine is a prevalent, disabling neurological disorder involving the trigeminovascular system." | ( Silberstein, SD; White, CS; Yuan, H, 2019) |
| "Migraine is one of the most severe and debilitating primary headache disorders." | ( Long, R; Zhou, S; Zhu, Y, 2019) |
| "Migraine is a common neuroinflammatory disorder characterized by recurrent attacks of pain." | ( Abdolahi, M; Abdollahi, H; Djalali, M; Jafarieh, A; Salehinia, F; Sarraf, P; Sedighiyan, M; Tafakhori, A; Yousefi, A, 2019) |
| "Migraine is a disease for which there is still no defined pathophysiological etiology and few translational models." | ( Borsook, D; De Icco, R; Demartini, C; Greco, R; Sances, G; Tassorelli, C; Zanaboni, AM, 2019) |
| "These migraines are usually treated with analgesics and resolve after a few months as the device endothelializes." | ( Fernandes, P; Fraisse, A; Magee, A; Michielon, G; Sharma, SR, 2019) |
| "Migraine is a disabling disorder that affects the quality of life of patients." | ( Heidari, M; Karimi, N; Razian, A, 2021) |
| "Migraine is a common, chronic, disabling headache disorder." | ( Cutler, H; Gauld, N; Gumbie, M; Haywood, P; Mumford, V; Parkinson, B, 2019) |
| "Migraine is one of the most prevalent chronic pain manifestations of childhood." | ( Guiducci, M; Ledda, MG; Maltoni, L; Moscano, F; Parisi, P; Raucci, U; Striano, P; Villa, MP; Zoroddu, F, 2019) |
| "Migraine is a prevalent, complex, painful, and disabling neurovascular disorder that places an enormous social and economic burden on patients." | ( Feng, R; Luo, M; Peng, C; Pu, ZH; Xie, XF; Xiong, L; Zhu, H, 2019) |
| "Migraine is a highly prevalent, disabling, and costly disorder worldwide." | ( Namdar, H; Talafi Noghani, M, 2019) |
| "Migraine is a strongly disabling disease characterized by a unilateral throbbing headache lasting for up to 72 h for each individual attack." | ( Edvinsson, L; Haanes, KA, 2019) |
| "Migraine is a debilitating condition; however, the pharmacological effects on central nervous system networks after successful therapy are poorly understood." | ( Barmettler, G; Becerra, L; Bishop, J; Borsook, D; Burstein, R; Chang, PC; Kainz, V, 2019) |
| "Migraine is the most common of all neurological disorders." | ( Martelletti, P; Negro, A, 2019) |
| "Migraine is the most disabling and expensive chronic disorders, the etiology of which is still not fully known." | ( Bertamino, E; Borro, M; Guglielmetti, M; Martelletti, P; Pomes, LM; Simmaco, M, 2019) |
| "Migraine is a disorder affecting an increasing number of subjects." | ( Bramanti, P; Mazzon, E; Tardiolo, G, 2019) |
| "Migraine is a risk factor for ischemic stroke in women of childbearing ages." | ( Alemdar, M; Selekler, HM, 2019) |
| "Migraine is a complex disorder that is characterized by an assortment of neurological and systemic effects." | ( Bertels, Z; Pradhan, AAA, 2019) |
| "Migraine is one of the most disabling and prevalent of all disorders." | ( Al-Karagholi, MA; Ashina, M; Guo, S; Hansen, JM; Olesen, J, 2019) |
| "Pain in migraine is mediated by the release of inflammatory mediators at the level of nerves and blood vessels." | ( Cione, E; Gallelli, L; Guidetti, V; Lochner, P; Michniewicz, A; Siniscalchi, A, 2019) |
| "Migraine is one of the most disabling neurological diseases worldwide; however, the mechanisms underlying migraine headache are still not fully understood and current therapies for such pain are inadequate." | ( Liu, S; Shu, H; Tang, Y; Tao, F; Yanagisawa, L, 2020) |
| "Migraine is a common recurrent headache disorder affecting 14% American adults." | ( Bertisch, SM; Buettner, C; Li, W; Mittleman, MA; Mostofsky, E, 2019) |
| "Chronic migraine is a disabling condition that is currently underdiagnosed and undertreated." | ( Agostoni, EC; Barbanti, P; Calabresi, P; Colombo, B; Cortelli, P; Frediani, F; Geppetti, P; Grazzi, L; Leone, M; Martelletti, P; Pini, LA; Prudenzano, MP; Russo, A; Sarchielli, P; Tedeschi, G, 2019) |
| "Migraine is one of the most common neurological disorder, which has long been related to brain serotonin (5-HT) depletion and neuro-inflammation." | ( Brunetti, L; Cataldi, A; Chiavaroli, A; di Giacomo, V; Di Valerio, V; Ferrante, C; Kindl, M; Leone, S; Menghini, L; Orlando, G; Rapino, M; Recinella, L; Ronci, M; Vladimir-Knežević, S, 2019) |
| "Migraine headache is the cause of an estimated 250,000,000 lost days from work or school every year and is often associated with decreased work productivity." | ( Berardelli, I; Canzonetta, V; De Angelis, V; Erbuto, D; Guglielmetti, M; Lamis, DA; Martelletti, P; Negro, A; Pompili, M; Rogante, E; Sarubbi, S; Sparagna, A, 2019) |
| "Migraines are a debilitating neurological disease affecting as many as 1 of 6 adults in the United States." | ( Dang, T; Ebied, AM; Nguyen, DT, 2020) |
| "Migraine is a complex brain disorder that involves abnormal activation of the trigeminocervical complex (TCC)." | ( Condés-Lara, M; García-Boll, E; González-Hernández, A; Martínez-Lorenzana, G, 2020) |
| "Migraine is one of the most common recurrent types of headache and is the seventh cause of disability." | ( Dolati, S; Mehdizadeh, A; Rikhtegar, R; Yousefi, M, 2020) |
| "Migraine headaches are among the most common and potentially debilitating disorders encountered by primary healthcare providers." | ( Biglione, B; Gitin, A; Gorelick, PB; Hennekens, C, 2020) |
| "Migraines are a common disease with limited treatment options and some dietary factors are recognized to trigger headaches." | ( Blasiak, J; Chojnacki, C; Chojnacki, J; Fila, M, 2019) |
| "Migraine is a primary headache disorder that has been associated with an increased risk of cardiovascular events." | ( Ahdab, R; Aoun Bahous, S; Daaboul, Y; El Khoury, C; Hariri, E; Korjian, S; Mansour, AG; Morrison, DA; Riachi, N; Salem, M, 2020) |
| "Migraine is a disabling neurovascular disorder, which increases risk of cardiovascular events and is a social burden worldwide." | ( Dong, RJ; Gao, MH; Ge, DY; Li, R; Li, YR; Luo, YM; Ma, L; Ren, QJ; Ren, XQ; Song, HR; Tao, XH; Wang, CG; Yang, XQ; Zhang, SJ; Zhou, RR, 2020) |
| "Pediatric migraine is common, accounting for 1% of pediatric emergency department visits." | ( Oakley, CB; Skora, CE; Worden, LT, 2020) |
| "Migraine is a neurovascular disorder involving neurogenic inflammation and transmission of trigeminovascular nociceptive pathways mediated by Calcitonin Gene-Related Peptide (CGRP)." | ( Capi, M; Cipolla, F; Cisale, GY; Curto, M; Lionetto, L; Martelletti, P, 2020) |
| "Migraine is a common, debilitating, primary headache disorder that can cause and be affected by odontalgia." | ( Hatori, K; Hsu, YC; Imamura, Y; Nishihara, C; Noma, N; Ozasa, K; Young, A, 2019) |
| "Migraine is one of the most common neurologic disorders in children and adolescents." | ( Barthel, J; Berde, CB; Gaab, J; Koechlin, H; Kossowsky, J; Lam, TL; Linde, K; Locher, C; Meissner, K; Schwarzer, G, 2020) |
| "Migraine is a very common, multifactorial, and recurrent central nervous system disorder that causes throbbing headache, photophobia, phonophobia, nausea, and disability." | ( Chen, J; Lin, Z; Wang, A; Wang, Q, 2019) |
| "Migraine is recognized as the second leading cause of disability globally." | ( Buchanan, A; Buse, DC; Krege, JH; Lipton, RB; Lombard, L; Loo, LS; Melby, TE; Ruff, DD, 2020) |
| "Migraine is a debilitating condition that affects approximately 16% of adults and is the fifth leading cause of emergency department visits in the United States." | ( Evangelatos, TM; Kangethe, A; Liebler, EJ; Mwamburi, M; Polson, M; Speicher, LC; Staats, PS; Tenaglia, AT, 2020) |
| "Status migrainosus is a condition with limited epidemiological knowledge, and no evidence-based treatment guideline or rational-driven assessment of successful treatment outcome." | ( Ashina, S; Burstein, R; Chua, A; Grosberg, B; Iljazi, A; Melo-Carrillo, A; Rich-Fiondella, R; Veronesi, M, 2020) |
| "Migraine is a highly disabling neurovascular disorder characterized by a severe headache (associated with nausea, photophobia and/or phonophobia), and trigeminovascular system activation involving the release of calcitonin-gene related peptide (CGRP)." | ( de Vries, T; MaassenVanDenBrink, A; Villalón, CM, 2020) |
| "Migraine is the second leading cause of years lived with disability after back pain." | ( Goadsby, PJ; Moreno-Ajona, D; Pérez-Rodríguez, A, 2020) |
| "Acute migraine is associated with significant personal, economic and work-related disability." | ( Akhlaghi, H; Gunasekera, L; Heywood, J; Sanders, L; Sun-Edelstein, C, 2020) |
| "Migraine is an extraordinarily prevalent and disabling headache disorder that affects one billion people worldwide." | ( Bertels, Z; Cippitelli, A; Kieffer, BL; Marcus, JL; Mielke-Maday, HK; Ozawa, A; Pradhan, AA; Rainey, AN; Targowska-Duda, KM; Toll, L; Zribi, G, 2020) |
| "Migraine is characterized by increased oxidative stress and neurogenic inflammation in the brain; therefore, antioxidants may have a migraine preventive effect." | ( Drummond, PD; Lee-Visser, JLA; Visser, EJ, 2020) |
| "Migraine is a complex disorder, involving peripheral and central brain structures, where mechanisms and site of attack initiation are an unresolved puzzle." | ( Ashina, M; Christensen, CE; Hougaard, A; Larsson, HB; Lindberg, U; Paulson, OB; Tolnai, D; Vestergaard, MB; Younis, S, 2021) |
| "Migraines are a broad spectrum of disorders classified by the type of aura with some requiring attentive treatment." | ( Daida, A; Go, S; Ishida, Y; Kashiwagi, Y; Kasuga, A; Kawashima, H; Morichi, S; Morishita, N; Nagao, R; Oana, S; Suganami, Y; Suzuki, S; Takeshita, M; Tomoko, T; Yamanaka, G, 2020) |
| "Migraine is highly prevalent and impacts functional ability substantially." | ( Cotton, S; Jackson, J; Joshi, S; Lombard, L; Nichols, R; Ye, W, 2020) |
| "Migraine is commonly reported among patients with temporomandibular disorders (TMDs), especially myogenic TMD." | ( Bellinger, LL; Bender, SD; Dolan, JC; Kramer, PR; Liu, S; Schmidt, BL; Shu, H; Tang, Y; Tao, F, 2020) |
| "Migraine is a leading cause of disability worldwide, but it is still underdiagnosed and undertreated." | ( Blumenfeld, AM; Clemow, DB; Hake, AM; Hochstetler, HM; Johnson, KW; Ossipov, MH, 2020) |
| "Migraine is one of the most disabling disorders worldwide but the underlying mechanisms are poorly understood." | ( Akopian, AN; Avona, A; Burgos-Vega, C; Dussor, G; Garcia-Martinez, LF; Lackovic, J; Mason, BN; Moldovan Loomis, C; Motina, M; Price, TJ; Quigley, L; Wajahat, N, 2020) |
| "Migraine is a symptomatically heterogeneous disorder." | ( Bose, PR; Goadsby, PJ; Karsan, N; O'Daly, O; Zelaya, FO, 2020) |
| "Pediatric migraine is a common, chronic, and disabling neurological disorder in children and adolescents." | ( Hershey, AD; Kabbouche, M; Maconochie, I; Murphy, B; Qaiser, S; Werner, K, 2020) |
| "Migraine is the primary headache disorder affecting a significant population worldwide." | ( Dhir, A, 2020) |
| "Migraine is an exhausting neuro-inflammatory disorder recognized as recurrent headache attacks." | ( Abdolahi, M; Djalali, M; Hatami, M; Honarvar, NM; Karzar, NH; Soveid, N, 2021) |
| "Migraine is a chronic disorder, and caffeine has been linked with migraine for many years, on the one hand as a trigger, and on the other hand as a cure." | ( Kaźmierczak, W; Nowaczewska, M; Wiciński, M, 2020) |
| "Although migraine is one of the most common primary headaches, its therapy is still limited in many cases." | ( Bohár, Z; Fejes-Szabó, A; Laborc, KF; Nagy-Grócz, G; Párdutz, Á; Spekker, E; Szűcs, M; Vécsei, L, 2020) |
| "Migraine is a neurovascular syndrome associated with a unilateral, throbbing headache accompanied by nausea, vomiting and photo/phonophobia." | ( Naduchamy, KP; Parthasarathy, V, 2021) |
| "Migraine is considered mostly a woman's complaint, even if it affects also men." | ( Airola, G; Allais, G; Benedetto, C; Chiarle, G; Schiapparelli, P; Sinigaglia, S, 2020) |
| "Migraine is characterized by moderate to severe recurrent headache lasting for 4-72 h." | ( Chung, CC; Hong, CT; Huang, YH; Kuan, YC; Tam, KW; Yen, PH, 2021) |
| "Given that migraine is comorbid with mood disorders, depressive and anxious symptoms were evaluated using the Beck Anxiety and Depression Inventories (BDI and BAI), respectively." | ( Bhering Martins, L; Braga Tibaes, JR; Ferreira, AVM; Gomez, RS; Rodrigues, AMDS; Silva de Miranda, A; Teixeira, AL, 2020) |
| "Migraine is a recurrent, primary cause of headache." | ( Aydin, H; Bucak, IH; Geyik, M, 2021) |
| "Chronic migraine is a particular classification of a headache that is typically unilateral and pulsatile and lasts for at least 3 months." | ( An, D; Bahrun, E; Kaye, AD; Lassiter, G; Merley, C; Orhurhu, V; Scoon, L; Urits, I; Viswanath, O; Yilmaz, M, 2020) |
| "Migraine is caused by hyperactivity of the trigeminovascular system, where trigeminal ganglia (TG) play an important role." | ( Chiou, LC; Cook, J; Fan, PC; Knutson, DE; Lai, TH; Lee, MT; Sieghart, W; Tzeng, HR, 2021) |
| "Migraine is a debilitating neurological condition, with a global prevalence rate of 10." | ( He, SD; Ji, XY; Jiang, H; Zhang, FZ; Zhang, H; Zhang, XM; Zong, DD, 2021) |
| "Migraine is highly prevalent and carries a significant personal, social and economic burden." | ( Luzeiro, I; Parreira, E; Pereira Monteiro, JM, 2020) |
| "Migraine is one of the top 5 most prevalent childhood diseases; however, effective treatment strategies for pediatric migraine are limited." | ( Amoozegar, F; Bell, T; Harris, AD; Khaira, A; Noel, M; Stokoe, M; Webb, M, 2021) |
| "Migraines are common upsetting headache disorders characterised by frequent recurrence and attacks aggravated by physical activity." | ( Lu, CC; Lu, YY; Qin, H; Wu, CH; Wu, MK; Zhang, CL, 2022) |
| "Migraine is a typically unilateral disorder in adulthood; however, the reasons for painful lateralization have been little investigated." | ( Brighina, F; Galati, C; La Pegna, GB; Manzo, ML; Nocera, GM; Quatrosi, G; Raieli, V; Reina, F; Vetri, L, 2021) |
| "Migraines are a common form of primary headache, affecting women more than men (17." | ( Berardino, K; Berger, AA; Cornett, EM; Kaneb, A; Kaye, AD; Kaye, AM; Popovsky, D; Urits, I; Viswanath, O; Winnick, A, 2020) |
| "Migraines are a chronic disease for millions worldwide and have been hypothesized to be hormonally mediated due to their higher prevalence in females and menstrual associations." | ( Desai, MN; Janis, JE; Reddy, N; Schneeberger, S; Schoenbrunner, A, 2021) |
| "Migraine is a common disease worldwide and migraine prevention is primarily currently based on pharmaceuticals." | ( Chen, CJ; Chen, YS; Fang, CJ; Hsu, YY; Hu, FW; Hung, YH; Lee, HF; Tsai, CH, 2022) |
| "Migraine is a common, incapacitating neurological condition." | ( Bourke, EM; Greene, SL; Harding, AM; Hodgson, SE; Taylor, DM, 2021) |
| "Migraine is one of the most disabling types of headache." | ( Banerjee, S; Bhattacharjee, M; Haidar, MR; Hossain, MI; Hossain, S; Islam, MS; Karim, MR, 2021) |
| "Migraine is a leading cause of morbidity and disability worldwide." | ( DeJulio, PA; Oswald, JC; Perese, JK; Schuster, NM, 2021) |
| "Lay abstract Migraine is a leading cause of pain and disability worldwide." | ( DeJulio, PA; Oswald, JC; Perese, JK; Schuster, NM, 2021) |
| "Migraine is the sixth most prevalent disease worldwide but the mechanisms that underlie migraine chronicity are poorly understood." | ( Ao, M; Baca, SM; Bertels, Z; Conway, C; Dripps, I; Karumudi, B; Mangutov, E; Petukhov, PA; Petukhova, V; Pradhan, AA; Rasenick, MM; Shah, P; Sheets, Z; Siegersma, K; Singh, H; Tipton, AF; Witkowski, WD, 2021) |
| "Migraines are a common brain disorder that affects 14% of the world’s population." | ( Ao, M; Baca, SM; Bertels, Z; Conway, C; Dripps, I; Karumudi, B; Mangutov, E; Petukhov, PA; Petukhova, V; Pradhan, AA; Rasenick, MM; Shah, P; Sheets, Z; Siegersma, K; Singh, H; Tipton, AF; Witkowski, WD, 2021) |
| "Migraine is a common neurovascular disorder, which is associated with severe to moderate disabling headaches." | ( Alavi Naeini, A; Askari, G; Heidari, Z; Khorvash, F; Rezaei Kelishadi, M, 2021) |
| "Migraine is one of the most common neurological disorders characterized by recurrent attacks of typically throbbing and unilateral headaches, affecting up to 20% of the population worldwide." | ( He, Y; Kashyap, Y; Messing, RO; Shi, Z; Wang, ZJ, 2021) |
| "Abdominal migraine is a variant of migraine headaches characterized by episodic attacks of severe abdominal pain with migrainous features, including anorexia, nausea, vomiting, and pallor." | ( Ho, JL; Monteferrante, NR; Uribe, JS; Wilhelmi, BG, 2021) |
| "Migraine is common and can be associated with significant morbidity, and several treatment options exist for acute therapy." | ( Abd-Rabu, R; Daraz, L; Farah, MH; Halker Singh, RB; Hasan, B; Morrow, AS; Murad, MH; Nayfeh, T; Prokop, LJ; Saadi, S; Shah, S; Torres Roldan, VD; Urtecho, M; VanderPluym, JH; Wang, Z, 2021) |
| "Migraine is a prevalent chronic disease with significant costs to the health care system." | ( Brown, JN; Bryan, WE; Mistry, VM; Morizio, PL; Pepin, MJ, 2021) |
| "Migraine is a common primary headache disorder diagnosed in the emergency department (ED)." | ( Cheng, W; Cortel-LeBlanc, M; Nath, A; Patel, D; Perry, JJ; Viau, JA, 2022) |
| "Migraine is the third most common disease worldwide, leading to severely decreased quality of life for the patients." | ( Fan, G; Guan, J; Li, H; Li, Z; Meng, Q; Sheng, H; Wang, Y; Wu, H; Wu, Y; Zhang, K; Zhang, X, 2021) |
| "Migraine is a common neurovascular disease which has been classified as the sixth most disabling disorder." | ( Chen, K; Deng, K; Jin, C; Wang, T; Wang, Z; Xue, Y; Yi, C; Zhong, W, 2021) |
| "Migraine is a debilitating neurological condition, affecting up to 15% of Americans." | ( Coric, V; Croop, R; Harris, L; Johnston, KM; L'Italien, G; Lipton, RB; Popoff, E; Powell, L; Thiry, A, 2021) |
| "Migraine is ranked as the second highest cause of disability worldwide and the first among women aged 15-49 years." | ( Edvinsson, L; Haanes, KA; Krause, DN; Warfvinge, K, 2021) |
| "Migraine is prevalent during pregnancy." | ( Albrecht, D; Bérard, A; Kori, S; Strom, S; Zhao, JP, 2021) |
| "Migraine is a very painful, disabling and extremely common disorder among the world's adult population, especially women, and it is associated with a variety of comorbidities." | ( Avallone, R; Bellei, E; Bergamini, S; Ferrari, A; Monari, E; Rustichelli, C; Tomasi, A, 2021) |
| "Migraine is a common neurological disease with extremely debilitating, but fully reversible symptoms." | ( Antoszewski, B; Kobus, M; Pełka, J; Rożniecki, J; Sitek, A; Żądzińska, E, 2021) |
| "Migraine is a common comorbidity in patients with epilepsy." | ( Biagio Mercuri, N; Consoli, S; Dainese, F; Dono, F; Fernandes, M; Gaspari, C; Izzi, F; Liguori, C; Pagliuca, M; Placidi, F; Renna, R, 2021) |
| "Migraine is the primary cause of headache in children." | ( Edem, P; Tekin, H, 2022) |
| "Migraine is one of the most complex and prevalent disorders." | ( Akopian, AN; Dussor, GO; Kallianpur, R; Mason, BN; Price, TJ, 2022) |
| "Migraines are neurovascular diseases." | ( Khandelwal, S; Meeta, M; Tanvir, T, 2022) |
| "Migraine is one of the most common neurological disorders associated with recurrent attacks of moderate to severe headache." | ( Faraji, F; Jafary, H; Malekirad, AA; Talaie, A, 2022) |
| "Migraine headache is commonly diagnosed in emergency departments (ED)." | ( Body, R; Chu, KH; Graham, CA; Horner, D; Kamona, S; Karamercan, MA; Keijzers, G; Kelly, AM; Kinnear, FB; Klim, S; Kuan, WS; Laribi, S; Roberts, T; Wijeratne, T, 2022) |
| "Migraine Is Associated With High Risk of Erectile Dysfunction: A Systematic Review and Cumulative Analysis." | ( He, W; Huang, Z; Jiang, J; Liang, H; Yang, Y, 2022) |
| "Migraine is a common neurovascular disorder that has a severe impact on the individual daily life." | ( Dai, Q; Meng, J; Tao, X; Wang, W; Wang, Z; Yan, Z; Zhou, Q, 2022) |
| "Migraine is recognized as a complex neurological disorder that has imposed a social burden." | ( Chitsaz, A; Matin, H; Taghian, F, 2022) |
| "Migraine is a complex disorder that is more than a simple headache." | ( Ariyanfar, S; Ghorbani, Z; Razeghi Jahromi, S; Togha, M, 2022) |
| "Status migrainosus is a disabling complication of migraine, which frequently results in hospitalisation." | ( Chen, Z; Germaine, J; Hutton, EJ; Ramsay, G; Ray, JC, 2022) |
| "Migraine is a complex neurovascular disorder that is one of the leading causes of disability and a reduced quality of life." | ( Kim, B; McKemy, DD; Wei, C, 2022) |
| "Migraine is a major neurological disorder affecting one in nine adults worldwide with a significant impact on health care and socioeconomic systems." | ( De Icco, R; De Matteis, E; Nappi, RE; Sacco, S; Tassorelli, C; Tiranini, L, 2022) |
| "Migraine is a disabling neurovascular disorder characterized by severe pain with still limited efficient treatments." | ( Della Pietra, A; Giniatullin, R; Savinainen, J, 2022) |
| "Migraine is a common brain-disorder that affects 15% of the population." | ( Campolo, M; Casili, G; Cuzzocrea, S; Esposito, E; Filippone, A; Giuffrè, L; Lanza, M; Paterniti, I; Scuderi, SA, 2022) |
| "As migraine is an underlying primary headache, the use of calcitonin gene-related peptide antibodies should be considered." | ( Nagata, E, 2022) |
| "Migraine is common in the workforce." | ( Burton, WN; Hines, D; Schultz, AB; Shepherd, ME, 2022) |
| "Migraine is known to be more prevalent, frequent, and disabling in women." | ( Ahmad, SR; Rosendale, N, 2022) |
| "Migraine is a complex neurological disorder with a high disability rate." | ( Hu, D; Li, S; Ma, Y; Wei, L; Xiao, F; Ye, S; Zeng, Y, 2022) |
| "Migraine is a disabling neurogenic disorder characterized by recurrent headache attacks." | ( Abdolahi, M; Alvandi, E; Athar, SS; Djalali, M; Jafari, E; Sedighiyan, M; Yekaninejad, MS, 2023) |
| "Migraine is common in primary headaches, and with the development of social economy and the increase in living pressure, the prevalence of migraine has an upward trend." | ( Chen, J; Zhang, K; Zhu, J, 2022) |
| "Migraine is a headache disorder associated with a high socioeconomic burden." | ( Evers, S; Gaul, C; Gendolla, A; Klein, D; Kühn, G; Lelleck, VV; Schröder, T; Schulz, F; Sina, C; Thaçi, D; Witt, O, 2022) |
| "Migraine is related to brain energy deficiency." | ( Chen, C; Dong, Z; Liu, H; Wang, L; Yu, S, 2022) |
| "Globally, migraine is a leading cause of disability with a huge impact on both the work and private life of affected persons." | ( Christensen, SL; Clement, A; Guo, S; Jansen-Olesen, I, 2022) |
| "Migraine is a chronic disease of global concern, regardless of socio-economic and cultural background." | ( Cegielska, J; Domitrz, I; Zduńska, A, 2022) |
| "Migraine is a common, neurovascular headache disorder with a complex molecular interplay." | ( Al-Karagholi, MA; Ashina, M; Hakbilen, CC, 2022) |
| "Severe headache and migraine are common and disabling neurological disorders worldwide." | ( Guo, Y; Li, D; Xia, M; Zang, W; Zhang, J, 2022) |
| "Migraine is a complex neurovascular disorder characterized by recurrent attacks of pain and other associated symptoms." | ( Demartini, C; Francavilla, M; Greco, R; Tassorelli, C; Zanaboni, AM, 2022) |
| "Migraine is a debilitating disorder with limited pharmacological options." | ( Bernstein, CA; Connor, JP; Lazaridou, A; Paschali, M; Rist, PM; Rozenkrantz, L; Vilsmark, ES; Wayne, PM, 2022) |
| "Chronic migraine is a common and highly disabling disorder." | ( Li, Z; Liu, X; Ren, X; Wang, W; Wang, Y; Wu, S; Zhang, K; Zhu, C, 2022) |
| "Vestibular migraine is in the process of recognition as an individual clinical entity." | ( Hamilton, L; Kontorinis, G; Slim, M; Yiannakis, C, 2023) |
| "Vestibular migraine is in the process of recognition as an individual clinical entity." | ( Hamilton, L; Kontorinis, G; Slim, M; Yiannakis, C, 2023) |
| "Migraine is a common disabling disease with a complex pathophysiology." | ( Al-Karagholi, MA; Ashina, M; Elbahi, FA; Thuraiaiyah, J; Zhuang, ZA, 2023) |
| "Migraine is a common neuronal disorder characterized by recurrent episodes of headache associated with a higher prevalence in women than men." | ( Basilotta, R; Bova, V; Casili, G; Esposito, E; Filippone, A; Lanza, M; Paterniti, I; Scuderi, SA, 2022) |
| "Migraine is a neurovascular disorder and is clinically characterized by episodic attacks of mild to severe headaches." | ( Jasrotia, R; Kumar, P; Kumar, S; Mahajan, K; Maharana, C; Panjalia, RK; Raina, JK; Sudershan, A, 2023) |
| "Migraine is a neurovascular disorder and is clinically characterized by episodic attacks of mild to severe headaches." | ( Jasrotia, R; Kumar, P; Kumar, S; Mahajan, K; Maharana, C; Panjalia, RK; Raina, JK; Sudershan, A, 2023) |
| "Migraine is a neurovascular disorder and is clinically characterized by episodic attacks of mild to severe headaches." | ( Jasrotia, R; Kumar, P; Kumar, S; Mahajan, K; Maharana, C; Panjalia, RK; Raina, JK; Sudershan, A, 2023) |
| "Migraine is a complex neurovascular disorder, which causes intense socioeconomic problems worldwide." | ( Körtési, T; Spekker, E; Vécsei, L, 2022) |
| "Migraine is a complex neurovascular disorder, which causes intense socioeconomic problems worldwide." | ( Körtési, T; Spekker, E; Vécsei, L, 2022) |
| "Migraine is common among females of reproductive age (estimated prevalence:17-24%) and may be associated with reproductive health through underlying central nervous system excitability, autoimmune conditions, and autonomic dysfunction." | ( Crowe, HM; Hatch, EE; Jick, SS; Mikkelsen, EM; Rothman, KJ; Sørensen, HT; Wesselink, AK; Wise, LA, 2022) |
| "Migraine is a disorder that is prevalent worldwide." | ( Heo, I; Hwang, EH; Hwang, MS; Kim, CY; Park, SY; Shin, BC, 2022) |
| "Migraine is a major health burden worldwide with complex pathophysiology and multifarious underlying mechanisms." | ( Giniatullin, R; Nistri, A, 2023) |
| "Although migraine is one of the most common chronic diseases and is the subject of numerous studies, there is still a considerable proportion of patients who are not satisfied with their acute treatment." | ( Fumal, A; Timmermans, G, 2023) |
| "Migraine is a devitalizing neurovascular disorder that affects millions of people worldwide." | ( Anwar, S; Irshad, N; Khan, AU, 2023) |
| "Migraine is a debilitating disorder affecting females more frequently than males." | ( Borończyk, A; Borończyk, M; Czarnacki, K; Paprocka, J; Podkowa, K, 2023) |
| "Migraine is a severe neurovascular disorder of which the pathophysiology is not yet fully understood." | ( Aktürk, T; Al-Hassany, L; Börner, C; Cernigliaro, F; de Vries, T; Kodounis, M; Lo Cascio, S; Maassen Van Den Brink, A; Messlinger, K; Mikolajek, D; Onan, D; Ragaglini, C; Ratti, S; Rivera-Mancilla, E; Szewczyk, AK; Tsanoula, S; Ulutas, S; Villino, R, 2023) |
| "Migraine is one of the world's most prevalent and disabling diseases." | ( Cheng, H; Guan, X; He, J; Huang, P; Li, K; Liu, K; Luo, X; Wu, X; Xu, X; Zeng, Q; Zhang, M; Zhao, F; Zhou, M, 2023) |
| "Migraine is a recurrent primary headache disorder with moderate to severe disability; however, the pathophysiology is not fully understood." | ( Lin, Q; Peng, YB; Wang, Z, 2023) |
| "Migraine is one of the most disabling diseases with a significant socioeconomic impact." | ( Kikui, S; Takeshima, T, 2023) |
| "Migraine is a highly disabling health burden with multiple symptoms; however, it remains undertreated because of an inadequate understanding of its neural mechanisms." | ( Dong, Z; Gong, Z; Han, X; Li, B; Miao, S; Wang, L; Wang, T; Xie, W; Yang, C; Yu, S; Zhang, X, 2023) |
| "Migraine is three times more prevalent in women than men, linked to circulating female hormones." | ( Ayata, C; Harriott, AM; Kudo, C; Moskowitz, MA; Waeber, C, 2023) |
| "Migraines are a considerable social problem and economic burden worldwide." | ( He, W; Wang, Y; Zhang, Y; Zhou, J, 2023) |
| "Migraine is a debilitating disorder, and while the introduction of monoclonal antibodies (mAbs) has led to efficacious and tolerable responses, a substantial number of patients are so-called "non-responders"." | ( Al-Hassany, L; Goadsby, PJ; Karsan, N; Lampl, C; MaassenVanDenBrink, A, 2023) |
| "Migraine is a highly prevalent, disabling neurological disorder that is also associated with gastrointestinal symptoms, autonomic dysfunction and allodynia." | ( Aurora, SK; Mallick-Searle, T; Shrewsbury, SB; Starling, AJ, 2023) |
| "Migraine is a very common headache disorder that often presents with pain and gastrointestinal symptoms." | ( Aurora, SK; Mallick-Searle, T; Shrewsbury, SB; Starling, AJ, 2023) |
| "Migraine is the third most common disease in the world with an estimated prevalence of 14." | ( Dosemane, D; Ebenezer, A; Islam, FN; Khadilkar, MN; Kumar, K, 2023) |
| "Migraine is a disabling and chronic neurovascular headache disorder." | ( Al-Hassany, L; Amin, FM; Boucherie, DM; Chen, HZ; Creeney, H; Farham, F; Favaretto, S; Gollion, C; Grangeon, L; Lyons, H; Marschollek, K; Onan, D; Pensato, U; Stanyer, E; van Drie, RWA; Waliszewska-Prosół, M; Wiels, W, 2023) |
| "Migraine is among the most common and debilitating neurological disorders typically affecting people of working age." | ( Asher, JM; Hibbard, PB; O'Hare, L; Romei, V; Tarasi, L, 2023) |
| "Menstrual migraine is a subtype of migraine disease that is typically more disabling, longer-lasting, and more challenging to treat." | ( Qi, JZ; Zhang, H; Zhang, ZH, 2023) |
| "Migraine is a common neurological disorder that is present in a large proportion of the global population." | ( Anderson, CC; VanderPluym, JH, 2023) |
| "Migraine is a leading cause of disability in young adults." | ( Beech, EL; Crewther, SG; Murphy, MJ; Riddell, N, 2023) |
| "Migraine is more prevalent in females, raising the possibility that sex and gonadal hormones modulate migraine." | ( Appiah-Danquah, V; Ayata, C; Berhanu, L; Harriott, AM; Morais, A; Waruinge, A, 2023) |
| "Migraine is a common, polygenic disorder that is characterized by moderate to severe headache attacks." | ( Cohen, AS; Demharter, S; Ernst, M; Falkenberg, K; Hansen, TF; Kogelman, LJA; Olesen, J; Ottosson, F; Russo, F; Stentoft-Hansen, V; Tfelt-Hansen, P, 2023) |
| "Migraine is a disabling neurovascular disease that imposes an enormous burden on both individuals and society." | ( Wang, Y; Xiao, Z; Yang, L; Zhang, L; Zhang, Y; Zhou, Y, 2023) |
| "Migraine is a debilitating neurological condition affecting millions of people worldwide." | ( Geppetti, P; Iannone, LF; Orologio, I; Russo, A; Silvestro, M; Tedeschi, G; Tessitore, A, 2023) |
| "Migraine is a complex neurological disorder that affects millions of people worldwide." | ( Bongsebandhu-Phubhakdi, S; Ha-Ji-A-Sa, N; Thanprasertsuk, S; Vongseenin, S, 2023) |
| "Migraine is a prevalent and disabling neurological disorder affecting a significant proportion of the global population." | ( Heo, I; Hwang, EH; Hwang, MS; Kim, CY; Park, SY; Shin, BC, 2023) |
| "Migraine is the second world's cause of disability." | ( Armani, A; Aurilia, C; Barbanti, P; Camajani, E; Caprio, M; Egeo, G; Feraco, A; Fiorentini, G; Gorini, S; Mammi, C; Marzolla, V; Moriconi, E; Proietti, S; Tomino, C; Vitiello, L, 2023) |
| "Migraine is a progressive neurological condition often accompanied by nausea and vomiting." | ( Alharbi, HM; Almari, AH; Batool, S; Din, FU; Fatease, AA; Lahiq, AA; Shafique, U; Sohail, S, 2023) |
| "Migraine is a common headache syndrome associated with various other comorbidities." | ( Cyriac, M; Dev, P; Favas, TT; Jaiswal, R; Mishra, VN; Pathak, A, 2023) |
| "Migraine is a neurovascular disorder that can be debilitating for individuals and society." | ( Körtési, T; Szabó, Á; Szok, D; Tajti, J; Tanaka, M; Vécsei, L, 2023) |
| "Migraine is the world's second most common disabling disorder, affecting 15% of UK adults and costing the UK over £1." | ( Duncan, C; Madan, J; Matharu, M; Mistry, H; Naghdi, S; Underwood, M, 2023) |
| Excerpt | Reference |
|---|
| "The concept that migraine results from an initial vasoconstriction due to increased release of noradrenaline from the sympathetic nerves to cranial blood vessels has been reappraised in the light of recently acquired knowledge of the mechanisms of action of drugs used in the treatment of migraine, physiological and pharmacological evidence implicating noradrenaline, and the observations by others that several migraine variants may be associated with some degree of sympathetic overactivity." | ( Johnson, ES, 1978) |
| "Attacks of migraine were terminated in the incipient stage by treatment with 0." | ( Staehelin, A, 1977) |
| "Severe migraine attacks in 47 patients who were unresponsive to clonidine hydrochloride were treated with 1." | ( Peet, KM, 1977) |
| "Patients having one or more attacks of migraine a week may need prophylactic treatment." | ( Wilkinson, M, 1976) |
| "Twenty-six patients with migraine attacks were treated for 3 to 16 months with flufenamic acid (125 mg four to six times per attack), an inhibitor of prostaglandin synthesis and action." | ( Lindner, HR; Rabey, IM; Schwartz, A; Streifler, M; Vardi, Y; Zor, U, 1976) |
| "26 untreated migraineurs and 19 migraineurs with history of self-medication with aspirin taken within 72 hours of the test, were studied in headache-free intervals." | ( Deshmukh, SV; Meyer, JS; Mouche, RJ, 1976) |
| "When considering treatment for migraine patient, the physician should bear in mind how little is known about this remarkably complex and diverse condition with no miracle cure or single uniform method of treatment." | ( Bousser, MG; Massiou, H, 1992) |
| "Other migraine symptoms were also more effectively treated by sumatriptan than by placebo." | ( Bayliss, EM; Ferrari, MD; Ludlow, S; Pilgrim, AJ; Visser, WH, 1992) |
| "Patients with migraine with aura treated each of six acute attacks with either nifedipine or vehicle administered in double-blind, randomized form." | ( Hoffert, MJ; Kanter, R; Scholz, MJ, 1992) |
| "Many patients with severe migraine remain refractory to the current treatment regimens or cannot tolerate the side effects." | ( Adly, C; Chesson, A; Straumanis, J, 1992) |
| "Forty-six patients with acute migraine attacks were treated with intramuscular injection of 75 mg diclofenac sodium, and another group of forty patients with intramuscular injection of paracetamol." | ( Chrisikos, N; Fotiadou, A; Karabetsos, A; Karachalios, GN; Kehagioglou, K, 1992) |
| "Exertional migraine, benign orgasmic cephalalgia, chronic paroxysmal hemicrania, cough headache, and "ice-pick" headache are treated with indomethacin." | ( Schulman, EA; Silberstein, SD, 1992) |
| "The drugs used in migraine therapy can be divided into two groups: agents that abort an established migraine attack and agents used prophylactically to reduce the number of migraine attacks." | ( Den Boer, MO; Saxena, PR, 1991) |
| "In an open pilot study 7 migraine attacks were treated in 6 patients." | ( Clifford Rose, F; Couturier, EG; Foster, CA; Hering, R; Steiner, TJ, 1991) |
| "Patients treated up to three migraine attacks at home over a 3-month period and recorded the results on a diary card." | ( , 1991) |
| "A similar number of patients reported migraine recurrence, within 24 h in both treatment groups." | ( , 1991) |
| "Pre-treatment with the antimigraine drugs dihydroergotamine and sumatriptan, two drugs that bind with high affinity to 5-HT1B/1D receptors, markedly attenuated plasma protein extravasation induced by electrical trigeminal ganglion stimulation." | ( Buzzi, MG; Moskowitz, MA, 1991) |
| "The usual drugs for migraine attacks carry risks of increased frequency, resistance to other treatment, drug dependency, and abuse." | ( Isler, H, 1991) |
| "Apart from the treatment of migraine attacks, prophylaxis may be required when certain criteria of frequency, duration, or severity are met." | ( Oestreich, W; Schmidt, R, 1991) |
| "A minimum of three migraine attacks were treated during each treatment period." | ( Banerjee, M; Findley, L, 1991) |
| "The response to prophylactic anti-migraine medication (propranolol or amitriptyline used alone or in combination) was gratifying, with 21 of 30 adequately treated patients (70%) reporting dramatic reduction in the frequency and severity of their headaches." | ( Goldberg, J; Stern, BJ; Weiss, HD, 1991) |
| "A milestone in migraine (M) treatment was the discovery of the dramatic analgesic action of a nonanalgesic drug, ergotamine." | ( Nicolodi, M; Sicuteri, F, 1991) |
| "The modal migraine sufferer treated in these studies was a female, about 37 years of age, who suffered from common (rather than classical) migraines and reported a 17-year history of problem migraines." | ( Cordingley, GE; Holroyd, KA; Penzien, DB, 1991) |
| "Patients presenting to the ED with migraine requiring parenteral treatment." | ( Allen, CL; Arthur, DC; McClellan, DS; Olshaker, JS; Tek, DS, 1990) |
| "The nystagmus resolved when her classic migraine headaches were controlled with medical therapy." | ( Jay, WM; Nazarian, SM, 1990) |
| "Ten selected patients documented their migraine attacks over a 2-month period of open treatment with ICI 169,369, 30 mg orally, for acute therapy." | ( Davies, PT; Steiner, TJ, 1990) |
| "The infants with ophthalmoplegic migraine failed to completely respond to any therapy." | ( Elser, JM; Woody, RC, 1990) |
| "Patients with vascular headaches of the migraine type who regularly experienced nervous tension and some form of gastrointestinal distress with their headaches were randomized to one of five treatment groups." | ( Di Serio, FJ; Friedman, AP; Hwang, DS, 1989) |
| "In the treatment of migraine demonstrated to date, the impressive effectiveness of GR43175 must reinforce the evidence in favour of an important vascular component being involved in the aetiology of the disease." | ( Connor, HE; Feniuk, W; Humphrey, PP; Oxford, AW; Perren, MJ, 1989) |
| "Patients with severe attacks of migraine have attended special pain or headache clinics for treatment and assessment." | ( Brand, J; Doenicke, A; Färkkilä, M; Goasguen, J; Perrin, VL; Tfelt-Hansen, P, 1989) |
| "In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist." | ( Brand, J; Dano, P; Doenicke, A; Findley, LJ; Iversen, HK; Melchart, D; Sahlender, HM; Tfelt-Hansen, P, 1989) |
| "Twenty-four patients with classic migraine attacks were treated with either nifedipine or placebo for up to 12 weeks." | ( Marek, K; McArthur, J; McArthur, JC; Peroutka, SJ; Pestronk, A, 1989) |
| "Moreover migraine headache is precipitated by intramuscular injection of reserpine, which releases 5-HT from body stores, is relieved by the intravenous infusion of serotonin, and is prevented by the regular administration of medications that act on 5-HT receptors." | ( Goadsby, PJ; Lambert, GA; Lance, JW; Zagami, AS, 1989) |
| "As many menstrual migraine headaches are refractory to abortive therapy, prophylactic therapy is often needed." | ( Gallagher, RM, 1989) |
| "When the diagnosis of migraine was considered, four patients improved on propranolol therapy; one failed this therapy but responded to verapamil." | ( James, HE; Nowak, TP, 1989) |
| "The number of attacks of migraine was significantly reduced after the 3-month treatment with Ep resp." | ( Bühling, M; Cruz, A; Seibel, K, 1985) |
| "The treatment of migraine includes the avoidance of precipitating factors when possible, psychological counselling and relaxation training." | ( Lance, JW, 1986) |
| "Treatment of migraine attacks and prophylactic treatment of migraine are each discussed under the four headings: patient selection, trial design, evaluation of results and statistics." | ( Olesen, J; Tfelt-Hansen, P, 1985) |
| "Thirty-three patients with common migraine underwent contingent negative variation (CNV) recordings before receiving prophylactic beta-blocker treatment with either metoprolol (27 patients) or propranolol (6 patients) at mean daily dosages of 110 mg and 122 mg, respectively." | ( Maertens de Noordhout, A; Schoenen, J; Timsit, M; Timsit-Berthier, M, 1986) |
| "The prophylactic treatment of migraine with beta blockers is at present well established, and non-selective as well as beta 1-selective beta blockers exert an effect." | ( Hedman, C; Winther, K, 1986) |
| "Recent advances in migraine therapy include the recognition of analgesic or ergotamine abuse as a cause of chronic daily migraine, the introduction of effective non-narcotic drugs such as chlorpromazine, dihydroergotamine and corticosteroids for the treatment of intractable migraine attacks, the increased number of beta-blockers now recognized as effective prophylactic agents and the introduction of calcium-channel blockers for prophylaxis." | ( Edmeads, JG, 1988) |
| "22 patients with severe migraine resistant to previous prophylactic treatments participated in a prospective open trial of valproate in migraine prophylaxis; 17 had common and 5 classic migraine." | ( Sørensen, KV, 1988) |
| "In fourteen untreated migraine patients with a mean age of 40 years platelet sensitivity to 5HT, EN and ADP was investigated during the prodromal phase (three patients), 12-48 h after headache (three patients) and during the headache-free period (eight patients)." | ( Fazekas, F; Lechner, H; Ott, E; Pilger, E, 1985) |
| "In control subjects without history of migraine, reserpine did not induce headache, and, furthermore, PET measurements 1 1/2 hours after drug administration consistently showed a global increase in RCMRGlu over resting values similar to that observed in a normal control (rest-rest) group not receiving reserpine." | ( Christman, DR; Russell, JA; Sachs, H; Wolf, A, 1986) |
| "One hundred and twenty-four migraineurs were treated randomly with 5-hydroxytryptophan (5-HTP) or with methysergide (M)." | ( Alom, J; Codina, A; Dávalos, A; Titus, F, 1986) |
| "In subarachnoid hemorrhage and migraine calcium antagonists are used to prevent and treat ischemia." | ( Hartmann, A, 1986) |
| "pharmacological) treatment for migraine headache has led to the development of numerous non-medical interventions (e." | ( Litt, MD, 1986) |
| "Benefits of migraine therapy include improvements in the patient's overall health and sense of well-being." | ( Gunderson, CH, 1986) |
| "Fifty migraine patients were tested prior to and after a three-month period of flunarizine treatment (10 mg per day) by means of a new computerized telethermography apparatus." | ( Gallo, MF; Giacovazzo, M; Martelletti, P; Romiti, A; Valducci, G; Valducci, M, 1985) |
| "We confirm flunarizine effectiveness in migraine treatment." | ( Boiardi, A; Bussone, G; Cocchini, F; Frediani, F; La Mantia, L; Sinatra, MG, 1985) |
| "Forty-two migraineurs with interval headache (MIH) were treated with flunarizine in a 6-month open trial, while indoprofen was administered to 23 patients with MIH and 7 with chronic tension headache (CTH) in a 2-month, double-blind, cross-over placebo-controlled study." | ( Cavallini, A; Gabellini, S; Mancuso, A; Micieli, G; Pacchetti, C; Piazza, D; Sinforiani, E; Trucco, M, 1985) |
| "The total number of the migraine attacks in a group of 14 patients on opipramol (as compared with the same patients during a pretreatment period of six weeks) showed a 33% reduction in the number of attacks experienced during the first six weeks." | ( Jacobs, H, 1972) |
| "It is concluded that retinal migraines occurring during oral contraceptive treatment must be considered as a warning sign, that may precede the onset of serious and irreversible disorders." | ( Jamotton, L; Michiels, J, 1972) |
| "Two patients being treated for migraine with methysergide developed extensive pleural fibrosis, and in addition one of them had bilateral pleural effusions, After treatment was stopped these complications, which are thought to have been due to the drug, cleared in the next few months." | ( Hindle, W; Posner, E; Sweetnam, MT; Tan, RS, 1970) |
| "Foods which provoked migraine in 9 patients with severe migraine refractory to drug therapy were identified." | ( Brostoff, J; Carini, C; Monro, J, 1984) |
| "Among 1,036 patients treated for migraine headache between 1973 and 1980, 865 were given a daily maximum dose of 320 mg of propranolol, while 171 served as differently treated controls." | ( Rosen, JA, 1983) |
| "Forty ambulant migraine patients were supplied with oral medication for six consecutive attacks; metoclopramide 10 mg was administered in all attacks, and paracetamol 500 mg and mefenamic acid 500 mg for three attacks each." | ( Peatfield, RC; Petty, RG; Rose, FC, 1983) |
| "Ten of the 12 patients had fewer migraines during verapamil therapy." | ( Solomon, GD; Spaccavento, LJ; Steel, JG, 1983) |
| "The main treatment of the acute migraine attack remains sleep, sedation, an anti-nauseant and analgesics, and in some patients 1 or 2 mg of ergotamine tartrate." | ( Wilkinson, M, 1983) |
| "Fifteen migraine patients were administered 2 mg ergotamine tartrate in a partial cross-over design as a single, oral tablet, rectal suppository and rectal solution." | ( Ibraheem, JJ; Paalzow, L; Tfelt-Hansen, P, 1983) |
| "The effects of flunarizine in migraine headache were investigated in 40 patients treated with single 10 mg evening doses for 16 weeks." | ( Magri, M; Micieli, G; Pacchetti, C; Piazza, D; Sances, G; Trucco, M, 1984) |
| "A basilar migraine with alexia without agraphia and episodes of dysmnesia was treated with naloxone." | ( Antoine, JC; Laurent, B; Michel, D; Montagnon, D, 1984) |
| "A group of 40 patients suffering from migraine underwent dihydroergotamine-retard therapy for a period of five months after a 30-day pre-treatment period." | ( Iaccarino, C; Mastrosimone, F, 1983) |
| "30 patients affected by migraine were studied; naloxone was administered acutely (2 mg e." | ( Albano, O; Attolini, E; Brucoli, C; Campanozzi, F; Centonze, V; Macinagrossa, G; Santoiemma, L, 1983) |
| "Three days after initiation of migraine headache therapy with ergotamine tartrate and propranolol, severe acute arterial insufficiency of the lower extremities developed in a 48-year-old woman who had been in general good health." | ( Greenberg, DJ; Hallett, JW, 1982) |
| "Drugs useful in treating migraine headache may mimic 5-HT at synapses in the trigeminal nucleus that are associated with projections from the MPR." | ( Haigler, HJ, 1982) |
| "Two pregnant patients with a history of migraine each developed evidence of cerebral ischemia while being treated with subcutaneous terbutaline, for asthma in one case and for tocolysis in the other." | ( Benedetti, TJ; Featherstone, HJ; Rosene, KA, 1982) |
| "In the 19 migraine patients the mean value of SPA in the second month of treatment showed a 48% reduction when compared with the mean value of SPA prior to treatment." | ( Mazal, S; Rachmilewitz, EA, 1980) |
| "One hundred and fifty patients with migraine attacks attending the Copenhagen acute migraine clinic were treated either with metoclopramide 10 mg i." | ( Aebelholt-Krabbe, A; Melgaard, B; Olesen, J; Tfelt-Hansen, P; Veilis, B, 1980) |
| "In an acute migraine clinic, patients were all treated with metoclopramide 10 mg i." | ( Olesen, J; Tfelt-Hansen, P, 1980) |
| "The incidence of the migraine-attacks decreased in both groups to an average of less than 6 to less than 1 per month, most of the (first) intervals of freedom from attacks lasted 1/2-3/4 of a year and extended to 1 year and more if the treatment was continued; about no more nausea and/or vomiting was reported." | ( Harder, HJ, 1981) |
| "Identification of migraine triggers is an extremely important part of migraine therapy." | ( Dworak, N; Nater, B; Regli, F, 1995) |
| "Aspirin is commonly used to treat migraine attacks, although sumatriptan, a much more expensive treatment, is also effective." | ( Chazot, G; Henry, P; Mulder, LJ; Scheldewaert, RG; Schoenen, J; Tfelt-Hansen, P, 1995) |
| "Twenty migraine patients received pretreatment with placebo or the histamine-H1-receptor antagonist, mepyramine, in a randomized, double blind fashion, followed in both groups by i." | ( Lassen, LH; Olesen, J; Thomsen, LL, 1995) |
| "Seventeen patients with migraine headaches, occurring at least twice a month, were successfully treated with an ACE inhibitor for prophylaxis." | ( Bender, WI, 1995) |
| "Patients (n = 667) treated up to three migraine attacks in a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial." | ( Alderton, CJ; Cutler, NR; Davis, RL; Ferrari, MD; Paulsgrove, LA; Rapoport, AM; Visser, WH, 1995) |
| "Fourteen children with abdominal migraine were treated with pizotifen and placebo in a double blind crossover trial." | ( Russell, G; Symon, DN, 1995) |
| "In a noncontrolled study, 23 migraine headache patients were treated with intranasal instillation of 0." | ( Kudrow, DB; Kudrow, L; Sandweiss, JH, 1995) |
| "During the treatment phase, the mean migraine headache frequency per 4 weeks was 3." | ( Deaton, RL; Markley, HG; Mathew, NT; Rankin, L; Rapoport, AM; Saper, JR; Silber, CJ; Silberstein, SD; Solomon, S, 1995) |
| "The medical treatment of migraine has two objective points: therapy for treating symptoms of an acute attack and prophylactic therapy for reducing frequency and severity of migraine attacks." | ( Marterer, A; Wessely, P, 1995) |
| "The management of migraine usually centers on two approaches: preventive and abortive therapy." | ( Baumel, B, 1994) |
| "Most of these patients had prolonged migraines that had resisted other forms of abortive therapy." | ( Saadah, HA, 1994) |
| "Twenty-nine patients with migraine headache who had failed to obtain relief with conventional therapy were trained to self-administer intramuscular DHE." | ( Blumenthal, HJ; el-Raheb, M; Weisz, MA, 1994) |
| "Eleven migraine patients, treated with flunarizine, 10 mg per day, underwent single photon emission computer tomography (SPECT) using [123I] labeled iodobenzamide, a ligand with high affinity and high specificity for D2 receptors." | ( Asenbaum, S; Brücke, T; Podreka, I; Wessely, P; Wöber, C; Wöber-Bingöl, C, 1994) |
| "The patients had to treat two migraine attacks with LAS-MCP (1620 mg lysine acetylsalicylate--the equivalent of 900 mg aspirin--combined with 10 mg metoclopramide) or placebo." | ( Bousser, MG; Chabriat, H; Danchot, J; Grippon, P; Joire, JE, 1994) |
| "In treating migraine the first and most important thing is to get the correct diagnosis which depends on the history and the absence of abnormal physical signs." | ( Wilkinson, M, 1994) |
| "Current treatment of migraine either abortive or prophylactic is often unsatisfactory." | ( Bánk, J, 1994) |
| "Optimal migraine therapy begins with an accurate diagnosis and knowledge of the symptoms that the patient finds most disturbing." | ( Lipton, RB; Silberstein, SD, 1994) |
| "The original migraine therapy, ergotamine, is highly effective in its rectal suppository formulation, when used at a subnauseating dosage." | ( Raskin, NH, 1994) |
| "Both drugs significantly reduced migraine attacks as judged from the reduction in the efficacy parameters (migraine hours, migraine days, and migraine intensity) in the treatment periods compared with the run-in period." | ( Borg, L; Hansen, PE; Holt Larsen, B; Kjaersgård Rasmussen, MJ; Soelberg Sørensen, P, 1994) |
| "Sumatriptan is a new anti-migraine drug which has been shown in clinical studies to be efficacious in up to 80% of attacks treated." | ( Midelfart, E; Winnem, M, 1994) |
| "Treatment with sumatriptan during the migraine attack was accompanied by a significant increase in the duration of ES2 (p < or = 0." | ( Dworschak, M; Ensink, FB; Göbel, H; Heuss, D; Krapat, S; Soyka, D, 1994) |
| "A patient suffering from migraine, whose symptoms were abolished by warfarin therapy, is reported." | ( Coupe, MO; Neal, D; Suresh, CG, 1994) |
| "In 20 patients with pure menstrual migraine either Estraderm TTS 50 patches (E) or placebo (P) patches were applied during three successive menstrual cycles, randomly allocated to the treatment sequences E-P-E or P-E-P." | ( Pfeil, JP; Rijnierse, JJ; Smits, MG; van der Meer, YG; Vos, AJ, 1994) |
| "Other migraine symptoms (nausea, vomiting, photo- and phonophobia) were effectively treated with sumatriptan." | ( Bulcke, J; Caekebeke, J; De Keyser, J; Dehaene, I; Hildebrand, G; Joffroy, A; Laloux, P; Louis, P; Monseu, G; Schoenen, J, 1994) |
| "A group of 26 common migraine patients and a group of 14 tension headache patients were treated by electromyographic biofeedback (EMG-BFB); blood samples were collected during the treatment (1st session; pre and post 10th session) and plasma catecholamines and cortisol measured to determine basal levels and changes induced by the behavioral therapy." | ( Bussone, G; Grazzi, L, 1993) |
| "Successful treatment of migraine requires that the physician understand the pathophysiology underlying migraine and educate the migraineur in the management of this chronic pain syndrome." | ( Cady, RK; Shealy, CN, 1993) |
| "Severity of headache, duration of migraine attack and overall efficacy of treatment were amongst the variables assessed in a randomized, double-blind, three-way cross-over comparison of 1 g paracetamol plus either domperidone 30 mg, domperidone 20 mg or placebo, taken at onset of headache." | ( Bancroft, K; MacGregor, EA; Wilkinson, M, 1993) |
| "The treatment of migraine during pregnancy and lactation is difficult because of the risks to the fetus and newborn." | ( Miles, CB, 1995) |
| "The different effect of apomorphine in migraineurs compared with controls and tension-type headache patients implies that migraineurs have increased sensitivity to dopaminergic stimuli and suggests that transcranial Doppler monitoring after apomorphine administration could be a useful tool in the evaluation of migraineurs." | ( Bonuccelli, U; Distante, A; Palombo, C; Pavese, N; Piccini, P; Pittella, G, 1995) |
| "The impact of short-term treatment for migraine attacks on these variables was evaluated in an open prospective 6-month study at the Gothenburg Migraine Clinic." | ( Dahlöf, CG, 1995) |
| "Patients using sumatriptan to treat migraines for up to 24 months experienced improvements in disability and productivity as well as in health-related quality of life as measured either by a general health status instrument or a disease-specific instrument." | ( Cady, RK; Grice, RB; Gutterman, DL; Jhingran, P; Miller, D; Rubino, J, 1996) |
| "She suffers from chronic migraine treated by ergotamine tartrate." | ( Chapuis, G; Fournier, D; Genton, A; Jayet, A; Martinet, O; Vuilleumier, H, 1995) |
| "Clinicians who treat migraineurs with divalproex sodium do not need to be overly preoccupied with monitoring of drug levels and liver function tests." | ( Silberstein, SD; Wilmore, LJ, 1996) |
| "Although in migraineurs a number of studies have been done after nitroglycerin-induced attacks, there is no reported EEG study before and after nitroglycerin-induced sumatriptan-treated attacks." | ( Karageorgiou, C; Tagaris, G; Thomaides, T, 1996) |
| "155 patients suffering from migraine, with or without aura were analysed; the main efficacy criteria being the evolution of the headache intensity: disappearance of headache 2 hours after administration or incomplete improvement (severe to moderate headache reduced to slight headache)." | ( Cajfinger, F; Guérard des Lauriers, A; Lacoste, JP; Peraudeau, P; Pradalier, A; Scheck, F, 1995) |
| "Patients can treat as many migraine headaches as desired with an oral treatment regimen of 311C90." | ( Geraud, GE, 1996) |
| "The number of days with migraine and the drug consumption for symptomatic treatment per patient also decreased significantly in the magnesium group." | ( Köhne-Volland, R; Peikert, A; Wilimzig, C, 1996) |
| "In the migraine study, treatment results with propranolol tended to be somewhat better than those with flunarizine, but a selection bias cannot be excluded." | ( Amery, WK; De Locht, P; Verspeelt, J, 1996) |
| "For each migraine, patients recorded migraine pain severity (none, mild, moderate, or severe) before treatment and 2 hours posttreatment and the time until onset of patient-defined meaningful relief." | ( Beall, DG; Beck, A; Clements, BD; Cohen, JA; Miller, DW; Pait, G, 1996) |
| "The number of migraine attacks (> or = 50% responders) and the migraine duration/month were compared based on the difference between baseline and the last 4 weeks of prophylactic treatment." | ( Diener, HC; Fischer, M; Föh, M; Iaccarino, C; Isler, H; Strenge, H; Taneri, Z; Wedekind, W; Wessely, P, 1996) |
| "Despite the benefits of antimigraine medications for patients with migraines, parenteral administration of these drugs has certain disadvantages for at-home patient use." | ( Gallagher, RM, 1996) |
| "Patients treated migraines with their usual therapy for 12 to 18 weeks followed by subcutaneous sumatriptan for 6 months." | ( Clements, B; Gutterman, DL; Miller, D; Mushet, GR; Pait, G, 1996) |
| "Most migraineurs have neither been diagnosed by physicians nor effectively treated." | ( Saper, JR, 1997) |
| "Patients were allowed to treat as many migraine headaches (mild, moderate, or severe) as desired with an initial dose." | ( Zagami, AS, 1997) |
| "Twelve children with migraine symptoms that did not respond to conventional analgesics completed a double-blind, placebo-controlled, cross-over study of two doses of oral dihydroergotamine (DHE) for acute treatment." | ( Hämäläinen, ML; Hoppu, K; Santavuori, PR, 1997) |
| "They then treated a migraines headache with a single dose of the study drug as an outpatient." | ( Elkind, A; Goldstein, J; Ryan, RE, 1997) |
| "Any subsequent recurrence of migraine headache was treated with a randomised second injection of sumatriptan or placebo." | ( Cull, RE; Dunbar, A; Price, WH, 1997) |
| "Up to 15% of patients with migraine experience significant recurrence of headache after successful treatment with subcutaneous sumatriptan, and this recurrence is effectively treated by a further dose of subcutaneous sumatriptan." | ( Cull, RE; Dunbar, A; Price, WH, 1997) |
| "In 1996, our knowledge of acute antimigraine therapy expanded in three major areas." | ( Schoenen, J, 1997) |
| "The patients were diagnosed with migraine based on IHS criteria but individual migraine attacks treated in the study were physician diagnosed; not necessarily required to meet IHS criteria." | ( Beach, ME; Cady, RK; Gutterman, D; Saiers, JA, 1997) |
| "The striking similarity to migraine, together with the absence of vascular risk factors and the striking efficacy of aspirin treatment supports the hypothesis that the ischemic neurologic and visual symptoms in ET are caused by shear rate-induced intravascular activation and aggregation of platelets with subsequent transient sludging or occlusion of the cerebral arterial microvasculature." | ( Koudstaal, A; Koudstaal, PJ, 1997) |
| "Acute therapy for athletes with migraines is best managed with sumatriptan or DHE 45 and prophylaxis can be accomplished with verapamil, antidepressants, or valproate." | ( Kaplan, B; Swain, RA, 1997) |
| "While on this therapy, 35 of the 42 migraine patients and 16 of the 17 patients with tension-type headache experienced good or very good improvement in their symptoms." | ( Amsler, F; Meienberg, O, 1997) |
| "Patients with moderate or severe migraine (n = 417) were treated with placebo (n = 67), rizatriptan 2." | ( Block, G; Ferrari, MD; Gijsman, H; Kramer, MS; Matzura-Wolfe, D; Polis, A; Sargent, J; Teall, J; Tuchman, M, 1997) |
| "We report a case of migraine-associated ischemic stroke causing amnesia, wherein treatment with propranolol may have been contributory." | ( Greiner, F; Hamilton, WJ; Mendizabal, JE; Rothrock, JF, 1997) |
| "Outpatients treated four migraine headaches of moderate or severe pain intensity with study drug according to a randomization schedule." | ( Goldstein, DJ; Mathew, NT; Saper, JR; Silberstein, SD; Stoltz, R; Wang, O, 1997) |
| "We studied six patients suffering from migraine without aura resistant to the prophylactic treatment and with high frequency of attacks." | ( Del Zompo, M; Lai, M; Loi, V; Pisano, MR, 1997) |
| "A validated migraine-specific questionnaire (24-h Migraine Quality of Life Questionnaire: 24-h MQoLQ) was used to assess the impact of migraine and migraine therapy on health-related quality of life during an acute migraine attack." | ( Block, GA; Hartmaier, SL; Kramer, MS; Polis, AB; Santanello, NC; Silberstein, SD, 1997) |
| "Management of migraine patients with or without aura must include appropriate medication to treat the attack and long-term preventive therapy, especially if the frequency of the attacks is greater than 2-4 per month." | ( Annoni, JM; Higelin, F, 1998) |
| "A total of 2058 patients treated 31,579 migraine attacks (average 15 per patient), for up to 1 year." | ( , 1998) |
| "It is an effective treatment for acute migraine attacks and the injectable form has also shown efficacy in the treatment of cluster headaches." | ( Markham, A; Perry, CM, 1998) |
| "Patients with moderate or severe migraine (n = 473) were randomized to one of five sequence groups, in which each patient was to treat four migraine attacks." | ( Amaraneni, PG; Feighner, J; Getson, A; Kramer, MS; Matzura-Wolfe, D; McHugh, W; Polis, A; Reines, SA; Silberstein, S; Solbach, MP, 1998) |
| "In the first migraine attack treated, headache improvement was experienced by 77." | ( Göbel, H; Heinze, A; Heuss, D; Kuhn, K; Lindner, V, 1998) |
| "Forty-two patients with migraine without aura underwent the test before and 2 months after antimigraine therapy." | ( Amato, D; Bonuso, S; Caruso, G; de Angelis, S; Di Stasio, E; Marano, E; Scellini, T, 1998) |
| "Mild migraine attacks are treated with antiemetics followed by analgesics such as aspirin (acetylsalicylic acid), paracetamol (acetaminophen) or nonsteroidal anti-inflammatory drugs (NSAIDs)." | ( Diener, HC; Kaube, H; Limmroth, V, 1998) |
| "The treatment of migraine in the Netherlands underwent important changes in the beginning of the 20th century." | ( Bruyn, GW; Koehler, PJ, 1998) |
| "The cGMP was measured during a migraine attack and 60 min following the administration of sumatriptan 6 mg subcutaneously." | ( Chalimoniuk, M; Stepien, A, 1998) |
| "In total, one or two migraine attacks were treated in 268 and 235 patients, respectively." | ( Geraud, G; Gómez, JP; Henry, P; Joffroy, A; Lainez, JM; Le Jeunne, C; Liaño, H; Pradalier, A; Titus i Albareda, F, 1999) |
| "Patients with abdominal migraine may benefit from prophylactic treatment with propranolol or cyproheptadine." | ( Lichtman, SN; Rhoads, JM; Ulshen, MH; Worawattanakul, M, 1999) |
| "The patients with common migraine responded to beta blocker therapy." | ( Ahmed, I, 1999) |
| "Menstrual migraine may be debilitating, long-lasting, and refractory to treatment." | ( Saiers, J; Salonen, R, 1999) |
| "Thirteen patients suffering from migraine with aura and 2 patients with aura but without migraine were enrolled and treated with lamotrigine." | ( Buzath, A; Klinger, D; Lampl, C; Neumann, K, 1999) |
| "Cataracts and migraine are either increased or decreased by hormone therapy." | ( Barrett-Connor, E, 1999) |
| "Adult patients with moderate to severe migraine initially received customary therapy for migraine episodes for 12 weeks, followed by 24 weeks' treatment with self-administered subcutaneous sumatriptan 6 mg." | ( Adams, J; Berto, P; Bouchard, J; Brueggenjuergen, B; Cortelli, P; Dahlöf, C; Edwards, CE; Heywood, J; Hirsch, J; Jansen, JP; Lindsay, P; Nyth, AL; Pham, S; Price, KL, 1997) |
| "The Short Form-36 Health Survey and the Migraine-Specific Quality of Life Questionnaire were completed at a screening visit (base-line), at the end of the 12-week customary therapy phase, and at 12 and 24 weeks of the sumatriptan phase." | ( Adams, J; Bouchard, J; Cortelli, P; Dahlöf, C; Heywood, J; Hirsch, J; Jansen, JP; Miller, DW; Pham, S, 1997) |
| "Patients diagnosed with migraine treated their symptoms for 24 weeks with subcutaneous sumatriptan after a 12-week period of treating symptoms with their customary (non-sumatriptan) therapy." | ( Adams, J; Bouchard, J; Cortelli, P; Dahlöf, C; Heywood, J; Hirsch, J; Jansen, JP; Miller, DW; Pham, S, 1997) |
| "Patients treated migraine attacks for 12 weeks with their customary therapy, followed by 24 weeks' treatment with subcutaneous sumatriptan 6 mg." | ( Babiak, L; Bouchard, J; Cortelli, P; Dahlöf, C; Heywood, J; Jansen, JP; Joseph, A; Pham, S; Price, KL, 1997) |
| "While the majority of migraine sufferers are treated by primary care providers, headache specialists can manage migraine much more cost-effectively--in some cases up to 87% less." | ( , 1998) |
| "Although also sometimes used to treat migraine, nonsteroidal anti-inflammatory drugs (NSAIDs) have not been systematically evaluated in controlled clinical trials, particularly in comparison with the newer drug sumatriptan." | ( , 1999) |
| "Effective, well-tolerated migraine therapy with rapid onset of relief could decrease work and productivity losses." | ( Block, GA; Davies, GM; Gerth, W; Lerner, D; Santanello, N, 1999) |
| "She used ergotamine as a treatment for migraine headaches for more than 4 years." | ( Bräunlich, S; Kröger, K; Massalha, K; Rudofsky, G, 1999) |
| "The treatment of migraine has been dramatically improved with the use of sumatriptan, other triptans, and serotonin-receptor subtype 1B and 1D agonists." | ( Dulli, DA, 1999) |
| "We believe that the use of these migraine models will provide even better treatment for migraine patients in the next millennium." | ( De Vries, P; Saxena, PR; Villalón, CM, 1999) |
| "It is a promising therapy for migraine." | ( Allegra, J; Eskin, B; Irving, C; Nashed, AH; Ostrow, A; Reischel, U; Richman, PB; Ritter, A; Szucs, P, 1999) |
| "Once diagnosed, migraine can be treated by preventive or abortive measures." | ( Goode, JV; Small, RE; Thomas, ML; Weitzel, KW, 1999) |
| "Mild or moderate migraine attacks are treated with antiemetics followed by analgesics such as aspirin, paracetamol, nonsteroidal anti-inflammatory drugs, or antiemetics combined with ergotamine or dihydroergotamine." | ( Diener, HC; Kaube, H; Limmroth, V, 1999) |
| "58 patients treated 1 migraine attacks at home using an autoinjector with a dose 6 mg of sumatriptan." | ( Stepień, A, 1999) |
| "administration of sumatriptan for acute migraine therapy is an effective treatment method, with reliable action, that can be used with good tolerability provided the contraindications are taken into account." | ( Göbel, H; Heinze, A; Heinze-Kuhn, K; Lindner, V; Stolze, H, 1999) |
| "Acute migraine therapies can usefully be regarded as non-specific and specific, from the perspective of migraine, since some medicines, such as aspirin or paracetamol, are used to treat pain more broadly." | ( Goadsby, PJ, 1999) |
| "For most migraine sufferers requiring a specific anti-migraine treatment, a triptan is generally a better option from both an efficacy and side-effect perspective." | ( Dahlöf, C; Diener, H; Ferrari, MD; Goadsby, PJ; Henry, P; Láinez, M; Pascual, J; Saxena, PR; Schoenen, J; Tfelt-Hansen, P, 2000) |
| "Of 2800 patients treating an initial migraine headache in Part 1, 989 patients took a second dose to treat persistent headache of moderate or severe intensity." | ( Farkkila, M; Hering-Hanit, R; Mauskop, A; Rapoport, A; Warner, J, 1999) |
| "Despite its efficacy to treat migraine and other pain, there are a few commercial NSAIDs available for intravenous (i." | ( Barbosa, J; Krymchantowski, AV, 1999) |
| "Three-hundred-and-twenty-eight migraine sufferers treated a first migraine attack with a nontriptan standard care medication: a mixture containing phenazone, butalbital and caffeine (optalidon) or indomethacin plus prochlorperazine plus caffeine (difmetre) or paracetamol 100 mg (tachipirine), depending on their habits." | ( Cavazzuti, L; Fabbri, L; Pini, LA, 1999) |
| "Patients treated three migraine attacks with study medication; a second, optional dose was available for treating recurrent headache." | ( Ashford, EA; Brautaset, NJ; Hassani, H; Reunanen, M; Saiers, J; Savani, N; Szirmai, I, 1999) |
| "Sumatriptan is an acute treatment for migraine which is often used by women in their child-bearing years, and who become unexpectedly pregnant." | ( Davis, RL; Ephross, SA; Fox, AW; Gutterman, DL; O'Quinn, S; Williams, V, 1999) |
| "Oral anticoagulant therapy can improve migraine." | ( Cornudella, R; Espada, F; Iñiguez, C; Mauri, JA; Morales-Asín, F; Mostacero, EE, 2000) |
| "Treating less severe migraine attacks, treating earlier within an attack, and obtaining complete relief post dose may enhance the low incidence of headache recurrence and achieve longer times to recurrence with naratriptan, 2." | ( O'Quinn, S; Pait, D; Sheftell, F; Watson, C; Winter, P, 2000) |
| "Clinical observation of a decrease in migraine frequency in patients with comorbid asthma taking montelukast, a specific D4 leukotriene receptor antagonist, or zafirlukast, another leukotriene receptor antagonist, prompted us to explore a possible role for leukotriene modifiers in the treatment of migraine." | ( Baskin, S; Gammerman, I; Rapoport, A; Sheftell, F; Walker, B; Weeks, R, 2000) |
| "The pharmacotherapy of migraine has advanced in parallel with our understanding of the pathophysiology of the disease." | ( Goadsby, PJ, 1999) |
| "The correct diagnosis of migraine and other headaches is of greatest importance as unless the right diagnosis is made, the right treatment cannot be given." | ( Bhagat, K; Kalangu, KK, 1999) |
| "Women with migraines were randomly assigned to one of five treatment sequences for the treatment of two migraine attacks." | ( Johnson-Pratt, L; Le Jeunne, C; Lines, CR; Massiou, H; McCarroll, KA; Silberstein, SD, 2000) |
| "Triptans, 5-HT1B/1D agonists used in migraine treatment, are rarely involved in serious coronary events due to vasospasm." | ( Hedenmalm, K, 2000) |
| "After treating 3 migraines, satisfaction with naratriptan therapy and preference for either previous or naratriptan therapy were assessed." | ( Bort, T; Cady, R; Cervi, M; Pangtay, D; Powers, C; Szeto, S, 2000) |
| "After treating 3 migraines with naratriptan, satisfaction with migraine therapy increased from 47% to 75%." | ( Bort, T; Cady, R; Cervi, M; Pangtay, D; Powers, C; Szeto, S, 2000) |
| "Naratriptan for first-line migraine therapy was preferred by most patients over previous nontriptan therapy." | ( Bort, T; Cady, R; Cervi, M; Pangtay, D; Powers, C; Szeto, S, 2000) |
| "Of these 140 patients, 119 received migraine treatment in the workplace (intent-to-treat population), 116 of whom comprised the study population." | ( Batenhorst, AS; Cady, RK; Henry, D; O'Quinn, SO; Putnam, DG; Schulman, EA; Watson, CB, 2000) |
| "Previous studies for treatment of migraine in adults have shown a greater than 50% reduction in migraine attack frequencies." | ( Brown, WD; Caruso, JM; Exil, G; Gascon, GG, 2000) |
| "The duration of the therapy of migraine between the attacks was 12 weeks." | ( Amelin, AV; Gonchar, MA; Korenko, LA; Skoromets, AA; Tumelevich, BCh, 2000) |
| "Following a fortuitous observation that migraine headaches ceased in a patient receiving glucosamine therapy for osteoarthritis, a further ten patients with migraine or migraine-like vascular headaches, refractory to established preventive or abortive therapies, have been treated with daily oral glucosamine." | ( McCarty, MF; Russell, AL, 2000) |
| "Four hundred and seventeen (417) migraine patients treated 15,301 migraine attacks over the course of the study." | ( Bomhof, MA; Hassani, H; Heywood, J; Pradalier, A; Thaventhiran, L; Winter, P, 2000) |
| "Thirty-eight adolescents treated 276 migraine attacks of any intensity." | ( Dowson, AJ; Linder, SL, 2000) |
| "Therapy for migraine can be classified as preventive or acute." | ( Saper, JR, 2000) |
| "Because of the recurrent nature of migraine, a major concern with pharmacologic therapy is whether it will remain effective, safe, and tolerable over the long term." | ( Silberstein, SD, 2000) |
| "Even a migraine of moderate intensity can impair function and productivity, which emphasizes the importance of therapy that achieves complete, as opposed to partial, pain relief." | ( Santanello, N; Solomon, GD, 2000) |
| "Patients with migraines have typically been given one group of medications for abortive treatment and another for preventative." | ( Norton, J, 2000) |
| "Overall 40 migraine-outpatients participated in this retrospective analysis of prophylactic migraine treatment over 3-8 months with 1600 to 2000 mg cyclandelate daily." | ( Dimpfel, W; Todorova, A; Vonderheid-Guth, B; Wedekind, W, 2000) |
| "Days with migraine were reduced by at least 50% in 14 participants for active treatment versus placebo and 17 patients for active treatment versus run-in period." | ( Bovim, G; Helde, G; Sand, T; Schrader, H; Stovner, LJ, 2001) |
| "1997, sumatriptan-treated migraineurs had significantly higher depression PCRs (22." | ( Croft, P; Frischer, M; Goadsby, PJ; Millson, D, 2000) |
| "in patients treating four separate migraine attacks." | ( Carides, GW; Dasbach, EJ; Gerth, WC; Pigeon, JG; Santanello, NC, 2000) |
| "Successful migraine relief was achieved with a combination of propranolol and naproxen, administered before and after ECT." | ( Delva, NJ; Hawken, ER; Lawson, JS, 2001) |
| "A total of 437 patients treated > or =1 migraine; 3272 total attacks were treated, with 3675 drug exposures (mean, 1." | ( Asgharnejad, M; Austin, R; Laurenza, A; Nett, R; Peykamian, M; Rothner, AD; Winner, P, 2000) |
| "Successful management of migraine headaches involves identifying and avoiding headache triggers and using appropriate abortive therapy once a headache is recognized." | ( Diamond, S, 2001) |
| "Apomorphine administration induces in migraineurs more yawns as well other dopaminergic symptoms e." | ( Alessandri, M; Del Rosso, A; Fanciullacci, M, 2000) |
| "In this study, migraine patients treated with almotriptan were significantly more satisfied with the side-effect profile of the drug than patients treated with sumatriptan." | ( Brod, MI; Colman, SS; Gomez-Mancilla, B; Jirgens, KJ; Krishnamurthy, A; Rowland, CR, 2001) |
| "Effective acute treatment of migraine is possible with the 4HT(1B/1D) agonists (triptans), but their use has been limited in the UK because of concerns about limited efficacy, recurrence of attacks, adverse events, and cost." | ( Cull, R, 2001) |
| "As patients who suffer from migraine need long-term treatment, the safety and consistent efficacy of such therapy is very important." | ( Göbel, H; Heinze, A; Heinze-Kuhn, K; Lindner, V, 2001) |
| "Early treatment of migraine with sumatriptan 50 mg and 100 mg, while pain is mild, has been reported to enhance pain-free response 2 hours and 4 hours postdose and sustained pain-free response 2 to 24 hours postdose compared with treatment when pain has become moderate to severe." | ( Cady, RK; Kwong, WJ; Lipton, RB; O'Quinn, S; Sheftell, F, 2001) |
| "Treatment of migraine with sumatriptan 50-mg and 100-mg tablets is effective regardless of whether pain is mild, moderate, or severe." | ( Cady, RK; Kwong, WJ; Lipton, RB; O'Quinn, S; Sheftell, F, 2001) |
| "Changes in migraine pain severity, clinical disability, and percent effectiveness following treatment with sumatriptan nasal spray, 20 mg, were significantly correlated with cognitive function measures across all subtests (P<." | ( Batenhorst, A; Bleiberg, J; Cady, R; Farmer, K; O'Quinn, S; Putnam, G; Reeves, D, 2001) |
| "As part of the stratified treatment of migraine, those patients whose headaches are mild or moderate may benefit from nontriptan medications." | ( Cady, R; DiSerio, F; Elkind, A; Freitag, FG; Gallagher, RM; Goldstein, J; Klapper, JA; Rapoport, AM; Sadowsky, C; Saper, JR; Smith, TR, 2001) |
| "Forty migraineurs (10 males, 30 females) were randomized according to a two-period (3-month), two-treatment, crossover design." | ( Ambrosoli, L; Cavallini, A; Mailland, F; Marcheselli, S; Micieli, G; Nappi, G, 2001) |
| "No differences were observed in the migraine characteristics or the number of treatments of the patients from the different groups." | ( Hering, R; Korczyn, AD; Kuritzky, A; Treves, TA, 1998) |
| "We report two patients with migraine successfully treated with amlodipine (Norvasc, Pfizer, Inc), a slow calcium-channel blocker." | ( Dandapani, BK; Hanson, MR, 1998) |
| "Fifty-four migraine with aura patients, 95 migraine without aura patients and 30 tension-type headache patients were treated with metamizol." | ( Bigal, ME; Bordini, CA; Speciali, JG, 2001) |
| "The treatment of migraine associated with changes in sex hormone levels is difficult, and patients often are refractory to therapy." | ( Silberstein, SD, 2001) |
| "The common strategy to treat a migraine attack as soon as it begins, made for classical acute antimigraine treatments such as ergotamine and analgesics, has not been transposed to the triptans." | ( Schoenen, J, 2001) |
| "One hundred consecutive migraine patients attending our clinics were asked to treat three attacks with each medication and then fill out a preference questionnaire." | ( Leira, R; Muñoz, R; Pascual, J, 2001) |
| "Patients treated one migraine with either rizatriptan ODT 10-mg or sumatriptan 50-mg tablet, then treated a second migraine with the alternate therapy." | ( Bohidar, N; Boyle, D; Brandes, JL; Guerra, F; Johnson-Pratt, L; Kolodny, A; Loder, E; Santanello, N; Silberstein, S; Skobieranda, F; Wang, L, 2001) |
| "For those patients who treated two migraine attacks and had drug severity measures for both attacks (n = 384), a significantly greater percentage of patients reported pain relief after taking rizatriptan ODT than sumatriptan at the 45- and 60-minute time points (38% versus 29% and 58% versus 49%, respectively) (P<." | ( Bohidar, N; Boyle, D; Brandes, JL; Guerra, F; Johnson-Pratt, L; Kolodny, A; Loder, E; Santanello, N; Silberstein, S; Skobieranda, F; Wang, L, 2001) |
| "All patients using an abortive migraine drug (ergotamine or sumatriptan) and subsequently treated with either coumarin (index group) or low-dose acetylsalicylic acid (control group) were analyzed." | ( Buurma, H; Egberts, AC; Leufkens, HG; Rahimtoola, H; Tijssen, CC, 2001) |
| "We followed 23 patients with pediatric migraine, ranging in age from 7 to 17 years, who were treated with preventive divalproex sodium for migraine prophylaxis." | ( Drake, ME; Greenberg, G; Pakalnis, A; Paolichi, J, 2001) |
| "Trials of eletriptan for acute migraine; randomised allocation to treatment groups, including a placebo group; double-blind design; International Headache Society diagnostic criteria for migraine with or without aura; single migraine attack; single-dose treatment at standard doses; adult population; baseline pain of moderate or severe intensity using a 4-point standardised rating scale (0 = no pain, 1 = mild pain, 2 = moderate pain and 3 = severe pain); and dichotomous or percentage data for at least one of the main efficacy outcomes." | ( McQuay, HJ; Moore, RA; Oldman, AD; Smith, LA, 2001) |
| "Patients with migraine using sumatriptan therapy." | ( Frick, KD; Locklear, JC; Lofland, JH, 2001) |
| "black triangle Consistent relief of migraine symptoms was achieved in patients who treated a number of consecutive attacks with frovatriptan and the incidence of 24-hour migraine recurrence was reduced." | ( Easthope, SE; Goa, KL, 2001) |
| "Both treatments reduced migraine-associated nausea, vomiting, phonophobia and photophobia." | ( Compagnon, A; Geraud, G; Rossi, A, 2002) |
| "For the acute treatment of migraine attacks or tension-type headache, ibuprofen (10 mg per kg body weight) or acetaminophen (15 mg per kg body weight) are recommended with highest evidence, intranasal sumatriptan (10 to 20 mg) can be given as second choice." | ( Evers, S; Gerber, WD; Naumann, E; Pothmann, R; Uberall, M, 2002) |
| "Almotriptan, a new treatment for acute migraine attacks, may improve health outcomes while reducing expenditures on drug costs and the costs associated with unwanted adverse events." | ( Mayo, KW; Osterhaus, JT, 2002) |
| "Sixty-one percent of migraineurs and 73% of cluster patients noted a decrease in pain with divalproex sodium and continued that therapy for more than 3 months." | ( Freitag, FG; Gallagher, RM; Mueller, LL, 2002) |
| "There exist increasing options for migraine treatment that may further improve the clinical effects of the older and newer triptans through early treatment of migraine at the stages of mild migraine pain, or even during the prodromal phase of the attack." | ( Freitag, FG, 2001) |
| "Evaluate the reduction in migraine-associated symptoms after administration of a single oral dose of almotriptan." | ( Cady, R, 2002) |
| "Almotriptan provides relief from migraine-associated symptoms of nausea, vomiting, photophobia, and phonophobia, and thus represents an attractive treatment option for a wide spectrum of migraine symptomatology." | ( Cady, R, 2002) |
| "The overall incidence of initiation of migraine-prophylactic therapy following the use of abortive migraine analgesics was 6." | ( Buurma, H; Egberts, AC; Leufkens, HG; Rahimtoola, H; Tijssen, CC, 2002) |
| "Most patients with migraine consider drugs that can be administered orally to be the most user-friendly." | ( Dahlöf, C, 2002) |
| "As with any other acute treatment for migraine, headache recurrence may occur in up to one-third of responders." | ( Barbosa, JS; Krymchantowski, AV, 2002) |
| "A total of 668 patients treated one migraine attack of moderate or severe intensity with study medication." | ( Cabarrocas, X; Dowson, AJ; Laínez, JM; Massiou, H, 2002) |
| "These migraines are often refractory to treatment." | ( Burke, BE; Cusack, BJ; Olson, RD, 2002) |
| "In conclusion, migraine therapy that provides rapid, complete, and sustained pain relief, with restoration of functional ability, has the most beneficial impact on short-term health-related quality of life for migraineurs." | ( Allen, C; Davies, G; Kramer, M; Lipton, R; Santanello, NC, 2002) |
| "Patients diagnosed with transformed migraine, episodic migraine, or cluster headache, who received topiramate either as add-on therapy or monotherapy were selected via retrospective chart review." | ( Kailasam, J; Mathew, NT; Meadors, L, 2002) |
| "For both patients with transformed migraine (add-on therapy) and patients with episodic migraine (first-line monotherapy), topiramate yielded significant reductions in migraine frequency, migraine severity, number of headache days/month, and use of abortive medications." | ( Kailasam, J; Mathew, NT; Meadors, L, 2002) |
| "The 28-day frequency of moderate/severe migraines declined significantly from baseline to end of treatment (10." | ( Adelman, JU; Mannix, LK; Von Seggern, RL, 2002) |
| "Patients with a history of migraine (n = 1,008) were randomly assigned to receive placebo, 40 mg of eletriptan, 80 mg of eletriptan, 50 mg of sumatriptan, or 100 mg of sumatriptan to treat up to three attacks." | ( Burgess, G; Färkkilä, M; Forster, E; Haughie, S; Sandrini, G, 2002) |
| "Menstrual migraines are a treatment challenge for both the migraineur and the health care professional." | ( Chavanu, KJ; O'Donnell, DC, 2002) |
| "The high prevalence of migraine in women during their reproductive years means that new drug treatments for migraine, such as the serotonin 5-HT(1B/1D) receptor agonists (the 'triptans'), are likely to be widely used by women of childbearing potential." | ( Loder, E, 2003) |
| "The acute treatment and prophylaxis of migraine headache are discussed in this article." | ( Vaitkus, A; Vilionskis, A, 2002) |
| "We included 12 patients with migraine without aura in this double-blind, placebo-controlled crossover study, in which placebo or sildenafil 100 mg was administered orally on two separate days." | ( Birk, S; Kruuse, C; Olesen, J; Thomsen, LL, 2003) |
| "After treating three migraine attacks, the proportion of patients fully or very satisfied with rizatriptan was over 79% for all the domains explored." | ( López Rodríguez, I; López-Gil, A; Mateos, V; Roig, C, 2002) |
| "The mainstay of migraine treatment is pharmacotherapy." | ( Corbo, J, 2003) |
| "The treatment of a migraine attack can be difficult when first-line medication is unsuccessful and options for parenteral "rescue" therapy are limited." | ( Alam, AS; Mendizabal, JE; Rothrock, JF; Silberstein, SD; Young, WB, 2003) |
| "In acute migraine treatment, their mechanisms of action involve constricting the pain-producing intracranial extracerebral blood vessels at the 5-HT1B receptors and inhibiting the trigeminal neurotransmission at the peripheral and central 5-HT1D receptors." | ( McCrory, DC; Silberstein, SD, 2003) |
| "Ninety patients with migraine were divided into three groups, the treated group treated with Shutianing Granule (STNG) 9 g, three times a day, the control A group treated with composite Yangjiao capsule, 5 capsules each time, three times a day and the control B group treated with flunarizine hydrochloride capsule, 5 mg, once a day." | ( Hu, ZQ; Mei, T; Song, LG, 2002) |
| "Elevated levels of CGRP during migraine are restored to normal coincident with headache relief after treatment with the antimigraine drug sumatriptan." | ( Durham, PL; Russo, AF, 2003) |
| "Six children developed severe daily migraine-type headaches during cancer treatment." | ( Khan, RB, 2002) |
| "They had previously undergone other migraine preventive treatment unsuccessfully." | ( Capone, C; Faienza, C; Fusco, C; Pisani, F, 2002) |
| "Adult migraineurs treated two migraine attacks with either rizatriptan 10-mg standard tablets or rizatriptan 10-mg orally disintegrating tablets in a crossover manner." | ( Cutrer, FM; Dayno, J; Goldstein, J; Hu, XH; Jamieson, D, 2003) |
| "VPA is also an effective drug in migraine prophylaxis and in treatment of bipolar disorders." | ( Bialer, M; Isoherranen, N; Yagen, B, 2003) |
| "Recent progress in the treatment of migraine has not been made readily available to all who suffer the condition." | ( Feldman, SR; Fleischer, AB; Gibbs, TS; O'Donovan, CA; Sam, MC, 2003) |
| "Even so, most patients with migraine continue to be treated with older and presumably less effective medications." | ( Feldman, SR; Fleischer, AB; Gibbs, TS; O'Donovan, CA; Sam, MC, 2003) |
| "Seventy-two consecutive migraineurs with unilateral cranial autonomic symptoms were given sumatriptan 50-mg tablets to treat 1 migraine attack and were asked to record their clinical response to the drug at different time points." | ( Barbanti, P; Buzzi, MG; Fabbrini, G; Pesare, M; Vanacore, N, 2003) |
| "The selection of an acute antimigraine drug also depends upon the stratification of the patient's migraine attack by peak intensity, time to peak intensity, level of associated symptoms such as nausea and vomiting, time to associated symptoms, comorbid diseases and concomitant treatments that might cause drug-drug interactions." | ( Bigal, ME; Rapoport, AM; Sheftell, FD; Tepper, SJ, 2003) |
| "After these treatment, his migraine attack disappeared." | ( Hayashi, T; Katou, H; Kougo, K; Morihara, Y; Nanri, K; Niiyama, K; Sekine, S; Utsumi, H, 2002) |
| "Despite a decade of progress, migraine headache remains prevalent, disabling, underdiagnosed, and undertreated in the United States." | ( Mathew, NT, 2001) |
| "The treatment of chronic migraine often poses a major challenge to the clinician." | ( Bigal, ME; Feleppa, M; Rapoport, AM; Sheftell, FD; Tepper, SJ; Volcy, M, 2003) |
| "The number of migraine drugs continues to expand, allowing for more flexible and tolerable treatment plans." | ( Ashkenazi, A; Silberstein, SD, 2003) |
| "New drugs expand the spectrum of migraine treatment both for the acute attack and for prevention." | ( Ashkenazi, A; Silberstein, SD, 2003) |
| "Seventy patients with a diagnosis of migraine were randomly assigned to topiramate-treated and placebo groups." | ( Edwards, KR; Hulihan, J; Kamin, M; Potter, DL; Wu, SC, 2003) |
| "The objectives of the Migraine And Zolmitriptan Evaluation (MAZE) survey were to assess the prevalence of migraine in the general population across 5 different countries, to understand migraineurs' experience of migraine and its management on a global level, and to assess patient perceptions and preferences of current and future treatment formulations." | ( Brandes, J; Eikermann, A; MacGregor, EA, 2003) |
| "Menstrual migraine may require both acute and preventive treatment." | ( Mannix, LK, 2003) |
| "We describe a patient whose migraine headaches responded dramatically to sustained-release niacin as preventive treatment." | ( Dodick, DW; Muir, JJ; Velling, DA, 2003) |
| "One hundred twelve patients with migraine with or without aura according to the diagnostic criteria of the International Headache Society were randomized to treat 2 migraine attacks with a fixed combination of indomethacin, prochlorperazine, and caffeine and 2 migraine attacks with sumatriptan." | ( Aloisio, A; Del Bianco, P; Di Monda, V; Fonzari, M; Grazioli, I; Nicolodi, M; Sicuteri, F; Uslenghi, C; Vecchiet, L, 2003) |
| "The efficacy of current preventive migraine treatments is limited." | ( Hernández-Gallego, J; Jiménez, MD; Láinez, JM; Leira, R; Mateos, V; Pascual, J; Sánchez del Rio, M, 2003) |
| "Patients treated migraine at the first sign of pain, while pain was mild, but not more than 2 hours after onset with oral sumatriptan, 50 mg or 100 mg, or matching placebo." | ( Kwong, J; Mannix, LK; McNeal, S; O'Quinn, S; Putnam, DG; Richardson, MS; Winner, P, 2003) |
| "Treatment of migraine at the first sign of pain with sumatriptan, 50-mg and 100-mg tablets, provides superior pain-free relief at 2 and 4 hours after treatment compared with placebo." | ( Kwong, J; Mannix, LK; McNeal, S; O'Quinn, S; Putnam, DG; Richardson, MS; Winner, P, 2003) |
| "Medical treatment of migraine has the twofold task of cutting short an acute attack and preventing further episodes." | ( Göbel, H, 2003) |
| "Patient satisfaction and migraine-specific quality-of-life scores were also significantly better for attacks treated with rizatriptan." | ( Baos, V; Bertral, C; Caloto, MT; Gerth, WC; Nocea, G; Serrano, A; Torrecilla, M, 2003) |
| "For many migraine patients, triptan therapy provides complete pain relief in some attacks but not in others." | ( Burstein, R; Collins, B; Jakubowski, M, 2004) |
| "The number of migraine treatments and our understanding of migraine pathophysiology are both increasing." | ( Ashkenazi, A; Silberstein, SD, 2004) |
| "For patients who continued abortive migraine drug use during and after ACE/Ang II or diuretic therapy, a significantly larger reduction in this estimate was observed during ACE/Ang II inhibition (68." | ( Buurma, H; Egberts, AC; Leufkens, HG; Rahimtoola, H; Tijssen, CC, 2004) |
| "A clear reduction in the TI of abortive migraine drug use during the use of ACE inhibitors as compared to diuretic treatment was observed." | ( Buurma, H; Egberts, AC; Leufkens, HG; Rahimtoola, H; Tijssen, CC, 2004) |
| "Triptans are widely used to treat migraine but have been associated with stroke, myocardial infarction (MI), and ischemic heart disease (IHD) in case reports." | ( Brown, MM; Hall, GC; MacRae, KD; Mo, J, 2004) |
| "Of these, 1312 treated a single migraine attack and recorded baseline and outcome data to be included in the intention-to-treat population." | ( Diener, HC; MacGregor, EA; Muirheads, N; Schoenen, J; Sikes, CR; Steiner, TJ, 2003) |
| "In > 5000 acute migraine patients enrolled in short-term trials and almost 1800 patients in long-term, open-label trials treating approximately 47000 attacks, rizatriptan was effective and well-tolerated." | ( Pascual, J, 2004) |
| "Although the migraine clinical trials literature is enormous, we identified only nine published double-blind studies which compare an oral triptan with a non-triptan acute treatment." | ( Bigal, ME; Goadsby, PJ; Lipton, RB, 2004) |
| "Frequent migraine attacks require prophylactic treatment." | ( Adriano, M; Krymchantowski, AV; Penteado Jd, Jde C; Tavares, C, 2004) |
| "Treatment of acute migraine headache with narcotics is potentially ineffective and may lead to abuse." | ( Colman, I; Rothney, A; Rowe, BH; Wright, SC; Zilkalns, B, 2004) |
| "A previous small open-label study in migraine patients suggested prophylactic efficacy for montelukast, an antagonist of the cysteinyl leukotriene receptor that is used in the treatment of asthma." | ( Brandes, JL; Farmer, MV; Lines, CR; Malbecq, W; Reines, SA; Schuhl, AL; Visser, WH; Vrijens, F, 2004) |
| "Only patients who experienced > or =3 migraine attacks in the second month were eligible to enter the subsequent 3-month, double-blind treatment phase of the study." | ( Brandes, JL; Farmer, MV; Lines, CR; Malbecq, W; Reines, SA; Schuhl, AL; Visser, WH; Vrijens, F, 2004) |
| "Patients with IHS migraine were randomized to one out of 3 groups, where they had to treat 6 consecutive moderate or severe attacks in counterbalanced order." | ( Bigal, ME; Krymchantowski, AV, 2004) |
| "Triptans are usually administered for migraine, but cannot be given to patients with malfunctioning cardiac or cerebral vascular systems, which commonly accompany hypertension." | ( Owada, K, 2004) |
| "To investigate the impact of migraine on migraineurs and their families and evaluate migraineurs' preference for different treatment formulations." | ( Brandes, J; Eikermann, A; Giammarco, R; MacGregor, EA, 2004) |
| "To optimise migraine management, treatment choice should be based on individual patients' needs and preferences." | ( Brandes, J; Eikermann, A; Giammarco, R; MacGregor, EA, 2004) |
| "Productivity and satisfaction with migraine therapy also were assessed." | ( Mackowiak, JI; Solari, PG; Weaver, MB, 2004) |
| "Ocular migraine, an uncommon cause of transient monocular visual loss, is an entity physicians should be able to recognize in order to provide appropriate treatment and to avoid unnecessary testing." | ( Chung, SM; Pradhan, S, 2004) |
| "OTFC successfully treated migraine episodes in all 18 outpatients; no patient went to an ED." | ( Landy, SH, 2004) |
| "Treatment of migraine with triptans is highly effective, although cost considerations may prompt a change in therapy." | ( Browning, D; Martin, A; Savani, N, 2004) |
| "In 241 patients who each treated 2 migraine attacks, Dose 1 frovatriptan was more effective than placebo in terms of the proportion of patients who were pain free at 2 h (28% vs 20%, p = 0." | ( Cady, R; Elkind, A; Goldstein, J; Keywood, C, 2004) |
| "Clinical trials of migraine therapy often require treatment when migraine pain intensity is moderate or severe, but many physicians find this practice artificial and patients often prefer to treat while pain is mild." | ( Charlesworth, B; Klapper, J; Lucas, C; Røsjø, Ø, 2004) |
| "Physicians treating patients with migraine can now choose from among 7 triptans, which differ on a range of attributes that may be important for treatment selection." | ( Cutrer, FM; Dodick, DW; Ferrari, MD; Goadsby, PJ; Lipton, RB; McCrory, D; Williams, P, 2004) |
| "Many migraineurs require a second dose/product, possibly indicating sub-optimal treatment efficacy." | ( Brandes, J; Gendolla, A; Giammarco, R; MacGregor, EA, 2004) |
| "The treatment of migraine takes into consideration the intensity of the headache and the accompanying symptoms." | ( Diener, HC; Gendolla, A, 2004) |
| "Symptomatic therapy of migraine now includes three main classes of drugs: ergot alkaloids, nonsteroidal antiinflammatory drugs (NSAIDs) and triptans." | ( Abbate, M; Gangemi, S; Narbone, MC, 2004) |
| "The largest clinical programme in migraine prevention, studying these or any other agents, was comprised of 2 pivotal trials, as well as other studies, evaluating topiramate for preventive therapy in migraine." | ( Silberstein, SD, 2004) |
| "The treatment of migraine occurring in the face is no different than that provided for pain occurring in the head." | ( Bagán, JV; Bandrés, A; Peñarrocha, M, 2004) |
| "It included 363 migraine patients treated with Seglor or placebo for 5 months after a 1-month placebo run-in phase." | ( Allain, H; Delgado, A; Géraud, G; Lantéri-Minet, M; Lucas, C; Pradalier, A, 2004) |
| "Dissatisfaction with migraine therapy on the basis of these factors is common." | ( Lawrence, EC, 2004) |
| "Patients expect their acute migraine treatment to have a rapid onset of action, achieve complete pain relief that is sustained for 24 h, and to have a good tolerability profile." | ( Gendolla, A, 2004) |
| "Developments in our understanding of migraine pathophysiology provide a rationale for this phenomenon, with improved efficacy seen when abortive treatment is administered before central sensitization develops." | ( Láinez, M, 2004) |
| "Gastric stasis during migraine attacks results in delayed absorption of several orally administered antimigraine agents." | ( Brucker, MJ; Carides, AD; Cutler, NR; Goldberg, MR; Jhee, SS; Kramer, MS; Majumdar, AK; Matzura-Wolfe, D; McLaughlin, D; Reines, SA, 1999) |
| "A follow-up study of 40 patients (migraine 39, cluster headache 1) previously treated for ergotamine abuse was conducted." | ( Krabbe, A; Tfelt-Hansen, P, 1981) |
| "Patients treated up to 2 migraine attacks as soon as possible after the start of their migraine pain." | ( Abu-Shakra, S; Adelman, J; Freitag, FG; Loder, E; Pearlmand, S, 2005) |
| "In treating migraine sufferers, physicians can choose from among seven triptans with different attributes." | ( Cutrer, FM; Dodick, DW; Ferrari, MD; Goadsby, PJ; Liberman, JN; Lipton, RB; McCrory, D; Williams, P, 2005) |
| "Telephone interviews with migraine sufferers, neurol ogists, and PCPs were conducted to elicit individual views on the relative importance of a prespecified set of acute treatment outcomes." | ( Cutrer, FM; Dodick, DW; Ferrari, MD; Goadsby, PJ; Liberman, JN; Lipton, RB; McCrory, D; Williams, P, 2005) |
| "Trials of topiramate monotherapy in migraine prevention found that 100 mg/d was associated with a > or =50% reduction in monthly migraine frequency in 49% to 54% of patients." | ( Ben-Menachem, E; Shank, RP; Silberstein, SD; Wiegand, F, 2005) |
| "Fourteen patients suffering from migraine without aura were monitored to evaluate mean flow velocity changes on both middle cerebral arteries during migraine attack 30 min before and 120 min after oral administration of rizatriptan 10mg." | ( Bellini, G; Bonanni, E; Gori, S; Iudice, A; Manca, L; Morelli, N; Murri, L; Orlandi, G, 2005) |
| "Physicians who treat migraine have long recognized that a subset of patients with episodic migraine evolve to chronic forms of the disorder that are difficult to treat and have a poor outcome." | ( Biondi, D; Loder, E, 2005) |
| "When treating patients with migraine, clinicians should consider prescribing appropriate combinations of acute and preventive therapies." | ( Brandes, JL, 2005) |
| "More than 50% of migraine sufferers rely on over-the-counter medications for the treatment of migraine." | ( Baggish, JS; Goldstein, J; Lipton, RB; Quiring, JN; Sorrentino, JV; Yataco, AR, 2005) |
| "We describe a case of status migrainosus precipitated by electroconvulsive therapy (ECT) that was refractory to treatment with triptan medications but which resolved with dihydroergotamine (DHE)." | ( Josephs, KA; Stead, M, 2005) |
| "This is mostly observed in patients with migraine headache background and specifically during the downregulation stage of treatment, when very low levels of 17-beta-E2 are observed." | ( Amir, BY; Gad, P; Gal, I; Guy, B; Itzhak, W; Yaacov, B, 2005) |
| "The debilitating effect of migraine has fueled the search for more specific agents to treat its characteristic and associated symptoms." | ( Loder, EW; Mathew, NT, 2005) |
| "With regard to acute treatment of migraine, clinical trials using per protocol primary endpoints do not reflect the more favorable experience with triptans in general practice." | ( Pascual, J, 2005) |
| "Menstrual migraines are particularly difficult-totreat." | ( Allais, G; Benedetto, C; Bussone, G; D'Amico, D; Grazzi, L; Moschiano, F; Roncolato, M; Usai, S, 2005) |
| "A total of 899 patients with migraine treated 1 (18." | ( Diener, HC, 2005) |
| "Severe migraine attacks are treated with triptans." | ( Göbel, H, 2005) |
| "The management of pediatric migraine requires a balance of biobehavioral measures coupled with agents for acute treatment and, if needed, daily preventive medicines." | ( Lewis, DW; Sowell, M; Winner, P; Yonker, M, 2005) |
| "Use of medication to treat the acute migraine attack was significantly reduced by topiramate compared with placebo (p < 0." | ( Bussone, G; Diener, HC; Pfeil, J; Schwalen, S, 2005) |
| "We describe an MS patient who developed migraine headaches, which followed a specific pattern coincident with interferon-beta administration." | ( Fast, A; Khromov, A; Nissinoff, J; Segal, M, 2005) |
| "Treatment of pediatric migraine includes an individually tailored regimen of both nonpharmacologic and pharmacologic measures." | ( Berger, MY; Bruijn, JK; Damen, L; Koes, BW; Passchier, J; Verhagen, AP, 2005) |
| "Most people who experience migraine use OTC medications to treat their symptoms, but no head-to-head clinical trials comparing these agents with prescription migraine therapies have been published." | ( Baggish, J; Battikha, JP; Elkind, AH; Gallagher, RM; Goldstein, J; Hoffman, H; Saper, JR; Silberstein, SD; Smith, TR, 2005) |
| "The pathogenesis of migraine involves multiple peripheral and central neural mechanisms that individually have been successful targets for acute (abortive) and preventive treatment." | ( Alexander, WJ; Littlefield, DE; Smith, TR; Spruill, SE; Stark, SR; Sunshine, A, 2005) |
| "Patients whose migraines are frequent, cause disruptions of daily routines, or are unresponsive to acute treatment are primary candidates for preventive migraine therapy." | ( Brown, JS; Friedman, M; Menzin, J; Miller, JD; Neumann, PJ; Papadopoulos, G, 2005) |
| "Treatment strategies for migraine are directed toward managing acute episodes." | ( Brown, JS; Friedman, M; Menzin, J; Miller, JD; Neumann, PJ; Papadopoulos, G, 2005) |
| "Model inputs included baseline migraine frequency (the base case assumed 6 per month, consistent with the average rate in the TPM trials), treatment discontinuation (including discontinuation due to adverse events), treatment response (ie, > or = 75%, 50% to 75%, and <50% reduction in migraine frequency), cost of preventive therapy (TPM plus physician visits for medication titration), cost of acute treatment per attack (including pharmacy and medical service costs), hours of disability per attack, hourly wage, and quality-of-life (utility) weights." | ( Brown, JS; Friedman, M; Menzin, J; Miller, JD; Neumann, PJ; Papadopoulos, G, 2005) |
| "A patient with migraine needs acute treatment as early as possible when the attack occurs." | ( Olesen, J, 2005) |
| "At present, FDCs are commonly used in migraine treatment, and more are in development." | ( Loder, E, 2005) |
| "In the acute migraine attack patients were treated intravenously with either 1000mg paracetamol (acetaminophen) or placebo." | ( Evers, S; Jürgens, T; Kaempfe, N; Kraemer, C; Leinisch, E; May, A; Sostak, P; Straube, A, 2005) |
| "Adult patients with migraine treated two migraine attacks, the first with their usual nontriptan therapy (nonsteroidal anti-inflammatory drugs, 57%; analgesics, 27%; or ergot derivatives, 16%) and the second with rizatriptan 10-mg wafer." | ( García-Moncó, C; López-Gil, A; Pascual, J; Roig, C; Yusta Izquierdo, A, 2005) |
| "Patient surveys have indicated that migraine sufferers consider complete pain relief, no recurrence, rapid onset and no side-effects to be the most important attributes of their acute treatment." | ( Dahlöf, CG; Mathew, N; Nappi, G; Sandrini, G, 2005) |
| "A modelled analysis of the costs of migraine-related productivity losses in US corporations indicated that the use of rizatriptan rather than usual care to treat migraines could result in annual cost offsets of approximately 84-118 US dollars (2000 values) per employee in lost productivity avoided." | ( Foster, RH; McCormack, PL, 2005) |
| "Single migraine attacks were treated successfully with triptanes." | ( Bickel, A; Kornhuber, J; Maihöfner, C; Ropohl, A, 2005) |
| "Patients treated all migraine attacks for 2 months with sumatriptan (100 mg) and for 2 months with placebo." | ( Aurora, SK; Dowson, AJ; Massiou, H, 2005) |
| "Ten healthy adult migraineurs (5 migrainous vertigo and 5 migraine without associated vestibular symptoms) with a history of motion sickness were tested in three sessions: a baseline vestibular battery and two motion sickness provocation sessions two hours following randomly ordered blinded pre-treatment with either oral rizatriptan 10 mg or placebo." | ( Furman, JM; Marcus, DA, 2006) |
| "Similarly, CGRP and VIP levels during a migraine headache were significantly reduced within 2 hours after sumatriptan treatment and reported symptom relief." | ( Bellamy, JL; Cady, RK; Durham, PL, 2006) |
| "Patients recorded migraine headache intensity before and after treatment using a 4-point scale." | ( Lewis, D; Rothner, AD; Stankowski, J; Wasiewski, W; Winner, P, 2006) |
| "Acute migraine therapy with almotriptan 12." | ( Diener, HC; Massiou, H; Pascual, J, 2006) |
| "Chronic daily administration of migraine prophylactic drugs dose-dependently suppressed CSD frequency by 40 to 80% and increased the cathodal stimulation threshold, whereas acute treatment was ineffective." | ( Ayata, C; Dalkara, T; Jin, H; Kudo, C; Moskowitz, MA, 2006) |
| "This may lead to misdiagnosis as migraine and delayed appropriate diagnosis and treatment." | ( Keller, H; Pfadenhauer, K; Schönsteiner, T, 2006) |
| "Effective assessment and treatment of migraine will lead to better anesthesia management." | ( McCabe, JT; O'Sullivan, J, 2006) |
| "Adult migraineurs (n = 783) treated one migraine attack with either rofecoxib (25 or 50 mg), ibuprofen 400 mg, or placebo in a randomized, double-blind study." | ( Barraclough, E; Dahlof, C; Klipfel, M; Lines, C; Loeys, T; Malbecq, W; Reines, S; Saper, J; So, Y; Tfelt-Hansen, P; Visser, H; Yuen, E, 2006) |
| "Histamine may prove to be effective in migraine prophylaxis, as an specific treatment aimed to limit excessive inflammatory responses involved in the pathophysiology of migraine." | ( Millán Guerrero, R; Tene, CE; Trujillo Hernández, B, 2006) |
| "A total of 64 patients with migraine headache, aged 14 to 57 years, were randomly allocated to the 2 treatment groups." | ( Ashtary, F; Ghorbani, A; Janghorbani, M; Nasr, V; Shaygannejad, V; Zakizade, N, 2006) |
| "The acute treatment of migraine has substantially changed over the past 15 years, and therefore, the substances associated with MOH may have changed as well." | ( Bigal, ME; Meskunas, CA; Rapoport, AM; Sheftell, FD; Tepper, SJ, 2006) |
| "The sequence and timing of taking migraine medications, whether prescription or over-the-counter, and the patient's response to their treatment, is unknown." | ( Hopkins, M; Malik, SN; Silberstein, SD; Young, WB, 2006) |
| "haloperidol in treatment of acute migraine headache in a double-blind, randomized, placebo-controlled study design." | ( Honkaniemi, J; Liimatainen, S; Rainesalo, S; Sulavuori, S, 2006) |
| "Menstrual migraine (MM) attacks are a challenge for the headache specialist, because they are particularly difficult to treat." | ( Acuto, G; Allais, G; Benedetto, C; Bussone, G; Cabarrocas, X; Esbri, R, 2006) |
| "TAME (Treat A Migraine Early)1 was conducted at 46 centers in the United States; TAME2, at 48 centers in the United States." | ( Cady, R; Hustad, CM; Martin, V; Mauskop, A; Ramsey, KE; Rodgers, A; Skobieranda, F, 2006) |
| "Gastroparesis frequently happens during migraine attacks, postponing the onset of action of orally administered drugs." | ( Bigal, ME; Filho, PF; Krymchantowski, AV, 2006) |
| "Assess the impact of migraine preventive therapy on patient-reported routine daily activities using the Migraine Specific Questionnaire (MSQ) and the Medical Outcomes Study Short Form-36 (SF-36) in patients with migraine who participated in a 26-week, randomized, double-blind, placebo-controlled trial of topiramate for migraine prevention." | ( Fairclough, D; Forde, G; Greenberg, S; Loder, E; Papadopoulos, G; Silberstein, SD, 2006) |
| "Adult patients treated 2 sequential migraine attacks with rizatriptan 10 mg and a usual-care prescription migraine medication in a crossover manner." | ( Barlas, S; Bell, CF; Foley, KA; Hu, XH; Solomon, G, 2006) |
| "The pharmacologic treatment of migraine includes preventive and acute strategies." | ( Bigal, ME; Krymchantowski, AV, 2006) |
| "Identifying further triggers for migraine headaches, in this case sucralose, may help alleviate some of the cost burden (through expensive medical therapy or missed work opportunity) as well as provide relief to migraineurs." | ( Grimsley, E; Patel, RM; Sarma, R, 2006) |
| "In this group of refractory migraine patients, zonisamide therapy did not result in a statistically significant beneficial effect on headache or on associated symptoms." | ( Ashkenazi, A; Benlifer, A; Korenblit, J; Silberstein, SD, 2006) |
| "All women kept a daily migraine diary and continued their usual treatment for migraine." | ( Aspinall, L; Ellis, J; Frith, A; Hackshaw, A; MacGregor, EA, 2006) |
| "The effect of study treatment on migraine pain was assessed immediately before dosing and at 0." | ( Almas, M; Elkind, A; Mulhern, SA; Olson, N; Sikes, C; Sunshine, A, 2006) |
| "Chronic migraine (CM) is a disabling condition with not many treatment strategies available." | ( Mercante, JP; Nunes, M; Peres, MF; Tanuri, FC; Zukerman, E, 2006) |
| "Patient-reported data from the Migraine Specific Questionnaire (MSQ) and the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) were collected at baseline and at weeks 8, 16, and 26 from an intent-to-treat population receiving either topiramate, 50, 100, or 200 mg/d, or placebo." | ( Brandes, JL; Fairclough, DL; Greenberg, SJ; Kudrow, DB; Rothrock, JF; Rupnow, MF, 2006) |
| "The treatment of migraine consists of the acute treatment of the migraine attack and prophylactic measures for either pharmacological or non-pharmacological management." | ( Göbel, H; Heinze, A; Heinze-Kuhn, K, 2006) |
| "Patients treated up to three migraine attacks per month with zolmitriptan orally disintegrating tablet (ODT) 2." | ( Almqvist, P; Dowson, A; Lacoste, JP; Shapero, G, 2006) |
| "Model inputs included baseline migraine frequency, treatment discontinuation and response, preventive and acute medical cost per attack [2005 GBP ( pound)] and gain in health utility." | ( Brown, JS; Friedman, M; Menzin, J; Neumann, PJ; Papadopoulos, G; Price, M, 2006) |
| "Most migraine patients with infrequent attacks are currently not treated with migrainespecific medication such as triptans." | ( Bach, FW; Daugaard, D; Riddersholm, B; Tfelt-Hansen, P; Tsiropoulos, I, 2006) |
| "Women kept a daily migraine diary and continued their usual treatment for migraine." | ( Aspinall, L; Ellis, J; Frith, A; Hackshaw, A; MacGregor, EA, 2006) |
| "One model of migraine headache is the systemic administration of nitric oxide (NO) donor nitroglycerin (NTG), which triggers a delayed attack without aura in many migraine patients but not in healthy volunteers." | ( Párdutz, A; Schoenen, J; Tajti, J; Varga, H; Vécsei, L, 2006) |
| "Eighty consecutive migraine patients who received preventive treatment with topiramate for 3 months with good response and tolerability were included in this observational study." | ( El Berdei, Y; Gómez-Sánchez, JC; Pascual, J, 2007) |
| "The model captured baseline migraine days, treatment discontinuation, treatment response (i." | ( Brown, JS; Friedman, M; Menzin, J; Neumann, P; Rupnow, MF, 2006) |
| "Thirty-six patients established on migraine prophylaxis were administered 500 mg sodium valproate intravenously against acute migraine attacks." | ( Marková, J; Mastík, J; Waberzinek, G, 2007) |
| "On average, patients treated 5 migraine attacks per month, with a median of 6 days between attacks." | ( Alexander, WJ; Cady, RK; Frishberg, BM; Kori, SH; Lener, SE; Ruoff, GE; Winner, P; Zhang, Y, 2007) |
| "Concomitant preventive migraine treatment was not allowed, and acute headache medication use was not to exceed 4 days per week during the double-blind maintenance period." | ( Ascher, S; Bigal, M; Brandes, JL; Dodick, DW; Freitag, FG; Greenberg, SJ; Hulihan, J; Jordan, DM; Lipton, RB; Mathew, N; Ramadan, N; Saper, J; Silberstein, SD, 2007) |
| "In menopause, hormonally associated migraine is most likely to be due to estrogen-replacement regimens, and treatment generally involves manipulating these regimens." | ( Golub, J; Loder, E; Rizzoli, P, 2007) |
| "Hormonal treatment of migraine is not a first-line treatment strategy for most women with migraine." | ( Golub, J; Loder, E; Rizzoli, P, 2007) |
| "Triptan's efficacy in the treatment of migraine has never been reported in Taiwanese." | ( Fuh, JL; Wang, SJ; Wu, ZA, 2007) |
| "Of 274 patients who treated a migraine attack, 267 were evaluated for efficacy (n = 138 eletriptan; n = 129 placebo) at 2 hours post-dose." | ( Almas, M; Linder, SL; Lipton, RB; Parsons, B; Pitman, V; Winner, P, 2007) |
| "45) is equally effective and safe for migraine with allodynia, when administered either early or late in an attack." | ( Bradley, KC; Gebeline-Myers, C; Hopkins, MM; Silberstein, SD; Young, WB, 2007) |
| "This report documents 3 cases of female migraineurs who received the dopamine modulator aripiprazole for treatment of co-occurring psychiatric disorders and experienced a decrease in migraine frequency and severity." | ( LaPorta, LD, 2007) |
| "Trials of eletriptan for acute migraine; randomised allocation to treatment groups, including a placebo group; double-blind design; International Headache Society diagnostic criteria for migraine with or without aura; single migraine attack; single-dose treatment at standard doses; adult population; baseline pain of moderate or severe intensity using a 4-point standardised rating scale (0 = no pain, 1 = mild pain, 2 = moderate pain and 3 = severe pain); and dichotomous or percentage data for at least one of the main efficacy outcomes." | ( McQuay, HJ; Moore, RA; Oldman, AD; Smith, LA, 2007) |
| "Preventive therapy is aimed at reducing migraine frequency, but should also improve the much deteriorated quality of life of the migraneur." | ( Bilbao, A; Foncea, N; Garcia-Monco, JC; Gomez-Beldarrain, M; Ruiz de Velasco, I, 2007) |
| "We have previously observed that migraine attacks impervious to triptan therapy were readily terminated by subsequent i." | ( Burstein, R; Jakubowski, M; Kainz, V; Kosaras, B; Levy, D; Zhang, XC, 2007) |
| "Forty-five migraine without aura outpatients (MO) were selected and randomly assigned to 100mg topiramate, 1000 mg levetiracetam or placebo treatment." | ( de Tommaso, M; Guido, M; Marinazzo, D; Nitti, L; Pellicoro, M; Serpino, C; Stramaglia, S, 2007) |
| "He reverted back to episodic migraines, which he treated with zolmitriptan (Zomig) nasal spray, which was effective." | ( Jung, S, 2007) |
| "Ninety-two patients with migraine were selected under criteria established by the International Headache Society and enrolled in a 12-week double-blind controlled clinical trial to evaluate the efficacy of subcutaneous administration of histamine (1-10 ng twice a week; n = 46) compared with oral administration of sodium valproate (500 mg daily dose; n = 46)." | ( Barreto-Vizcaíno, S; Garcia-Solorzano, A; Isais-Millán, R; López-Blanca, C; Membrila-Maldonado, M; Millán-Guerrero, RO; Muñoz-Solis, R; Rivera-Castaño, L, 2007) |
| "Frequency, severity, and impact of migraine disability were measured at baseline and compared to values obtained after 2 months of treatment." | ( Adelman, JU; Freeman, MC; Taylor, AP, 2007) |
| "Thirty to forty percent of migraineurs do not respond to any given triptan treatment." | ( Almas, M; Diener, HC; Dodick, DW; Goadsby, PJ; Lipton, RB; Parsons, B, 2008) |
| "As primary treatment for their migraine, all subjects received IV metoclopramide." | ( Baccellieri, A; Bania, TC; Bijur, PE; Cheung, P; Chew, E; Chu, J; Clark, S; Corbo, J; Esses, D; Fearon, S; Friedman, BW; Gallagher, EJ; Greenwald, P; Hochberg, M; Lipton, RB; Paternoster, J; Solorzano, C, 2007) |
| "The Patient Perception of Migraine Questionnaire (PPMQ) was administered at screening and 24 hours post treatment to capture patient satisfaction." | ( Ames, MH; Burch, SP; DeRossett, SE; Landy, S; McDonald, SA; Rapoport, A; Rothrock, J, 2007) |
| "Acute treatment of menstrual migraine (MM) attacks is often incomplete and unsatisfactory, and perimenstrual prophylaxis with triptans, oestrogen supplementation or naproxen sodium may be needed for decreasing frequency and severity of the attack." | ( Barrilà, C; Belloni, C; Guidotti, F; Guidotti, M; Mauri, M, 2007) |
| "However, migraine remains underdiagnosed, and patients with migraine remain undertreated." | ( Mueller, LL, 2007) |
| "Use of preventive therapy for migraine is often recommended for only 6-9 months, but no randomised, placebo-controlled trials have investigated migraine frequency after the end of prophylaxis." | ( Agosti, R; Allais, G; Bergmans, P; Bussone, G; Davies, B; Diener, HC; Ertas, M; Lanteri-Minet, M; Reuter, U; Sánchez Del Río, M; Schoenen, J; Schwalen, S; van Oene, J, 2007) |
| "The correlation between CGRP release and migraine headache points to the potential utility of CGRP receptor antagonists as novel therapeutics in the treatment of migraine." | ( Burgey, CS; Corcoran, HA; Fay, JF; Graham, SL; Hershey, JC; Johnston, VK; Kane, SA; Koblan, KS; Moore, EL; Mosser, SD; Paone, DV; Salvatore, CA; Shaw, AW; Vacca, JP; Williams, TM, 2008) |
| "Patients treated a moderate or severe migraine headache at the earliest sign of nausea with either rizatriptan 10 mg ODT or placebo (2 : 1)." | ( Freitag, F; Hamid, MA; Hustad, CM; Ramsey, KE; Rodgers, A; Skobieranda, F; Taylor, FR, 2008) |
| "Adult patients with physician-diagnosed migraine were treated with intravenous phenothiazine and at discharge were randomised to receive either 8 mg oral dexamethasone or placebo as a single dose." | ( Clooney, M; Kelly, AM; Kerr, D, 2008) |
| "Twenty patients affected by migraine were treated with TPM monotherapy." | ( Cervellino, A; Corona, M; Izzi, F; Marciani, MG; Massoud, R; Placidi, F; Romigi, A; Torelli, F; Uasone, E; Zannino, S, 2008) |
| "Prior to treatment, the presence of migraine-associated characteristics including aura, allodynia-associated symptoms, photophobia, phonophobia, and nausea were similar for both MRM and nonMRM attacks." | ( Biondi, DM; Cady, RK; Diamond, ML; Finlayson, G; Greenberg, SJ; Mao, L; Wright, P, 2008) |
| "To test this hypothesis in migraine patients in vivo using PET and alpha-[(11)C]methyl-l-tryptophan as a surrogate marker of brain 5-HT synthetic rate during different phases of their migraine attack and after acute antimigraine therapy with sumatriptan, and to compare them with normal controls." | ( Aubé, M; Diksic, M; Dobson, C; Hamel, E; Sakai, Y, 2008) |
| "Ninety patients with migraine were selected in a 12-week double-blind controlled clinical trial to evaluate the efficacy of subcutaneous administration of histamine (1-10 ng twice a week) compared with oral administration of topiramate (100 mg daily dose)." | ( Baltazar, LM; Barreto-Vizcaíno, S; Gutiérrez, I; Isais-Millán, R; Millán-Guerrero, RO; Rivera-Castaño, L; Trujillo-Hernández, B, 2008) |
| "Administration of opioids for migraine headache may result in longer ED stays when compared with non-opioid migraine treatments." | ( Chan, TC; Davis, DP; Deutsch, R; Tornabene, SV; Vilke, GM, 2009) |
| "Based on the belief that migraine was due to increased sympathetic activity, ergotamine was first used in the acute treatment of migraine by Maier in Switzerland in 1925." | ( Koehler, PJ; Tfelt-Hansen, PC, 2008) |
| "Of 173 patients who treated a migraine, 123 patients (71." | ( Diamond, M; Diamond, S; Freitag, F; Janssen, I; Rodgers, A; Skobieranda, F, 2008) |
| "Research suggests treating a migraine at the first sign of pain increases the likelihood of the best clinical outcome." | ( Ames, MH; Byrd, SC; Couch, JR; Goldstein, J; Lener, SE; Mannix, LK; McDonald, SA; Silberstein, SD; Toso, C, 2008) |
| "Patients treated a single migraine within 1 hour of onset of migraine head pain and while the pain was mild with either sumatriptan/naproxen or placebo." | ( Ames, MH; Byrd, SC; Couch, JR; Goldstein, J; Lener, SE; Mannix, LK; McDonald, SA; Silberstein, SD; Toso, C, 2008) |
| "In a randomized, cross-over design, 112 migraineurs treated two moderate or severe attacks with almotriptan 12." | ( De Klippel, N; Giurgea, S; Herroelen, L; Jacquy, J; Louis, P; Monseu, G; Schoenen, J; Vandenheede, M, 2008) |
| "An important issue in the management of migraine is the advice given to patients as to when to take their treatment in the course of the attack." | ( Goadsby, PJ, 2008) |
| "At present, frontline therapies in migraine's acute treatment include the use of NSAIDS and triptans." | ( Farinelli, I; Martelletti, P; Missori, S, 2008) |
| "The paradigm of early treatment of the migraine attack at mild pain intensity has become one alternative to circumventing the problem of compromised oral absorption of symptomatic drugs due to migraine-induced gastrointestinal dysmotility." | ( Dahlöf, C, 2006) |
| "Drug prevention of migraine is recommended if more than three attacks occur per month, acute drug treatment is insufficient, or very severe attacks with aura are the main problem." | ( Evers, S, 2008) |
| "As many as 30% of young patients with migraine experience such frequent and disabling attacks, or have unsatisfactory results and/or experience adverse effects with pharmacologic treatment of acute migraine attack, that daily preventive medications are required." | ( Cuvellier, JC; Riquet, A; Vallée, L, 2008) |
| "After nitroglycerin administration, the migraine rat model was established according to ethology evaluation." | ( Gu, T; Li, CF; Ma, XX; Ma, Z; Wang, SJ, 2008) |
| "We included subjects with refractory migraine (episodic migraine with 8-14 days of headache per month or transformed migraine, who had previously failed at least 2 trials of adequate preventive therapy)." | ( Bigal, M; Rapoport, A; Sheftell, F; Tepper, D; Tepper, S, 2008) |
| "Six cases of chronic migraine were treated with acupuncture at Fengchi (GB 20), Waiguan (TE 5), Yang-lingquan (GB 34) on the Shaoyang Channel." | ( Li, XZ; Liang, FR; Liu, XG; Song, WZ; Tang, Y; Zeng, F, 2008) |
| "Frequent migraine headaches can have a significant impact on disability, prompting the need for early recognition and treatment." | ( Oztürk, A; Unalp, A; Uran, N, 2008) |
| "One hundred patients with migraine were selected in a 12-week double-blind controlled clinical trial to evaluate the efficacy of subcutaneous administration of histamine (1-10 ng twice a week) n = 50, compared with administration of 50 U of BoNTA (one injection cycle) n = 50." | ( Barreto-Vizcaíno, S; Isais-Millán, S; Millán-Guerrero, RO; Rios-Madariaga, C; Rivera-Castaño, L, 2009) |
| "We then briefly discuss migraine treatment behavior issues, including early treatment and adherence to treatment." | ( Bigal, ME; Cady, R; Hu, H; Kurth, T; Santanello, N, 2009) |
| "The surgical treatment of migraine headache is a recent innovation that has broadened the potential patient population who may benefit from craniofacial surgical techniques to millions of affected adults." | ( Eshraghi, Y; Gosain, AK; Kung, TA; Scher, MS; Totonchi, A, 2009) |
| "We believe that surgical treatment of migraine headaches may be a realistic option for these patients." | ( Eshraghi, Y; Gosain, AK; Kung, TA; Scher, MS; Totonchi, A, 2009) |
| "Experienced migraineurs who reported a mild migraine pain phase, dissatisfaction with the previous sumatriptan treatment and some dissatisfaction with their current treatment regimen had no experience with sumatriptan at the 100 mg dose were enrolled in an open-label, single group study." | ( Burch, SP; Cady, RK; Kwong, WJ; Landy, S; McDonald, SA; Nelsen, AC; Newman, LC; O'Carroll, P, 2008) |
| "The role of glutamate in migraine treatment has not been much studied, even if this amino acid seems to be crucial in the pathogenesis of migraine." | ( Bertolini, A; Ferrari, A; Pinetti, D; Spaccapelo, L; Tacchi, R, 2009) |
| "Topiramate treatment for migraine prevention was associated with significantly lower healthcare resource use (ER visits, diagnostics, acute treatment) in the first 6 months of treatment, with continuing decreases, including physician office visits, during the second 6 months of treatment." | ( Quimbo, RM; Rupnow, MF; Wertz, DA; Yaldo, AZ, 2009) |
| "Treatment patterns in migraine patients with cardiovascular risk factors are largely unknown." | ( Egberts, AC; Tijssen, CC; Wammes-van der Heijden, EA, 2009) |
| "For episodic migraine, specific treatment was used by 19." | ( Bigal, ME; Borucho, S; Lipton, RB; Serrano, D, 2009) |
| "In the moderate/severe migraine studies of 2068 individuals treated with rizatriptan, 284 (13." | ( Bigal, ME; Ho, TW; Rodgers, A, 2009) |
| "GW273629 1500 mg was administered to 15 migraine patients both ictally and interictally." | ( de Hoon, JN; Depré, M; Guillard, F; Laurijssens, BE; Lunnon, MW; Palmer, J; Van der Schueren, BJ; Van Hecken, A; Vanmolkot, FH, 2009) |
| "Pre-treatment 81% of migraine patients and 43." | ( Ruangsuwan, S; Sri-udomkajorn, S, 2008) |
| "Treatment childhood tension-type and migraine headache by reassurance, avoid the probably precipitating factors, intermittent analgesics and usage of amitriptyline or propanolol had good efficacy in reducing the severity of attack." | ( Ruangsuwan, S; Sri-udomkajorn, S, 2008) |
| "The goals of acute treatment of migraine are cost-effective rapid relief, consistent reduction of disability, and reduced use of rescue medications." | ( Spears, RC; Tepper, SJ, 2009) |
| "The course of migraine attacks during 24 hours treated with almotriptan and ergotamine plus caffeine was modelled with a decision tree, using efficacy data from a recent randomized, double-blind clinical trial comparing the two drugs." | ( Comas, A; Heras, J; Láinez, JM; Slof, J, 2009) |
| "Although the pharmacotherapy of migraine has advanced in parallel with our understanding of the pathophysiology of the disease, there is still a considerable unmet need to find more effective treatments." | ( Andreou, AP; Goadsby, PJ, 2009) |
| "To reexamine the efficacy of terminating migraine headache by administration of sumatriptan during the visual-aura phase of the attack." | ( Aurora, SK; Barrodale, PM; Burstein, R; Jakubowski, M; McDonald, SA, 2009) |
| "Stimuli known to elicit migraine, such as nitric oxide donors or stress, produce hyperalgesia in morphine- but not in saline-pretreated rats even long after the discontinuation of the opiate." | ( De Felice, M; Porreca, F, 2009) |
| "Participants treated their menstrual migraine attack during the mild pain phase (within 1 hour of onset) with sumatriptan 85 mg and naproxen sodium 500 mg in a single fixed-dose formulation (sumatriptan-naproxen) or placebo." | ( Cady, RK; Derosier, FJ; Diamond, ML; Lener, SE; Mannix, LK; Martin, VT; McDonald, SA; White, JD, 2009) |
| "Treatment options for pediatric migraine are limited." | ( Cruz, MJ; Hardison, HH; Khurana, DS; Kothare, SV; Legido, A; Marks, HG; Melvin, JJ; Valencia, I; Yum, S, 2009) |
| "In the treatment of acute migraine, patients need a drug that provides convenient dosing and consistent effectiveness." | ( Evans, RW, 2000) |
| "Because of various contraindications, migraine-specific medications may not be a treatment option in up to 50% of patients seen in the ED." | ( Feldon, S; Fisher, S; Friedman, D; Holloway, R, 2009) |
| "Menstrual-related migraine (MRM) affects the majority of female migraineurs, with menstrual-associated attacks reported to be more disabling, longer lasting, and less responsive to traditional treatments than nonmenstrual attacks." | ( Calhoun, AH; Hutchinson, S, 2009) |
| "Adults with migraine with or without aura (International Headache Society criteria) treated a moderate or severe attack with oral telcagepant 50 mg (n = 177), 150 mg (n = 381), 300 mg (n = 371), or placebo (n = 365) in a randomized, double-blind trial." | ( Assaid, C; Connor, KM; Diener, HC; Fan, X; Fei, K; Ho, TW; Kost, J; Lines, C; Lucas, S; Shapiro, RE, 2009) |
| "It is effective as a monotherapy for migraine prophylaxis." | ( Atakay, S; Kececi, H, 2009) |
| "This finding suggests that in migraineurs childhood maltreatment may be a risk factor for development of comorbid pain disorders." | ( Aurora, SK; Brandes, JL; Dafer, RM; Drexler, E; Eloff, A; Herial, NA; Hutchinson, S; Khuder, SA; Martin, VT; Peterlin, BL; Recober, A; Stein, MR; Tietjen, GE; Utley, C; White, L, 2010) |
| "Two cases with severe migraines resistant to conventional therapy were evaluated to see the response to dextroamphetamine sulfate." | ( Check, D; Check, JH; Cohen, R, 2009) |
| "Case 2 showed that even premenstrual migraines can respond to this therapy." | ( Check, D; Check, JH; Cohen, R, 2009) |
| "For the treatment of migraine, hydroxypropyl methylcellulose (HPMC) K4M and K15M based microspheres containing sumatriptan succinate (SS) were prepared by spray-drying technique." | ( Chauk, DS; Gattani, SG; Jain, SA; Mahajan, HS; Tekade, AR, 2009) |
| "The majority of patients with migraine headaches are treated in non-specialized institutions though data on treatment outcomes are largely derived from tertiary care centers." | ( Becker, V; Bornhoevd, K; Fritzsche, D; Humbert, T; Nelles, G; Sandow, P; Schäuble, B; Schmitt, L, 2010) |
| "Symptomatic acute treatment of migraine should provide rapid and effective relief of the headache pain." | ( Nappi, G; Perrotta, A; Sandrini, G; Tassorelli, C, 2009) |
| "Development of migraine has also been observed in patients treated with ganglion blockage for sympathetic reflex dystrophy." | ( Dogrukol-Ak, D; Korkmaz, OT; Tore, F; Tunçel, N, 2010) |
| "For treatment and control of the migraine, in patients with normal encephalogram, propranolol with tricyclic antidepressive drugs advised and for abnormal encephalogram sodium valprovate can be the better treatment for management and reduction of headache attacks." | ( Abolfazl, MB; Keyvan, G, 2009) |
| "Patients with migraine headaches are frequently prescribed topiramate to treat their condition." | ( Aronwald, RM; Cole, KL; Wang, EE, 2012) |
| "Severe, frequent and disabling migraine attacks, as well as those poorly responsive to acute care medication, require preventive treatment, which is often under-utilized." | ( Rapoport, AM; Vikelis, M, 2010) |
| "Patients with frequent migraine with or without aura episodes who received topiramate in our clinic were treated in a homogeneous way." | ( Cacabelos, P; Conde, A; El Berdei, Y; Pascual, J; Rivas, MT; Riveira, C, 2009) |
| "It is possible that some migraineurs with PFO may benefit from evaluation and treatment of toxoplasmosis in the future once more information is known." | ( Prandota, J, 2010) |
| "In summary, in this small sample of migraine patients topiramate treatment was associated with increased insulin sensitivity, increased adiponectin concentration and a reduction of body fat in all treated patients." | ( Brinkhoff, J; Drenckhan, M; Lehnert, H; Schütt, M; Sommer, C, 2010) |
| "Optimum acute treatment of migraine requires prevention of headache as a top priority." | ( Taylor, FR, 2010) |
| "While triptans are the primary line of migraine treatment, nonsteriodal anti-inflammatory drugs are the most commonly prescribed therapy for dysmenorrhea symptoms." | ( Cady, R; Derosier, F; Durham, PL; Martin, V; McDonald, S; Vause, CV, 2010) |
| "Chronic migraine sufferers were randomized into two groups and treated with 25 or 50mg/day of amitriptyline or 250U of botulinum toxin type A." | ( Cardeal, M; Magalhães, E; Melo, A; Menezes, C, 2010) |
| "To describe the perception of migraine by neurologists in France, to compare perceptions between neurologists who did and did not suffer from migraines and to describe treatments used for their own migraines." | ( Allaf, B; Becker, H; Donnet, A; Lantéri-Minet, M, 2010) |
| "Patients with migraine are usually undertreated, as treatment guidelines are frequently not followed and, therefore, resulting treatment satisfaction is low." | ( Allaf, B; Becker, H; Donnet, A; Lantéri-Minet, M, 2010) |
| "Neurologists who considered themselves migraineurs also provided data on migraine impact, treatment and on treatment satisfaction." | ( Allaf, B; Becker, H; Donnet, A; Lantéri-Minet, M, 2010) |
| "Given the role of CGRP in migraine pathology, the potential of CGRP receptor antagonists in the treatment of migraine has been investigated." | ( Durham, PL; Vause, CV, 2010) |
| "Chronic migraine is a common cause of chronic daily headache, which is often refractory to standard treatment." | ( Lovell, BV; Marmura, MJ, 2010) |
| "From a database of 700 patients with migraine, those with episodic migraine and who had followed a course of preventive treatment, for the first time, with topiramate or nadolol were selected for the study." | ( Artal-Roy, J; García-Gómara, MJ; Gracia-Naya, M; Huerta-Villanueva, M; Latorre-Jiménez, AM; Mauri-Llerda, JA; Ríos-Gómez, C; Sánchez-Valiente, S; Santos-Lasaosa, S, 2010) |
| "On 23 migraineurs showing pain at pressure on scalp arteries, we administered topical capsaicin 0." | ( Cianchetti, C, 2010) |
| "Pain relief responses for treated migraines of moderate or severe intensity at baseline were 61." | ( Armstrong, RB; Berenson, F; Biondi, DM; Mao, L; Pakalnis, A; Vasconcellos, E, 2010) |
| "We report a case of a patient with status migrainosus unresponsive to analgesic therapy in whom electroencephalographic recording revealed an epileptic origin." | ( Belcastro, V; Calabresi, P; Pierguidi, L; Striano, P; Tambasco, N, 2011) |
| "Frequent migraine sufferers who failed to respond to 5 weeks of optimized acute migraine drug therapy were randomized to a 2 (Behavioral Migraine Management+, Behavioral Migraine Management-) × 2 (β-blocker, placebo) treatment design." | ( Holroyd, KA; Seng, EK, 2010) |
| "Patients with a clinical diagnosis of migraine underwent standard ED treatment and were discharged with 2 tablets of either secobarbital 100 mg or placebo." | ( Crawford, DM; Gerhardt, RT; Hermstad, E; Hunter, CJ; Pfaff, J; Rayfield, J, 2011) |
| "This review will provide an overview of migraine in adolescents focusing on epidemiology, pathophysiology, classification and a review of treatment options with attention on the evidence from the past 5 years surrounding almotriptan." | ( Lewis, DW, 2010) |
| "Adult sufferers with an established migraine diagnosis according to the International Classification of Headache Disorders, second edition (ICHD-II), treated one moderate or severe attack with 50 mg diclofenac potassium for oral solution (dissolved in approximately 2 ounces of water; N=343) or matching placebo (N=347)." | ( Grosberg, B; Lipton, RB; Pearlman, SH; Quiring, JN; Saper, JR; Singer, RP; Sorrentino, JV, 2010) |
| "In a double-blind-cross-over study, 13 migraine without aura (MO) patients were administered GTN 0." | ( Jensen, LT; Olesen, J; Petersen, KA; Tfelt-Hansen, P; Tvedskov, JF, 2010) |
| "Adults with migraine were randomized, double-blind, to telcagepant 140 mg, telcagepant 280 mg, or control treatment sequences to treat four moderate-to-severe migraine attacks." | ( Ashina, M; Dahlöf, CG; Froman, S; Ho, AP; Ho, TW; Kost, JT; Leibensperger, H; Lines, CR; Saper, JR; Silberstein, SD, 2010) |
| "A 40-year-old woman with migraine headache who was under topiramate treatment referred with bilateral ocular pain and visual blurring." | ( Jabbarpoor Bonyadi, MH; Soheilian, M; Soheilian, R, 2011) |
| "It is currently unknown whether migraine patients who cannot be adequately helped with triptans might benefit from treatment with telcagepant." | ( Dodick, DW; Ferrari, MD; Ho, TW; Kost, J; Lines, C; Olesen, J, 2011) |
| "Recently, chronic treatment with five migraine prophylactic drugs was shown to suppress cortical spreading depression, implicating spreading depression as a common therapeutic target in migraine prophylaxis." | ( Ayata, C; Dileköz, E; Hoffmann, U; Kudo, C, 2011) |
| "An understanding of which migraine patients are likely to benefit maximally from treatment with DHE in its various forms." | ( Galvez-Jimenez, N; Morren, JA, 2010) |
| "Thirty-nine migraine patients with a body mass index <25 kg/m(2) and without endocrinological or metabolic diseases were assigned to two treatment groups, one receiving amitryptiline, the other flunarizine, for 3 months." | ( Calabresi, P; Caproni, S; Corbelli, I; Cupini, ML; Pini, LA; Sarchielli, P, 2011) |
| "chuanxiong, traditionally used to treat migraine." | ( Feng, Y; He, CY; Hong, YL; Liang, S; Lin, X; Wang, YH; Xu, DS, 2011) |
| "Acute treatment of migraine remains a clinical challenge despite the availability of triptans and other agents." | ( Aurora, SK; Borland, SW; Dodick, DW; Kori, SH; Silberstein, SD; Tepper, SJ; Wang, M, 2011) |
| "In patients whose migraine attacks have historically failed to respond to oral triptans, this route of administration has also proven to be more consistent and effective." | ( Freitag, FG, 2011) |
| "A woman with severe migraine headaches resistant to standard therapy was treated with dextroamphetamine sulfate." | ( Check, JH; Cohen, R, 2011) |
| "Menstrually related migraine (MRM) is a particularly difficult-to-treat pain condition, associated with substantial disability." | ( Allais, G; Benedetto, C; Bussone, G; Omboni, S; Tullo, V; Zava, D, 2011) |
| "Treatment of migraine headache using a mix of metoclopramide and an NSAID has been patented (European Patent EP1014961) as well as a short series showing great efficacy and tolerability of metoclopramide in patients wtih migraine attacks." | ( Cuello, D; Fragoso, M; Salazar, G; Sergio, P; Vergez, L, 2011) |
| "A total of 140 patients with migraine without aura were recruited and assigned randomly to 2 different groups: the acupuncture group treated with verum acupuncture plus placebo and the control group treated with sham acupuncture plus flunarizine." | ( Guo, J; Li, SS; Liu, CZ; Liu, HL; Wang, LP; Yi, JH; Zhang, XZ; Zhang, Y; Zhao, JP, 2011) |
| "The 'Migraine Intervention Score' (MIS) is a new self-administered scale that can be used to quantify the severity of specific migraine symptoms." | ( Göbel, H; Heinze, A, 2011) |
| "Of 800 patients with migraine who required preventive treatment for the first time, the drop-out rate was 19." | ( Artal-Roy, J; García-Gomara, MJ; Gracia-Naya, M; Latorre-Jiménez, AM; Mauri-Llerda, JA; Ríos-Gómez, C; Sánchez-Valiente, S; Santos-Lasaosa, S, 2011) |
| "Whether the migraine was episodic or chronic, the presence of medication abuse and the drugs used to treat the seizures were not related with dropping out of preventive treatment." | ( Artal-Roy, J; García-Gomara, MJ; Gracia-Naya, M; Latorre-Jiménez, AM; Mauri-Llerda, JA; Ríos-Gómez, C; Sánchez-Valiente, S; Santos-Lasaosa, S, 2011) |
| "Intractable migraine headaches can be added to the list of various pain syndromes related to a disorder of the sympathetic nervous system resistant to standard therapy but showing dramatic improvement with treatment with sympathomimetic amines." | ( Check, D; Check, JH; Cohen, R, 2011) |
| "Subjects were instructed to treat migraines as early as possible and were allowed to rescue 2 hours post dose with a single dose of a naproxen-containing product, over-the-counter pain reliever, or anti-emetics." | ( Derosier, FJ; Hershey, AD; Lewis, D; Linder, SL; McDonald, SA; Pearlman, E; Richard, NE; Rothner, D; Runken, MC; Winner, PK, 2011) |
| "Overall, 42% of the migraine attacks were pain-free within 2 hours of treatment with sumatriptan/naproxen sodium, subjects reported improvements from baseline in 2 of 3 quality of life domains over time, and were generally satisfied with the efficacy and overall treatment at the end of the study." | ( Derosier, FJ; Hershey, AD; Lewis, D; Linder, SL; McDonald, SA; Pearlman, E; Richard, NE; Rothner, D; Runken, MC; Winner, PK, 2011) |
| "Stepped care in migraine management uses symptomatic treatments as first-line, reserving triptans for those in whom this proves ineffective." | ( Lampl, C; Steiner, TJ; Voelker, M, 2012) |
| "In neither migraine nor ETTH does pre-treatment headache intensity predict success or failure of aspirin." | ( Lampl, C; Steiner, TJ; Voelker, M, 2012) |
| "Evidence suggests that allodynic migraineurs may demonstrate a better response when treated prior to developing central sensitization, and that these patients are treated more effectively with a compound of sumatriptan and naproxen sodium than either drug alone." | ( Hoagland, NA; Hoagland, R; Landy, S, 2012) |
| "In the 90 patients with baseline Migraine-ACT scores ≤2 (indicating the need for a change in therapy), efficacy data were collected from patient diaries, and satisfaction was measured with the revised Patient Perception of Migraine Questionnaire (PPMQ-R)." | ( Aurora, SK; Brandes, JL; Cady, RK; Farr, SJ; Fox, AW; Myers, JA; Rothrock, JF, 2011) |
| "Serum magnesium in migraine patients was significantly lower than the normal population and related to the frequency of migraine attacks, supporting the use of magnesium in prevention and treatment of migraine." | ( Farhoudi, M; Ghaemmaghamihezaveh, S; Hamdi, A; Hasani, A; Mohammadzade, S; Savadi-Oskouei, D; Talebi, M, 2011) |
| "A sizeable proportion of migraineurs in need of preventive therapy do not significantly benefit from monotherapy." | ( Bigal, ME; da Cunha Jevoux, C; Krymchantowski, AV, 2012) |
| "Twenty patients with migraine, aged from 23 to 45 years, were treated with agomelatin in dose 25 mg per day during 3 months." | ( Gromova, SA; Sergeev, AV; Tabeeva, GR, 2011) |
| "Patients with migraine with or without aura and no history of hypertension were randomized to sumatriptan/naproxen sodium (n=135), sumatriptan (n=136), or naproxen sodium (n=136) to treat migraine attacks for 6 months in a double-blind, parallel-group trial." | ( Adams, BE; Derosier, FJ; Goodman, DK; Thompson, AH; White, WB, 2011) |
| "Dihydroergotamine (DHE), a proven migraine treatment, currently has product labeling warning against concomitant use of CYP3A4 inhibitors because of potential drug interactions." | ( Chang, J; Dodick, D; Febbraro, S; Forst, A; Kellerman, D; Kori, S; Taylor, G; Thomas, T; Wutann, L, 2012) |
| "Traditionally, preventive treatment of migraine required daily medication." | ( Beach, ME; Browning, R; Cady, RK; Farmer, K; Tarrasch, J; Voirin, J, 2012) |
| "MEDLINE was searched using the terms "migraine" and "emergency," and "therapy" or "treatment." | ( Kelley, NE; Tepper, DE, 2012) |
| "Baseline demographic and migraine headache characteristics were generally similar between the treatment groups." | ( Schulman, EA, 2012) |
| "The impact of migraine on health-related quality of life (HRQoL) among patients with major depressive disorder (MDD) after acute antidepressant treatment has not been addressed." | ( Hung, CI; Liu, CY; Wang, SJ; Yang, CH, 2012) |
| "Acute migraine treatment options for children are limited despite a rising migraine prevalence." | ( Fraser, IP; Han, L; Han, TH; Hreniuk, D; Li, CC; Linder, S; Stoch, SA; Wagner, JA; Winner, P, 2012) |
| "In pediatric migraineurs, a weight-based dosing scheme generated plasma rizatriptan AUC((0-∞)) and C(max) values that were generally similar to those historically observed in adults administered a 10-mg dose of rizatriptan ODT (a proven effective dose)." | ( Fraser, IP; Han, L; Han, TH; Hreniuk, D; Li, CC; Linder, S; Stoch, SA; Wagner, JA; Winner, P, 2012) |
| "Patients diagnosed with migraine who had participated in a randomized, double-blind, Phase III study of the NP101 patch were given the option to use NP101 to treat migraine episodes with moderate or severe headache pain for up to 12 months in this open-label trial." | ( Goldstein, J; Pierce, MW; Pugach, N; Silberstein, S; Singer, R; Smith, TR, 2012) |
| "Forty patients (18-71 years old) with migraine were treated with 100 mg of topiramate/day over a period of 3 months." | ( Demirbas, H; Genc, A; Karabacak, H; Koyuncu, G; Oruc, S; Ucok, K; Yaman, M, 2013) |
| "Using the terms ("migraine" AND "emergency") AND ("therapy" OR "treatment"), the author searched MEDLINE for reports from ED and urgent care settings that involved all routes of medication delivery." | ( Kelley, NE; Tepper, DE, 2012) |
| "For the understanding of migraine pathophysiology, it is very important to note that a selective 5-HT(1F) receptor agonist like lasmiditan is effective in the acute treatment of migraine." | ( Olesen, J; Tfelt-Hansen, PC, 2012) |
| "The clinical implications of HAPR in migraine warrant further exploration due to the risk of stroke and MI and the potential need for antiplatelet therapy in this population." | ( Fuller, CJ; Jesurum, JT; Lucas, SM; Murinova, N; Truva, CM, 2012) |
| "For the acute treatment of migraine, we recommend the use of ibuprofen or acetaminophen for mild, moderate or severe headache." | ( Hershey, AD; Kabbouche, MA; O'Brien, HL, 2012) |
| "Acute treatment of migraine is actually based on the use of triptans, class drug which presents a clear limitation due to its cardiovascular side effects." | ( Lionetto, L; Martelletti, P; Negro, A; Simmaco, M, 2012) |
| "Treatment of adolescent migraine remains a significant unmet medical need." | ( Derosier, FJ; Goodman, DK; Granberry, WK; Hershey, AD; Jimenez, TB; Lewis, D; Linder, SL; Pearlman, E; Rothner, AD; Runken, MC; Winner, PK, 2012) |
| "A sizeable proportion of migraineurs in need of preventive treatment does not significantly benefit from monotherapy." | ( Casucci, G; Cologno, D; D'Onofrio, F; Villani, V, 2012) |
| "Any pain medication was used in 1,570 migraine attacks while study treatments were used in 1,047 attacks." | ( Baykan, B; Ertaş, M; Özge, A; Öztürk, V; Sirin, H, 2013) |
| "The clinical effect of migraine treated with pine needle moxibustion is better than that with the medicated thread moxibustion of Zhuang medicine." | ( Huang, SZ; Lai, LY; Meng, WG; Shi, L; Song, RX; Wu, LY, 2012) |
| "The pharmacologic treatment of migraine is classically divided in the management of the acute attack and preventive strategies." | ( Casolla, B; D'Alonzo, L; Lionetto, L; Martelletti, P; Mastropietri, F; Negro, A; Simmaco, M, 2012) |
| "Best practice suggests that acute migraine treatment should be stratified based on the severity of the individual event, with a goal of returning the patient to full function within 2 hours of treatment." | ( Rizzoli, PB, 2012) |
| "Acute migraine treatment options for children are limited." | ( Assaid, C; Bachman, R; Ceesay, P; Connor, KM; Dupre, N; Hämäläinen, M; Harper Mozley, L; Hewitt, DJ; Ho, TW; Lewis, D; Lines, C; Mahoney, E; Michelson, D; Pearlman, E; Strickler, N, 2013) |
| "The use of ECARD to treat a series of migraines by controlling premonitory leg edema has not been reported." | ( Akiyama, H; Hasegawa, Y, 2013) |
| "During the onset of a migraine attack of moderate-to-severe intensity, patients were asked to administer a 6-mg subcutaneous dose of sumatriptan using the auto-injector." | ( Landy, SH; Ramos, E; Schweizer, E; Tepper, SJ; Wein, T, 2013) |
| "Acute migraine headaches are common emergency department presentations, and despite evidence for various treatments, there is conflicting evidence regarding the use of KET." | ( Campbell, S; Doran, S; Kokotillo, A; Rowe, BH; Taggart, E; Villa-Roel, C, 2013) |
| "Participants completed Migraine Disability Assessment (MIDAS) and Headache Impact Test (HIT-6) questionnaires before and after treatment." | ( Bostani, A; Moradian, N; Rajabi, A; Razazian, N; Rezaei, M, 2013) |
| "Frequency, intensity and duration of migraine headaches as well as MIDAS score and administration of symptomatic medications decreased significantly between repeated follow-up visits in both groups." | ( Bostani, A; Moradian, N; Rajabi, A; Razazian, N; Rezaei, M, 2013) |
| "Eligible subjects had episodic migraine in both 2008 and 2009 and provided data on acute treatment use in both years." | ( Buse, DC; Fanning, KM; Holland, S; Lipton, RB; Reed, ML; Serrano, D, 2013) |
| "Fifty outpatients with chronic migraine refractory to at least two prophylactic medications were treated with an antioxidant formulation of 1200 mg Pinus radiata bark extract and 150 mg vitamin C daily for 3 months." | ( Chayasirisobhon, S, 2013) |
| "In this pilot study of women episodic migraineurs, the HMW : LMW ADP ratio level was associated with migraine severity and predictive of acute treatment response." | ( Dash, PD; Gower, BA; Hammond, ER; Haythornthwaite, JA; Peterlin, BL; Tepper, SJ; Tietjen, GE; Ward, TN; White, LW, 2013) |
| "Preventive migraine treatments might act by stabilizing cortical excitability level and thus the habituation to external stimuli." | ( Biasiotta, A; Cruccu, G; Di Clemente, L; Di Piero, V; Puledda, F; Truini, A; Vicenzini, E; Viganò, A, 2013) |
| "The pharmacologic treatment of migraine is classically divided in the management of the acute attack and preventive strategies." | ( Casolla, B; D'Alonzo, L; Lionetto, L; Marsibilio, F; Martelletti, P; Negro, A; Simmaco, M; Vignaroli, G, 2013) |
| "Recurrence of migraine headaches after treatment is common." | ( Cai, X; Hu, Y; Huang, Y; Song, X; Tang, H; Xie, S, 2013) |
| "Despite a number of antimigraine drugs belonging to different pharmacological classes are available, there is a huge unmet need for better migraine pharmacotherapy." | ( Galeotti, N; Ghelardini, C, 2013) |
| "Given the nature of migraine attacks, fully reversible and treatable, the headache- or migraine-provoking property of naturally occurring signaling molecules can be tested in a human model." | ( Ashina, M; Hansen, JM; Olesen, J, 2013) |
| "After treating up to three episodes of migraine in 3 months with the first treatment, patients switched to the alternate treatment for the next 3 months." | ( Allais, G; Barbanti, P; Benedetto, C; Bussone, G; Cortelli, P; Curone, M; Omboni, S; Peccarisi, C; Pezzola, D; Tullo, V; Zava, D, 2013) |
| "Studies on the acute treatment of migraine in children and adolescents are rare and difficult to design." | ( Evers, S, 2013) |
| "Acute treatments for migraine are often modified in clinical practice." | ( Buse, DC; Cunanan, CM; Kori, SH; Lipton, RB; Manack, AN; Papapetropoulos, S; Reed, ML; Serrano, D, 2013) |
| "Patterns of acute treatment for migraine were monitored from 1 year to the next in the American Migraine Prevalence and Prevention (AMPP) Study for the following couplets (2005-2006, 2006-2007, 2007-2008, and 2008-2009)." | ( Buse, DC; Cunanan, CM; Kori, SH; Lipton, RB; Manack, AN; Papapetropoulos, S; Reed, ML; Serrano, D, 2013) |
| "The acute treatment of migraine requires matching patient need to drug and formulation." | ( Tepper, SJ, 2013) |
| "A history of migraine with aura was associated with an increased risk of post-treatment neurological symptoms." | ( Hill, DA, 2014) |
| "Patients were treated for a single migraine attack." | ( Dodick, D; Fischer, TZ; Goadsby, PJ; Manos, G; Marcus, R; Stock, D, 2014) |
| "The chronic migraine headaches almost completely disappeared shortly following therapy." | ( Check, JH; Cohen, R, 2013) |
| "Duration of migraine from treatment to pain free decreased in both groups, but was more robust in group B from baseline to month 3." | ( Beach, ME; Cady, R; Dexter, K; Freitag, F; Manley, HR; Nett, R, 2014) |
| "Subjects recorded headache days, migraine attacks, duration of attacks, treatment, and treatment results daily on paper diaries." | ( Cady, R; Dexter, K; Freitag, F; O'Carroll, P; Shade, CL, 2014) |
| "The treatment of migraine was transformed in 1992 with the introduction of the first triptan-based therapy, subcutaneous (SC) sumatriptan." | ( Farr, SJ; Freitag, FG; Rothrock, JF; Smith, EF, 2013) |
| "Nausea is a common symptom of migraine, and current treatment guidelines recommend non-oral formulations for nauseated or vomiting patients." | ( Felker, E; O'Neill, C; Pierce, M; Sebree, T, 2013) |
| "Studies in which patients could treat a migraine of any severity have documented significant headache response or relief with zolmitriptan NS at 10 minutes." | ( Chen, S; Rapoport, AM; Reidenbach, F; Tepper, SJ, 2013) |
| "Chest wall pain in the presence of migraine headache, although not a common occurrence, is intriguing when it resolves with antimigraine treatment." | ( Roldan, CJ, 2014) |
| "In women with TMD and migraine, migraine significantly improved only when both conditions were treated." | ( Bigal, ME; Camparis, CM; Castanharo, SM; Goncalves, DA; Lipton, RB; Speciali, JG; Ujikawa, LT, 2013) |
| "Efficient treatment of migraine attacks could benefit patients by reducing their disability and the need for health care resources, and improving economic productivity." | ( Amini, A; Asadollahi, S; Forouzanfar, MM; Heidari, K; Shahrami, A; Vafaee, R, 2014) |
| "The efficacy of eletriptan in treating migraine attacks associated with menstruation vs those outside a defined menstrual period has not been evaluated." | ( Abdulsattar, Y; Almas, M; Bhambri, R; Chatterjee, A; Martin, VT; Ramos, E; Silberstein, S, 2014) |
| "A pain visual analogue scale (VAS) and migraine therapy assessment questionnaire (MTAQ) were completed before treatment, after 6 and 18 sections of treatment, and 1 month after completion of therapy." | ( Fathimoghadam, F; Mohseni, M; Rezvani, M; Yaraghi, A, 2014) |
| "Frequency and severity of migraine attacks, nausea, the need for rescue treatment, and work absence rate decreased similarly in both groups." | ( Fathimoghadam, F; Mohseni, M; Rezvani, M; Yaraghi, A, 2014) |
| "In six subsequent migraine attacks, each participant received either placebo or Maxalt (10-mg rizatriptan) administered under three information conditions ranging from negative to neutral to positive (told placebo, told Maxalt or placebo, told Maxalt) (N = 459 documented attacks)." | ( Burstein, R; Hoaglin, DC; Jakubowski, M; Kam-Hansen, S; Kaptchuk, TJ; Kelley, JM; Kirsch, I, 2014) |
| "The therapy for chronic migraine with botulinum toxin is now established in adults." | ( Bernhard, MK; Bertsche, A; Merkenschlager, A; Syrbe, S; Weise, S, 2014) |
| "Patients with migraine were sensitive to exposure to the earthquake and their headaches worsened despite successful prophylactic treatment with lomerizine before the Tohoku-Pacific Ocean earthquake." | ( Ishii, M; Katoh, H; Kawamura, M; Shimizu, S; Takagi, M, 2014) |
| "Once the diagnosis of migraine has been made, the ED physician is faced with the challenge of determining appropriate abortive treatment." | ( Meckler, GD; Sheridan, DC; Spiro, DM, 2014) |
| "Abortive therapy for migraine headache in the PED with chlorpromazine is associated with greater need for rescue medication and hospitalization, and higher rates of hypotension." | ( Kanis, JM; Timm, NL, 2014) |
| "Recurrent headaches and migraines are common and undertreated in children with sickle cell disease." | ( Casella, JF; DeBaun, MR; Dowling, MM; Hirtz, DG; Ichord, RN; Kirkham, FJ; Kwiatkowski, JL; Noetzel, MJ; Quinn, CT; Roach, ES; Rodeghier, MJ, 2014) |
| "Sixty patients with migraine were selected and enrolled in a 12-week double-blind controlled clinical trial to evaluate the efficacy of subcutaneous administration of N-alpha methyl histamine (1 to 3 ug twice a week ) n=30, compared to administration of 120 mg/day of oral propranolol n=30." | ( Castillo-Varela, G; Guzmán-Chávez, B; Isais-Millán, R; Millán-Guerrero, RO, 2014) |
| "Consecutive 21 patients with status migrainosus were received intra-venous chlorpromazine (maximum 25mg) with fluid treatment and their results were documented." | ( Benli, EM; Dinc, A; Gokce, M; Tuncel, D; Utku, U, 2014) |
| "Successfully screened adult migraineurs who returned baseline diaries showing 2 to 7 migraine attacks monthly and < 15 headache and/or neck pain days/month received blister packs containing 3 sumatriptan/naproxen/1 placebo for treatment of 4 migraines." | ( Calhoun, AH; Ford, S, 2014) |
| "With truly episodic migraineurs, pain freedom was significant as soon as 15 minutes following treatment with sumatriptan/naproxen (5." | ( Calhoun, AH; Ford, S, 2014) |
| "Vitamin D given in addition to anti-migraine treatment reduced the number of migraine attacks." | ( Cayir, A; Tan, H; Turan, MI, 2014) |
| "In the Netherlands, treatment of migraine is commonly performed by general practitioners (GPs)." | ( de Coo, IF; de Jong, G; van den Berg, JS; Zielman, R, 2014) |
| "Promising tools to treat migraine patients are herbal products." | ( Cevoli, S; Cologno, D; D'Andrea, G, 2014) |
| "Preventive therapy in migraine must be started with frequent or disabling headaches in children, while, no drugs have been approved for migraine preventive therapy of them up to now." | ( Fallah, R; Ferdosian, F; Shoroki, FF, 2015) |
| "Ninety cases of acute migraine attack admitted to the emergency department were randomly allocated into two treatment groups: (1) 6 mg of sumatriptan subcutaneously or (2) propofol injected intravenously in 30 to 40 mg boluses, followed by 10 to 20 mg intermittent bolus doses to sedate the patients to Ramsey score of 3 to 4." | ( Esmaeili, A; Hashemian, H; Heiranizadeh, N; Hekmatimoghaddam, S; Moshtaghion, H; Rahimdel, A, 2015) |
| "A few of these may suffer from abdominal migraine and can be treated well with antimigraine medication." | ( Nøjgaard, C; Rasmussen, E, 2014) |
| "Patients with chronic migraine (CM) and medication abuse are difficult to treat, and have a greater tendency towards chronification and a poorer quality of life than those with other types of headache." | ( Artal-Roy, J; Garcia-Gomara, MJ; Gracia-Naya, M; Hernando-Quintana, N; Latorre-Jimenez, AM; Mauri-Llerda, JA; Rios, C; Sanchez-Valiente, S; Santos-Lasaosa, S, 2014) |
| "Early treatment of migraine headaches is associated with improved outcome, but medication absorption after oral delivery may be delayed in migraineurs because of reduced gastric motility." | ( Cady, RK; Carothers, J; Djupesland, PG; Mahmoud, RA; McAllister, PJ; Messina, J; Spierings, EL, 2015) |
| "Total migraine freedom (patients with no headache, nausea, phonophobia, photophobia, or vomiting) reached significance following treatment with AVP-825 at 1 hour (19% vs 9%; P=." | ( Cady, RK; Carothers, J; Djupesland, PG; Mahmoud, RA; McAllister, PJ; Messina, J; Spierings, EL, 2015) |
| "Compared with patients without migraine, patients with migraine had a greater severity of PPS at baseline and post-treatment." | ( Chen, CY; Hung, CI; Liu, CY; Wang, SJ; Yang, CH, 2014) |
| "Integrating the treatment of migraine and anxiety disorders into the management of depression might help to improve PPS and the prognosis of MDD." | ( Chen, CY; Hung, CI; Liu, CY; Wang, SJ; Yang, CH, 2014) |
| "Ninety pediatric patients with migraine between January 2011and January 2014 were randomly divided into treatment group (45 cases) and control group (45 cases)." | ( Chen, YZ; Li, N; Zhou, KY, 2014) |
| "Because chronic treatment with migraine prophylactic drugs suppresses SD susceptibility, we tested whether migraine prophylaxis can also suppress ischemic depolarizations and improve stroke outcome." | ( Ayata, C; Can, A; Daneshmand, A; Eikermann-Haerter, K; Ferrari, MD; Lee, JH; Sengul, B; van den Maagdenberg, AM; Wei, Y; Yalcin, N; Yu, ES; Zheng, Y, 2015) |
| "The treatment of migraine depends on the frequency, severity and concomitant diseases." | ( Fehér, G; Pusch, G, 2015) |
| "Intravenous migraine therapy reduces PTH pain scores for children presenting within 14 days after mTBI." | ( Byczkowski, T; Chan, S; Kurowski, B; Timm, N, 2015) |
| "MD subjects with and without migraine demonstrated a decrease in both vertigo spells and migrainous attacks during combined therapy (from 9." | ( Benazzo, M; Bussi, M; Gatti, O; Quaglieri, S; Sykopetrites, V; Teggi, R, 2014) |
| "Both pretreatment migraine pain severity and treatment response are associated with changes in adipokine levels." | ( Chai, NC; Dash, PD; Gelaye, B; Gower, BA; Peterlin, BL; Scher, AI; Tietjen, GE; Ward, TN; White, LW, 2015) |
| "Headaches or migraines are common adverse effects associated with the administration of IVIG." | ( Brown, DA; Henneman, A; Thornby, KA, 2015) |
| "Globally migraine affects more than 10% of the adult population and it is treated with simple analgesics, combined with a triptan for a stronger treatment effect." | ( Kaltoft, AK; Kasch, H; Møller-Helgestad, OK, 2015) |
| "We present a serie of 8 patients with migraine who developed eyelid myokymia after treatment with topiramate." | ( Fernández-Izquierdo, S; Francés-Pont, I; Mallada-Frechin, J; Medrano-Martínez, V; Moltó-Jordá, JM; Pérez-Sempere, A; Piqueras-Rodríguez, L, 2015) |
| "There are many options for acute migraine attack treatment, but none is ideal for all patients." | ( Becker, WJ, 2015) |
| "Patterns of acute treatment for migraine were monitored from one year to the next over the following couplets of years (2005-2006, 2006-2007, 2007-2008, and 2008-2009)." | ( Adams, AM; Buse, DC; Cunanan, CM; Kori, SH; Lipton, RB; Reed, ML; Serrano, D, 2015) |
| "130 adult migraineurs (age 18 - 65 years) with ≥ three migraine attacks per month were randomized into two treatment groups: dietary supplementation or placebo in a double-blind fashion." | ( Danesch, U; Diener, HC; Gaul, C, 2015) |
| "Subjects experiencing 2-8 migraines/month in the past year were randomized 1:1 using computer-generated sequences to AVP-825 plus oral placebo tablet or an identical placebo delivery system plus 100 mg oral sumatriptan tablet for the first period; patients switched treatment for the second period in this controlled comparative design." | ( Cady, RK; Djupesland, PG; Mahmoud, RA; Messina, J; Shin, P; Siffert, J; Silberstein, S; Tepper, SJ, 2015) |
| "Acute migraine headache among children and adolescents is common and treatment is challenging." | ( Goldman, RD; Meckler, GD, 2015) |
| "Thirty percent of children with severe migraine attacks have school absence and reduced quality of life that need preventive therapy." | ( Bakhshandeh Bali, M; Ghofrani, M; Karimzadeh, P; Rahbarimanesh, AA; Sadeghi, M; Sedighi, M, 2015) |
| "haloperidol to treat ED migraine patients." | ( Bruner, DI; Frumkin, K; Gaffigan, ME; Pritchard, A; Wason, C, 2015) |
| "AVP-825 has the potential to provide migraine patients with improved intranasal administration of sumatriptan that may enhance efficacy and tolerability." | ( Cady, R, 2015) |
| "Ninety-one patients with chronic migraine were randomly divided into four groups: in the control group (group A, 22 cases in total), nimodipine was used in the treatment of chronic migraine for two months; in the infrared polarized light therapy group (group B, 22 cases in total), infrared polarized light was adopted in the treatment of chronic migraine for 50-60d; in the botulinum toxin treatment group (group C, 24 cases in total), ultrasound-and-hyponome-guided type A botulinum toxin was injected into frontal, temporal, and occipital muscles in treating chronic migraine; in the joint treatment group (group D, 23 cases in total), ultrasound-and-hyponome-guided type A botulinum toxin injection in group C and infrared polarized light in group B were both used here in the treatment of chronic migraine." | ( Chen, HX; Ding, XD; Hong, Y; Huang, L; Song, JH; Zhang, GB, 2015) |
| "Participants who treated their migraine attacks while nausea-free were identified." | ( Bigal, ME; Lipton, RB; Newman, LC; Pierce, MW; Silberstein, SD, 2015) |
| "One of the human and animal models of migraine is the systemic administration of the nitric oxide donor (NO) nitroglycerin (NTG)." | ( Bohár, Z; Fejes-Szabó, A; Laborc, KF; Nagy-Grócz, G; Párdutz, Á; Spekker, E; Tar, L; Vécsei, L, 2016) |
| "Mild migraine attack can be treated with acetaminophen or NSAIDs either alone or combined with metoclopramide." | ( , 2015) |
| "An optimal therapy for migraine has not yet been developed." | ( Chen, C; Du, JR; Long, FY; Mao, XN; Wan, JY; Wang, PH; Zhang, L; Zhang, S; Zhao, LX, 2016) |
| "Chronic migraine (CM) is a common and disabling disorder that remains underdiagnosed and poorly treated." | ( Rapoport, AM; Sun-Edelstein, C, 2016) |
| "Patients with chronic migraine (n = 274) were treated with a course of IV DHE." | ( Eller, M; Gelfand, AA; Goadsby, PJ; Riggins, NY; Schankin, C; Shiboski, S, 2016) |
| "All prescriptions of ergots, migraine prophylactic treatment, and psychotropic medications were extracted from the GHIS database." | ( Allaria-Lapierre, V; Braunstein, D; Donnet, A; Lanteri-Minet, M; Micallef, J; Pradel, V; Sciortino, V, 2016) |
| "Patients were treated for a migraine headache with a combination of ketorolac and one of the following dopamine antagonists: prochlorperazine, metoclopramide, or promethazine." | ( Fu, R; Hansen, ML; Laurie, A; Ma, OJ; Meckler, GD; Pacheco, S; Sheridan, DC, 2018) |
| "Prophylactic therapy response varies in migraine patients." | ( Ak, S; Atasayar, G; Can, FE; Cecener, G; Egeli, U; Eryilmaz, IE; Karli, N; Taskapilioglu, O; Tezcan, G; Tunca, B; Yildirim, O; Zarifoglu, M, 2016) |
| "We characterised migraine patterns and treatment responses in CADASIL, and examined associations between migraine and both stroke risk and encephalopathy." | ( Markus, HS; Tan, RY, 2016) |
| "Clinicians who see children with migraine in a pediatric headache clinic setting should consider these factors before initiating a treatment program." | ( Haimi-Cohen, Y; Markus, TE; Moad, B; Zeharia, A, 2016) |
| "In the paper, by taking acupuncture and migraine as the key words to retrieve CNKI and PubMed database, the literature analysis was done on the mechanism study on experimental migraine treated with acupuncture in rat model." | ( Liu, L; Pei, P; Wang, L, 2016) |
| "Refractory/intractable migraine headaches are associated with chronic pain that does not respond to standard care of treatment." | ( Dhir, A, 2016) |
| "Treatment of headache, specifically migraine attacks, has always been a challenging subject, especially for neurologist and pain specialists." | ( Ansari, H; Kouti, L, 2016) |
| "Current considerations for migraine treatment emphasize the utility of the biopsychosocial model in understanding and treating migraine, noting both the importance of addressing psychological factors such as cognitive beliefs as well as psychiatric comorbidities." | ( Kulich, RJ; Stone, MT; Weed, V, 2016) |
| "Despite the fact that antimigraine medications were commonly used, the majority of the women felt that their migraine was suboptimally treated during pregnancy and postpartum." | ( Amble, NM; Amundsen, S; Nordeng, H; Poole, AC; Øvrebø, TG, 2016) |
| "A 17-year old male migraineur developed a sudden episode of unconsciousness after receiving a single dose of intranasal sumatriptan for the treatment of prolonged migraine-associated symptoms." | ( Brander, A; Heikkilä, HT; Herrala, L; Långsjö, JW; Lehtimäki, K; Ruohonen, J; Saarinen, K; Sajanti, A; Sandell, S, 2016) |
| "Many migraine sufferers use daily prophylactic therapy to reduce the frequency of their headache attacks." | ( Golding, AN; Houle, TT; Turner, DP, 2016) |
| "Most admissions were to treat chronic migraine with (n = 53) or without (n = 46) aura." | ( Goadsby, PJ; Ito, H; Robbins, NM; Scheinman, MM, 2016) |
| "The treatment and prevention of migraine within the last decade has become largely pharmacological." | ( Kokavec, A, 2016) |
| "There are many similarities between migraine and epilepsy and the medications used to treat one of these disorders can effectively be used to treat the other." | ( Jand, A; Palizvan, MR, 2017) |
| "The development of new anti-migraine treatments is limited by the difficulty inassessing migraine pain in laboratory animals." | ( Kandasamy, R; Lee, AT; Morgan, MM, 2017) |
| "AITC and the migraine medication sumatriptan were administered in the hour prior to onset of the dark phase." | ( Kandasamy, R; Lee, AT; Morgan, MM, 2017) |
| "Subjects diagnosed with migraine with or without aura according to the criteria set forth in the International Classification of Headache Disorders, 2nd edition, who experienced 2 to 6 attacks per month with fewer than 15 headache days per month and at least 48 headache-free hours between attacks, used DFN-02 to treat their migraine attacks acutely over the course of 6 months." | ( Allenby, K; Brand-Schieber, E; Cady, RK; Munjal, S; Rapoport, AM; Spierings, ELH, 2017) |
| "A total of 2211 migraine attacks was reported, and 3292 doses of DFN-02 were administered; mean per subject monthly use of DFN-02 was 3." | ( Allenby, K; Brand-Schieber, E; Cady, RK; Munjal, S; Rapoport, AM; Spierings, ELH, 2017) |
| "Vestibular migraine is a challenging disease process to both diagnose and treat." | ( Isildak, H; O'Connell Ferster, AP; Priesol, AJ, 2017) |
| "Although chronic migraine (CM) is a common disorder that severely impacts patient functioning and quality of life, it is usually underdiagnosed, and treatment responses often remain poor even after diagnosis." | ( Cho, SJ; Chu, MK; Song, TJ, 2017) |
| "Chronic migraine is a common debilitating disease with limited treatment options." | ( Akçali, D; Babacan, A; Belen, AD; Bolay, H, 2017) |
| "Most NTG migraine models entail a single NTG administration and quantification of evoked allodynia." | ( Black, JR; Carpenter, JM; Harris, HM; Smitherman, TA; Sufka, KJ, 2017) |
| "Patients with 2-8 migraine attacks/month were randomized 1:1 to AVP-825 (22 mg) plus oral placebo or an identical placebo delivery system plus 100 mg oral sumatriptan for the first period, and then patients switched treatments for the second period." | ( Halker, R; Mahmoud, RA; McAllister, PJ; Siffert, J; Silberstein, S; Tepper, SJ; Winner, PK, 2017) |
| "For patients who treated multiple migraine attacks in both treatment periods, a greater proportion had consistent pain relief and pain freedom following treatment with AVP-825 compared to oral sumatriptan across multiple attacks, a difference that achieved statistical significance at 30 minutes postdose." | ( Halker, R; Mahmoud, RA; McAllister, PJ; Siffert, J; Silberstein, S; Tepper, SJ; Winner, PK, 2017) |
| "Stroke-like migraine attacks after radiation therapy (SMART) syndrome manifests as prolonged episodes of cortical dysfunction, years after cranial irradiation." | ( Balabanski, A; Chia, N; Kleinig, T; Wai, K, 2017) |
| "Current migraine treatment offers pain relief only for a small proportion of migraine patients and might not be adequate for patients with cardiovascular comorbidity due to side effects." | ( Edvinsson, L; Fulop, F; Lukacs, M; Tajti, J; Toldi, J; Vecsei, L, 2017) |
| "Background Migraine is a highly prevalent and disabling disorder of the brain with limited therapeutic options, particularly for preventive treatment." | ( Akerman, S; Goadsby, PJ; Martins-Oliveira, M; Zhao, Y, 2018) |
| "Fast relief of migraine pain, associated symptoms, and migraine-related disability are priorities in the acute treatment of migraine." | ( Buse, DC; Lipton, RB; McGinley, JS; Shulman, KJ; Wirth, RJ, 2017) |
| "The role of oxidative stress markers in migraine and effect of treatment on these has been reported." | ( Kalita, J; Misra, UK; Tripathi, GM, 2018) |
| "Preventive migraine treatment is used to reduce frequency, severity and duration of attacks and therefore lightens the burden on the patients' quality of life and reduces disability." | ( Hebestreit, JM; May, A, 2017) |
| "Nausea is often a symptom of migraine, but nausea may also be a consequence of treatment (ie, treatment emergent nausea [TEN])." | ( Buse, DC; Lipton, RB; McGinley, JS; Shulman, KJ; Silberstein, SD; Wirth, RJ, 2018) |
| "Moderate to severe acute migraine attacks can be treated with dihydroergotamine mesylate (DHE), an ergot derivative that is especially effective in non-responders to triptan derivatives." | ( Banga, AK; Eangoor, P; Joyce, JC; Knaack, JS; Nguyen, HX; Prausnitz, MR; Tas, C, 2017) |
| "Sumatriptan, an acute migraine treatment blocked acute blood flow changes in response to TRPA1 or transient receptor potential vanilloid receptor-1 agonists." | ( Hurley, JH; Johnson, PL; Kunkler, PE; Oxford, GS; Zhang, L, 2018) |
| "The treatment of menstrual migraine is highly complex." | ( Allais, G; Benedetto, C; Chiarle, G; Sinigaglia, S, 2018) |
| "The management of migraine is multifaceted and is generally dichotomized into acute and preventive strategies, with several treatment modalities." | ( De Felice, M; Ong, JJY, 2018) |
| "We present the first successful migraine headache treatment with therapy specifically targeting HSV infection." | ( Morimoto, M; Napier, BL; Napier, E, 2018) |
| "She initially was treated with standard migraine headache medications without symptomatic improvement." | ( Morimoto, M; Napier, BL; Napier, E, 2018) |
| "Specific prophylactic migraine treatments are urgently needed because of the unmet needs of many migraine patients." | ( MaassenVanDenBrink, A; Terwindt, GM; van den Maagdenberg, AMJM, 2018) |
| "Glutamate plays an important role in migraine pathogenesis but there is paucity of studies on glutamate in migraine subtypes, effect of treatment on glutamate levels and the changes in glutamate receptors." | ( Kalita, J; Misra, UK; Tripathi, GM, 2018) |
| "The course of frequent migraine treatment lasted 7 weeks." | ( Mu, H; Wang, L, 2018) |
| "Patients with migraine (N=14) were treated with LEV for 12 weeks." | ( Chen, C; Gong, T; Li, Q, 2018) |
| "The characterization of migraine-specific biomarkers would be fundamental in a perspective of precision medicine, enabling risk assessment and tailored treatments." | ( Aurilia, C; Barbanti, P; Egeo, G; Ferroni, P; Fofi, L; Fratangeli, F; Guadagni, F; Spila, A, 2019) |
| "Nitroglycerin (NTG)-induced migraine-type headache is the most prominent side effect of nitrate therapy." | ( Ghavami, H; Imani, N; Khalkhali, HR; Radfar, M; Shams, SA, 2018) |
| "The acute management of migraine should incorporate a stratified care model in concert with evidence-based treatment options." | ( Vargas, BB, 2018) |
| "Chronic migraines (CM) are the third most common disease and are refractory to medical treatment in 15% of patients." | ( Burdette, C; Frith, L; Gannon, S; Gee, L; Ghoshal, G; Hellman, A; Kaszuba, B; Kumar, V; Maietta, T; Neubauer, P; Panse, D; Pilitsis, JG; Qian, J; Shin, DS; Walling, I; Williams, E, 2018) |
| "With a diagnosis of retinal migraine, her symptoms remitted in response to prophylactic treatment with topiramate and propranolol for 8 months." | ( Cha, J; Chung, CS; Kim, ST; Lee, MJ; Park, JH; Park, KA, 2019) |
| "Subjects averaging 2 to 6 episodic migraine attacks per month were randomized to DFN-11 or placebo to treat a single attack of moderate-to-severe intensity and then entered the extension study to assess the efficacy, tolerability, and safety of DFN-11 in multiple attacks of any pain intensity." | ( Brand-Schieber, E; Landy, S; Munjal, S; Rapoport, AM, 2018) |
| "A total of 848 migraine episodes were treated with 1042 doses of open-label DFN-11 and subjects treated a mean (SD) of 3." | ( Brand-Schieber, E; Landy, S; Munjal, S; Rapoport, AM, 2018) |
| "Patients with acute migraine who reported persistence of a moderate or severe headache for at least 1 hour or longer after treatment with 10 mg of intravenous metoclopramide were randomized to bilateral GONB with a total of 6 mL of 0." | ( Friedman, BW; Irizarry, E; John Gallagher, E; Mohamed, S; Pearlman, S; Robbins, MS; Tarsia, V, 2018) |
| "We calculated the percent of migraine patients given each treatment in each time period." | ( Allegra, JR; Eskin, B; Richman, P; Ruzek, M, 2019) |
| "Prolonged exposure to migraine treatments followed by an acute nociceptive stimulation caused long-lasting alterations in descending pain modulation, shown by a loss of diffuse noxious inhibitory controls." | ( Dodick, DW; Nation, KM; Navratilova, E; Porreca, F, 2019) |
| "We identified 72 pregnant women with migraine who were treated with pain medications." | ( Hamilton, KT; Robbins, MS, 2019) |
| "Adult patients with migraine were randomized (1:1:1) to a double-blind dose of oral lasmiditan 200 mg, lasmiditan 100 mg, or placebo and were asked to treat their next migraine attack within 4 hours of onset." | ( Berg, PH; Dozier, G; Kuca, B; Lipton, RB; Silberstein, SD; Wietecha, L, 2018) |
| "Topiramate for the treatment of migraine prophylaxis may cause side effects such as cognitive dysfunction." | ( Karadaş, Ö; Övünç Özön, A; Öztürk, B, 2019) |
| "Using nitroglycerine to trigger migraine attacks, we investigated whether cranial allodynia could be triggered experimentally, observing its response to treatment." | ( Akerman, S; Bose, P; Goadsby, PJ; Hoffmann, JR; Holland, PR; Karsan, N; Romero-Reyes, M, 2019) |
| "Currently available prophylactic migraine treatment options are limited and are associated with many, often intolerable, side-effects." | ( Cichon, S; Fischer, D; Gross, E; Orsini, AL; Putananickal, N; Sandor, P; Schmidt, S; Vogt, DR, 2019) |
| "The discovery of novel targets in migraine therapy has opened new horizons for compounds that have not been clinically tested or that previously failed in clinical trials as potential antimigraine drugs." | ( Tauchen, J, 2020) |
| "The frequency of migraine attacks was also reduced in the MO group during treatment (T0: 9." | ( Guiducci, M; Ledda, MG; Maltoni, L; Moscano, F; Parisi, P; Raucci, U; Striano, P; Villa, MP; Zoroddu, F, 2019) |
| "Collectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine." | ( Ashina, M; Do, TP; Guo, S, 2019) |
| "A breakthrough in migraine treatment emerged in the early nineties with the introduction of 5-HT1B/D receptor agonists called triptans." | ( Martelletti, P; Negro, A, 2019) |
| "A total of 28 female patients with migraine without aura underwent a baseline MRI scan, ingested cilostazol, developed a migraine-like attack, and underwent an USPIO-enhanced MRI scan > 24 hours after intravenous administration of USPIO." | ( Amin, FM; Ashina, M; Birgens, H; Christensen, CE; Daldrup-Link, H; Fliedner, FP; Khan, S; Kjær, A; Larsson, HBW; Lindberg, U; Olinger, ACR; Tolnai, D; Younis, S, 2019) |
| "Use of opioids in the ED to treat migraine in youth is fairly common, with rate variation reflecting broader trends in for whom opioids tend to be more likely to be prescribed." | ( Bickel, J; Connelly, M; Glynn, EF; Hoffman, MA, 2021) |
| "Consecutive migraineurs from a tertiary center to whom SD was prescribed as monotherapy from January 2017 until September 2018 were studied retrospectively." | ( Jevoux, C; Krymchantowski, AG; Krymchantowski, AV, 2019) |
| "CONCLUSIONS In a rat model of migraine, combined therapy with liposomal curcumin and naproxen showed an improved antioxidant effect and anti-nociceptive effect." | ( Bolboacă, SD; Bulboacă, AC; Bulboacă, AE; Dogaru, G; Porfire, AS; Stănescu, IC; Suciu, ȘM; Tefas, LR, 2019) |
| "Treatment of a migraine attack with the oral calcitonin gene-related peptide receptor antagonist rimegepant resulted in a higher percentage of patients who were free of pain and free from their most bothersome symptom than placebo." | ( Conway, CM; Coric, V; Croop, R; Dubowchik, GM; Frost, M; Goadsby, PJ; Lipton, RB; Morris, BA; Stock, DA; Stock, EG, 2019) |
| "In the acute treatment of migraine, a single 75 mg dose of rimegepant in an orally disintegrating tablet formulation was more effective than placebo." | ( Conway, CM; Coric, V; Croop, R; Forshaw, M; Goadsby, PJ; Lipton, RB; Stock, DA; Stock, EG, 2019) |
| "Patients were randomized to treat a migraine attack with oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo." | ( Ailani, J; Baygani, S; Hundemer, HP; Krege, JH; Loo, LS; Port, M; Schim, J, 2019) |
| "Pretreatment with PL ameliorated migraine headache behaviors in the NTG-induced migraine rat model, suggesting pretreatment with PL is beneficial for migraine headache treatment." | ( Chen, CH; Hsieh, CL; Li, JM; Liao, CC; Lin, CL, 2019) |
| "No acute treatments were effective for migraine-related nausea or vomiting; some triptans were effective for migraine-related phonophobia and photophobia." | ( Billinghurst, L; Gersz, EM; Gloss, D; Hershey, AD; Holler-Managan, Y; Leininger, E; Licking, N; Mack, K; Oskoui, M; Potrebic, S; Pringsheim, T; Sowell, M; Victorio, MC; Yonker, M; Zanitsch, H, 2019) |
| "After stratification by migraine type as episodic or chronic, patients with chronic migraine were submitted to more magnetic resonance imaging test, acupuncture, psychotherapy, used preventive drugs, and reported to have used topiramate without beneficial effects." | ( de Oliveira, AB; Peres, MFP; Silva-Neto, RP; Swerts, DB, 2019) |
| "Safe and effective migraine treatment options are needed for patients with migraine and a history of CV or cerebrovascular disease or with increased risk for CV events." | ( Berg, PH; Dennehy, EB; Doty, EG; Hochstetler, HM; Khanna, R; Shapiro, RE; Starling, AJ, 2019) |
| "Chronic migraine is a disabling condition that is currently underdiagnosed and undertreated." | ( Agostoni, EC; Barbanti, P; Calabresi, P; Colombo, B; Cortelli, P; Frediani, F; Geppetti, P; Grazzi, L; Leone, M; Martelletti, P; Pini, LA; Prudenzano, MP; Russo, A; Sarchielli, P; Tedeschi, G, 2019) |
| "Patients with chronic migraine require prophylactic therapy to reduce the frequency of migraine attacks, but the only currently available evidence-based prophylactic treatment options for chronic migraine are topiramate and onabotulinumtoxinA." | ( Agostoni, EC; Barbanti, P; Calabresi, P; Colombo, B; Cortelli, P; Frediani, F; Geppetti, P; Grazzi, L; Leone, M; Martelletti, P; Pini, LA; Prudenzano, MP; Russo, A; Sarchielli, P; Tedeschi, G, 2019) |
| "Treatment of chronic migraine is a dynamic and rapidly advancing area of research." | ( Agostoni, EC; Barbanti, P; Calabresi, P; Colombo, B; Cortelli, P; Frediani, F; Geppetti, P; Grazzi, L; Leone, M; Martelletti, P; Pini, LA; Prudenzano, MP; Russo, A; Sarchielli, P; Tedeschi, G, 2019) |
| "Patients treated with lasmiditan for a migraine attack reported an earlier onset of efficacy compared with those treated with placebo." | ( Ashina, M; Doty, EG; Gray, E; Jin, L; Kinchen, KS; Lombard, L; Tassorelli, C; Vasudeva, R; Yunes-Medina, L, 2019) |
| "Of the children with chronic migraine, the headache specialist evaluated 135 patients while the non-headache specialists treated 334 children." | ( Farooqi, AA; Gutta, R; Kaur, G; Sivaswamy, L; Valentini, KJ, 2019) |
| "The development of new migraine-specific classes of medications provides more treatment options for both acute and preventive treatment of migraine." | ( Ceriani, CEJ; Silberstein, SD; Wilhour, DA, 2019) |
| "The outcomes observed were migraine pain before and after administration within the same initial encounter of receiving an occipital nerve block using a numeric pain rating scale, injection direction, medications used, duration of effect and frequency of additional injections, and adverse reactions." | ( Dang, T; Ebied, AM; Nguyen, DT, 2020) |
| "In a model of migraine induced by intravenous systemic infusion of nitroglycerin (NTG), rats with chronic exposure to acetaminophen exhibited significantly more frequent neuronal firing in the TNC and greater Fos-IR than those without the acetaminophen treatment." | ( le Grand, SM; Potewiratnanond, P; Srikiatkhachorn, A; Supronsinchai, W, 2019) |
| "Subjects treated a single migraine attack with 120 mg DFN-15 or placebo as soon as possible after the onset of pain of moderate to severe intensity." | ( Brand-Schieber, E; Dodick, DW; Lipton, RB; Munjal, S; Tepper, SJ, 2020) |
| "Mg has been extensively used in migraine prophylaxis and treatment." | ( Dolati, S; Mehdizadeh, A; Rikhtegar, R; Yousefi, M, 2020) |
| "In the treatment of acute migraine and the prevention of recurrent attacks, there are prescription drugs of proven benefit." | ( Biglione, B; Gitin, A; Gorelick, PB; Hennekens, C, 2020) |
| "Among adults with migraine, acute treatment with ubrogepant compared with placebo led to significantly greater rates of pain freedom at 2 hours with 50-mg and 25-mg doses, and absence of the most bothersome migraine-associated symptom at 2 hours only with the 50-mg dose." | ( Ailani, J; Dodick, DW; Finnegan, M; Lipton, RB; Lu, K; Szegedi, A; Trugman, JM, 2019) |
| "We assigned adults with migraine, with or without aura, in a 1:1:1 ratio to receive an initial dose of placebo, ubrogepant at a dose of 50 mg, or ubrogepant at a dose of 100 mg for treatment of a single migraine attack, with the option to take a second dose." | ( Ailani, J; Dodick, DW; Finnegan, M; Lipton, RB; Lu, K; Szegedi, A; Trugman, JM, 2019) |
| "Having these migraine-specific prescriptions may improve self-treatment at home should a migraine attack recur." | ( Miller, L; Minen, MT; Zhou, K, 2020) |
| "To compare pediatric migraine treatment efficacy in the emergency department before and after the implementation of a comprehensive migraine initiative, consisting of a standardized treatment protocol, provider educational series and standardized physician documentation template." | ( Oakley, CB; Skora, CE; Worden, LT, 2020) |
| "In treatment of refractory migraine headache, CAMBIA® may provide similar benefits as IM ketorolac without increasing the risk of treatment failure, major bleeding, or cardiovascular events." | ( Cheng, J; Engel, ER, 2020) |
| "For mild migraine, symptomatic treatment with high dose simple analgesics is suggested, while for moderate to severe migraines triptans or non-steroidal anti-inflammatory drugs, or both, should be administered following an individually tailored therapeutic strategy." | ( Arvaniti, C; Constantinidis, TS; Fakas, N; Giannouli, E; Kalamatas, T; Kararizou, E; Kouremenos, E; Mitsikostas, DD; Naoumis, D, 2019) |
| "as an acute treatment for migraine." | ( Scott, LJ, 2020) |
| "All patients were diagnosed as migraine by headache specialists and were treated with triptans, which resulted in satisfactory pain relief." | ( Hatori, K; Hsu, YC; Imamura, Y; Nishihara, C; Noma, N; Ozasa, K; Young, A, 2019) |
| "In a mouse model of chronic migraine, we observed that repeated nitroglycerin (NTG, a reliable trigger of migraine in patients) administration doubled the number of CD3 T cells in the trigeminal ganglia without altering the number of Treg cells, suggesting a deficiency in Treg-mediated immune homeostasis." | ( Cao, YQ; Cloud, ME; Czerpaniak, K; Hotchkiss, RS; Huang, L; Li, D; Liu, X; Unsinger, J; Zhang, J, 2020) |
| "Primary outcomes were efficacy (ie, migraine frequency, number of migraine days, number of headache days, headache frequency, or headache index), safety (ie, treatment discontinuation owing to adverse events), and acceptability (ie, treatment discontinuation for any reason)." | ( Barthel, J; Berde, CB; Gaab, J; Koechlin, H; Kossowsky, J; Lam, TL; Linde, K; Locher, C; Meissner, K; Schwarzer, G, 2020) |
| "There are several treatment options for migraines; opioids are frequently prescribed." | ( Evangelatos, TM; Kangethe, A; Liebler, EJ; Mwamburi, M; Polson, M; Speicher, LC; Staats, PS; Tenaglia, AT, 2020) |
| "Patients with episodic and chronic migraine who experienced continuous and prolonged attacks for more than 72 hours were treated with dexamethasone (4 mg orally twice daily for 3 days), ketorolac (60 mg intramuscularly), bilateral nerve blocks (1-2% lidocaine, 0." | ( Ashina, S; Burstein, R; Chua, A; Grosberg, B; Iljazi, A; Melo-Carrillo, A; Rich-Fiondella, R; Veronesi, M, 2020) |
| "BACKGROUND SMART (Stroke-like Migraine Attacks after Radiation Therapy) syndrome is an uncommon delayed complication of cerebral radiotherapy." | ( Biju, RD; Dower, A; Gan, P; Moon, BG, 2020) |
| "Furthermore, adjuvant migraine treatment can lead to decrease in number of IT injections, thus reducing procedure-related risks and complications." | ( Abouzari, M; Chua, JT; Djalilian, HR; Goshtasbi, K; Lin, HW; Saber, T; Sarna, B; Tan, D, 2021) |
| "We evaluated the average migraine frequency per month as a baseline and after 3 months of riboflavin therapy to determine the effectiveness and clinical predictors of response." | ( Daida, A; Go, S; Ishida, Y; Kawashima, H; Morichi, S; Morishita, N; Nara, S; Nishimata, S; Oana, S; Shimura, M; Suzuki, S; Takamatsu, T; Takeshita, M; Yamanaka, G, 2020) |
| "Regarding the treatment-prevention of migraine, 7 RCTs and 9 non-randomized studies were retrieved." | ( Brotis, A; Dardiotis, E; Liampas, I; Siokas, V; Vikelis, M, 2020) |
| "Adult migraine remains underdiagnosed and undertreated, despite significant negative effects on physical and emotional functioning." | ( Cao, H; Yao, Y; Yu, S; Zhang, Y, 2020) |
| "Much of the research on migraine treatment regimens involves antidopaminergic antiemetics such as prochlorperazine and metoclopramide." | ( Heilbrunn, B; Talai, A, 2020) |
| "Many patients with chronic migraine are difficult to treat." | ( González-Quintanilla, V; Madera, J; Pascual, J; Pérez-Pereda, S, 2020) |
| "Screening for migraine was conducted using the self-administered ID-Migraine™ questionnaire." | ( Alias, H; Bhoo-Pathy, N; Chong, YC; Chung, I; Kalra, S; Shah, ZUBS; Wong, LP, 2020) |
| "And all of gepants were safe for migraine treatment with single dose." | ( Hong, P; Liu, Y; Tan, T; Xiao, J, 2020) |
| "Of 2,388 respondents with migraine using prescription medications for acute treatment, 36." | ( Adams, AM; Buse, DC; Fanning, KM; Feder, L; Friedman, BW; Lipton, RB; Reed, ML; Schwedt, TJ, 2020) |
| "OnabotulinumtoxinA is a chronic migraine preventive treatment that significantly reduces headache frequency." | ( Blumenfeld, AM; Brin, MF; Burstein, R; Manack Adams, A; Silberstein, SD, 2020) |
| "To induce acute model of migraine, a single dose of nitroglycerin was intraperitoneally administered to male rats." | ( Ankarali, S; Dagistan, Y; Kilinc, E; Torun, IE, 2022) |
| "To model chronic migraine-associated pain, nitroglycerin (NTG) (5 mg/kg/IP) was administered to test subjects every second day for 9 days." | ( Abbasnejad, M; Esmaeili-Mahani, S; Kooshki, R; Raoof, M; Sheibani, V, 2020) |
| "Although migraine is one of the most common primary headaches, its therapy is still limited in many cases." | ( Bohár, Z; Fejes-Szabó, A; Laborc, KF; Nagy-Grócz, G; Párdutz, Á; Spekker, E; Szűcs, M; Vécsei, L, 2020) |
| "Rimegepant ODT is an efficacious migraine treatment option with a novel mechanism of action, convenient dosage form, and limited adverse effect profile." | ( Cope, NE; DeFalco, AP; Lazim, R, 2021) |
| "As an acute treatment for pediatric migraine, both low and high doses of melatonin were associated with pain reduction; however, study drop-out was high." | ( Allen, IE; Gelfand, AA; Greene, KA; Irwin, SL; Qubty, WF; Ross, AC, 2020) |
| "Patients with migraine of moderate or severe intensity were randomized to receive bilateral GONB with each side administered 3 mL of bupivacaine 0." | ( Bijur, PE; Del Valle, M; Friedman, BW; Gallagher, EJ; Harrilal, MA; Irizarry, E; Robbins, MS; Solorzano, C; Williams, A; Zias, E, 2020) |
| "Of a total of 619 migraine attacks, 284 (46%) were treated with timolol, 271 (44%) were treated with the placebo, and 64 (10%) occurred during the washout period when no study medications were used." | ( Kurian, A; Nair, U; Reghunadhan, I; Soman, I; Thilak, P, 2020) |
| "Chronic migraine (occurring for more than 15 days a month) and refractory migraine (treatment resistant), especially when there is also analgesic overuse, are the most disabling forms of migraine." | ( Luzeiro, I; Parreira, E; Pereira Monteiro, JM, 2020) |
| "Opioid administration for migraine in EDs across the US declined 10% annually between 2010 and 2017, demonstrating improved adherence to migraine guidelines recommending against opioids." | ( Campbell, MJ; Lopez, R; Phelan, MP; Seballos, SS; Udeh, BL; Wang, PR, 2021) |
| "Sixty-six episodic migraine patients were enrolled and randomized 1:1 to receive either flunarizine or topiramate treatment." | ( Chen, C; Li, G; Li, W; Liu, R; Liu, W, 2023) |
| "The NHS of migraine in the two groups were significantly better after treatment than before treatment in premonitory phase (PP), headache phase (HP), and resolution phase (RP)." | ( Chen, C; Li, G; Li, W; Liu, R; Liu, W, 2023) |
| "The two classical prophylactic drugs of migraine were significantly effective in treating the NHS of migraine, but there was no significant difference between the two drugs." | ( Chen, C; Li, G; Li, W; Liu, R; Liu, W, 2023) |
| "Overall, 1471 patients treated ≥1 migraine attack with the study drug." | ( Ashina, M; Bragg, S; Doty, EG; Dowsett, SA; Klise, SR; Krege, JH; Krikke-Workel, J; Lin, Q; Reuter, U; Smith, T, 2021) |
| "There have been three new acute migraine treatment options (i." | ( Hennessey, EK; Peters, GL, 2021) |
| "Twenty-four subjects with episodic migraine (MIG) and 19 healthy controls (HC) underwent blood sampling and investigation of nociceptive withdrawal reflex thresholds (RTh: single-stimulus threshold; TST: temporal summation threshold) before and 30 (T30), 60 (T60), and 120 (T120) minutes after sublingual NTG administration (0." | ( Allena, M; De Icco, R; Demartini, C; Greco, R; Grillo, V; Realini, N; Reggiani, A; Sances, G; Tassorelli, C; Tumelero, E; Vergobbi, P; Zanaboni, A, 2021) |
| "Prior to 2018, the burden of migraine was high for patients initiating preventive treatments." | ( Dodick, DW; Kawata, AK; Lipton, RB; Poon, JL; Sapra, S; Shaffer, S; Shah, N; Shah, S; Tepper, SJ; Wilcox, TK, 2021) |
| "Non - pharmacological management of migraine, tension-type headache (TTH), and cervicogenic headache (CGH) may include spinal manual therapy and exercise." | ( Bedekar, N; Hall, T; Satpute, K, 2021) |
| "Although triptans have improved migraine treatment, their efficacy and tolerability may limit their utility in some individuals." | ( Blumenfeld, AM; Dodick, DW; Finnegan, M; Goadsby, PJ; Hutchinson, S; Liu, C; Szegedi, A; Trugman, JM, 2021) |
| "To review carnitine's role in migraine and headache, present a case of a patient with intractable chronic migraine refractory to medications but exquisitely responsive to mitochondrial cofactors with a particularly prompt response to L-carnitine supplementation with dose response, and suggest scenarios where L-carnitine could be considered for prophylactic treatment in migraine and intractable headache with migraine features." | ( Charleston, L; Khalil, S; Young, WB, 2021) |
| "People taking CGRP-targeted mAbs for migraine prevention sometimes take ubrogepant, an oral small-molecule CGRP receptor antagonist, for acute treatment of breakthrough migraine attacks." | ( Blumenfeld, AM; Boinpally, R; Borbridge, L; Butler, M; Contreras-De Lama, J; Jakate, A; Lipton, RB; McGeeney, D; Periclou, A, 2021) |
| "Triptans were the first migraine-specific drug class developed and have proven efficacy in treatment of this neurological disease." | ( DeJulio, PA; Oswald, JC; Perese, JK; Schuster, NM, 2021) |
| "We use validated mouse models of migraine to show that HDAC6-inhibition is a promising migraine treatment and reveal an undiscovered cytoarchitectural basis for migraine chronicity." | ( Ao, M; Baca, SM; Bertels, Z; Conway, C; Dripps, I; Karumudi, B; Mangutov, E; Petukhov, PA; Petukhova, V; Pradhan, AA; Rasenick, MM; Shah, P; Sheets, Z; Siegersma, K; Singh, H; Tipton, AF; Witkowski, WD, 2021) |
| "Twenty-seven migraine patients were assessed during a spontaneous migraine attack, including headache characteristics and treatment effect." | ( Buil, A; Courraud, J; Erola, P; Falkenberg, K; Hansen, TF; Kogelman, LJA; Laursen, SS; Michoel, T; Olesen, J, 2021) |
| "Among 335 participants who treated ≥1 migraine attack, 257 completed 6 months and 127 completed 1 year of treatment." | ( Elbuluk, N; Foreman, PK; Friedman, DI; Hindiyeh, N; Kellerman, DJ; Nahas, SJ; Schmidt, P, 2021) |
| "There are several acute treatments for migraine, with varying strength of supporting evidence." | ( Abd-Rabu, R; Daraz, L; Farah, MH; Halker Singh, RB; Hasan, B; Morrow, AS; Murad, MH; Nayfeh, T; Prokop, LJ; Saadi, S; Shah, S; Torres Roldan, VD; Urtecho, M; VanderPluym, JH; Wang, Z, 2021) |
| "Treatment outcomes for migraine and other chronic headache and pain conditions typically demonstrate modest results." | ( Aguila, MR; Foster, S; Galloway, G; Leaver, AM; Ng, K; Oeltzschner, G; Peek, AL; Puts, NA; Rebbeck, T; Refshauge, K; Sterling, M, 2021) |
| "A reduction in number of migraine days and headache severity were shown in all four studies in the participants treated with memantine." | ( Brown, JN; Bryan, WE; Mistry, VM; Morizio, PL; Pepin, MJ, 2021) |
| "In two patients with status migrainosus, migraine-related disability 3 months prior and after treatment using MIDAS (Migraine Disability Assessment) questionnaire was recorded." | ( Babar, S; French, BR; Gomez, CR; Huang, W; Ishfaq, MF; Lobanova, I; Pfeiffer, K; Qureshi, AI; Siddiq, F, 2021) |
| "Childhood and Adolescent Migraine Prevention study participants completed headache diaries during a 28-day baseline period and a 168-day active treatment period during which youth took amitriptyline, topiramate, or placebo." | ( Chamberlin, LA; Coffey, CS; Ecklund, DJ; Hershey, AD; Kabbouche, MA; Kacperski, J; Klingner, EA; Korbee, LL; Peugh, J; Porter, LL; Powers, SW; Reidy, BL; Yankey, JW, 2022) |
| "In a nitroglycerin-induced migraine animal model, pretreatment with tetrahydropalmatine or protopine substantially lessened the aberrant migraine-like symptoms." | ( Fan, G; Guan, J; Li, H; Li, Z; Meng, Q; Sheng, H; Wang, Y; Wu, H; Wu, Y; Zhang, K; Zhang, X, 2021) |
| "Current migraine therapy was triptans, however, riptans can cause contraction of blood vessels." | ( Chen, K; Deng, K; Jin, C; Wang, T; Wang, Z; Xue, Y; Yi, C; Zhong, W, 2021) |
| "Following lasmiditan treatment of a migraine attack with moderate or severe head pain, we contrast those who achieve pain freedom with those who achieve mild pain but not pain freedom 2 h post dosing." | ( Baygani, SK; Hauck, PM; Krege, JH; Lipton, RB; Loo, LS; Pearlman, EM; Tepper, SJ; Vasudeva, R, 2021) |
| "Monotherapy with triptans in acute migraine is ineffective in many patients and contraindicated in certain cardiovascular diseases where alternative therapeutic options are necessary to explore." | ( Jena, M; Maiti, R; Mishra, A; Puliappadamb, HM; Srinivasan, A, 2021) |
| "Many migraine patients rely on over-the-counter analgesics for the treatment of migraine attacks." | ( Diener, HC; Gaul, C; Lehmacher, W; Weiser, T, 2022) |
| "The primary endpoint was the number of migraine days in the last four weeks of treatment, adjusted for baseline." | ( Cichon, S; Fischer, D; Gocheva, V; Gross, EC; Hafner, P; Henzi, BC; Nagy, S; Orsini, AL; Putananickal, N; Rubino, D; Sandor, P; Schmidt, S; Vogt, DR, 2022) |
| "In the treatment of migraine attacks with 6 mg subcutaneous sumatriptan the number needed to treat (NNT) is 2." | ( Förderreuther, S; Gaul, C, 2022) |
| "A rat model of migraine induced by recurrent administration of nitroglycerin (NTG) (5 mg/kg/i." | ( Abbasnejad, M; Esmaeili-Mahani, S; Kooshki, R; Pourrahimi, AM; Raoof, M, 2021) |
| "Chronic migraine patients aged above 18 years and less than 65 years of age, not on any preventive treatment were randomly allocated to receive topiramate (100 mg/day) or propranolol (160 mg/day)." | ( Bansal, L; Chowdhury, D; Datta, D; Duggal, A; Gupta, A; Koul, A; Krishnan, A; Mundra, A, 2022) |
| "For patients with migraine, who fail to improve after treatment with a first-line medication, it is reasonable to use an intravenous NSAID or intravenous acetaminophen." | ( Fakherddine, M; Friedman, BW; Kazi, F; Manyapu, M; Mekuria, K, 2021) |
| "Many patients with refractory chronic migraine have experienced treatment failure with the Raskin protocol." | ( Lauritsen, C; Mojica, JJ; Nahas, SJ; Schwenk, ES, 2021) |
| "We observed people with chronic migraine (ICHD-3) over 3-months as their treatment was escalated in line with the Australian Pharmaceutical Benefits Scheme (PBS)." | ( Foster, S; Galloway, G; Henderson, L; Leaver, AM; Ng, K; Oeltzschner, G; Peek, AL; Puts, NA; Rebbeck, T; Refshauge, K, 2021) |
| "The Pediatric Migraine Disability Assessment Score (PedMIDAS) score, severity, duration, and frequency of the headache attacks were evaluated from the medical records and pre- and post-treatment values were compared." | ( Edem, P; Tekin, H, 2022) |
| "Chronic migraine places a disabling burden on patients, which is extensively modeled by the nitroglycerin (NTG)-treated animal model." | ( Chen, H; Hu, B; Li, J; Ma, T; Tang, X; Xu, S; Yang, W; Zhan, M, 2022) |
| "Our results demonstrated that the anti-migraine treatment of DCXF was highly associated with fatty acid synthesis, suggesting that DCXF ameliorated pain response through reducing endothelin-1 level and regulating fatty acid synthesis." | ( Chen, Y; Chen, Z; Gao, C; Vong, CT; Wang, S; Wang, Y; Yang, F, 2022) |
| "The present study revealed the anti-migraine effect of DCXF in migraine mice and provided insights into the mechanisms of DCXF-mediating anti-migraine treatment." | ( Chen, Y; Chen, Z; Gao, C; Vong, CT; Wang, S; Wang, Y; Yang, F, 2022) |
| "Zolmitriptan is a widely used antimigraine drug, and its brain targeting by nasal route in the form of mucoadhesive nanoparticles is more effective in migraine treatment as it provides fast relief and good bioavailability as compared to its oral drug delivery." | ( Jha, S; Mishra, D, 2022) |
| "In women, the frequency of migraine attacks shows variations over the menstrual cycle and pregnancy, and the use of combined hormonal contraception (CHC) or hormone replacement therapy (HRT) can unveil or modify migraine disease." | ( De Icco, R; De Matteis, E; Nappi, RE; Sacco, S; Tassorelli, C; Tiranini, L, 2022) |
| "In people with migraine who are TIRs, individuals treated with ubrogepant had favorable 2-h outcomes, as measured by the FDS, satisfaction with medication, and PGIC, compared with placebo." | ( Dodick, DW; Lateiner, JE; Lipton, RB; Revicki, DA; Shewale, AR; Singh, RBH; Zhao, S, 2022) |
| "OTC medications are widely used for migraine; however, it is not clear which treatment works best for each patient without going through the trial and error process." | ( Armand, CE; Buse, DC; Ezzati, A; Fanning, KM; Lipton, RB; Martin, VT; Pavlovic, JM; Reed, ML, 2022) |
| "Two items from the Migraine Treatment Optimization Questionnaire were used to evaluate treatment response, adequate 2-h pain freedom (2hPF) and 24-h pain relief (24hPR), which were defined by a response to treatment ≥half the time at 2 h and 24 h post treatment, respectively." | ( Armand, CE; Buse, DC; Ezzati, A; Fanning, KM; Lipton, RB; Martin, VT; Pavlovic, JM; Reed, ML, 2022) |
| "In patients with chronic migraine, tiapride was found to be an effective, safe and well-tolerated prophylactic treatment when compared to topiramate." | ( Condeza-Riquelme, F; Contreras-Espinoza, L; Fuentealba-Sandoval, M; González-Burboa, A; Herrera-Hormazábal, C; Juica-Avello, S; Klaassen-Pinto, G; Pérez-Villalobos, C; Riquelme-Vergara, C; Vera-Calzaretta, A; Werlinger-Estay, E, 2022) |
| "Stroke-like migraine attacks after radiation therapy (SMART) syndrome, is a late complication of brain radiotherapy (1)." | ( Bozkurt, S; Dizdar, Ö; Güven, DC; Kertmen, N; Oğuz, KK; Parlak, Ş; Toprak, B; Yıldırım, HÇ, 2023) |
| "Most migraineurs treat their headaches with acute treatment, but preventive treatment is often not chosen appropriately." | ( Ishizaki, K; Takeshima, T, 2022) |
| "The prophylactic treatment of migraine includes anticonvulsant drugs such as valproic acid and topiramate." | ( Evers, S; Frese, A; Husstedt, IW; Marziniak, M; Summ, O, 2022) |
| "Vestibular migraine (VM) is a rare migraine variant with limited information about its treatment in children." | ( Cetin, H; Cokyaman, T, 2022) |
| "Some patients with migraine, particularly those in primary care, require effective, well-tolerated, migraine-specific oral preventive treatments." | ( Blumenfeld, AM; Dabruzzo, B; Dodick, DW; Finnegan, M; Li, Y; Lipton, RB; Lu, K; McAllister, P; Miceli, R; Pozo-Rosich, P; Severt, L; Trugman, JM, 2022) |
| "In paediatric migraine, ibuprofen, acetaminophen and triptans are safe, effective therapies but there is scant paediatric data informing second-line emergency treatment." | ( Babl, FE; Hill, A; Löllgen, RM; Mackay, MT; Palmer, GM, 2022) |
| "The mechanism of SPD in treating migraine was studied through network pharmacology, which was further verified using pharmacological experiments." | ( Cui, Y; Du, H; Feng, Y; Mao, Q; Ouyang, H; Wu, J; Yang, S; Zhou, M, 2022) |
| "Some migraine treatments are contraindicated for patients with cardiovascular disease (CVD) or risk factors (CVRFs)." | ( Hashimoto, Y; Hirata, K; Komori, M; Ozeki, A; Tanji, Y, 2022) |
| "A total of 118 patients with chronic migraine complicated with depression and anxiety disorder admitted to our hospital from June 2018 to August 2020 were selected and divided into two groups according to treatment methods, 59 cases in each group." | ( Chen, J; Zhang, K; Zhu, J, 2022) |
| "Current preventive treatment of migraine includes nutraceuticals as well as conventional drugs." | ( Quintana, S; Russo, M; Torelli, P, 2022) |
| "Perimenstrual migraine attacks in women with menstrual migraine is difficult to treat." | ( Baygani, S; Igarashi, H; Komori, M; Krege, JH; MacGregor, EA; Pavlovic, J; Vincent, M, 2022) |
| "Lasmiditan treatment of perimenstrual migraine attacks was associated with freedom from migraine-related head pain at two hours, early onset of efficacy, and sustained efficacy." | ( Baygani, S; Igarashi, H; Komori, M; Krege, JH; MacGregor, EA; Pavlovic, J; Vincent, M, 2022) |
| "Many migraine medications can have intolerable side effects leading patients to seek complementary and integrative health (CIM) approaches for treatment." | ( Bernstein, CA; Connor, JP; Lazaridou, A; Paschali, M; Rist, PM; Rozenkrantz, L; Vilsmark, ES; Wayne, PM, 2022) |
| "Two cases are reported of people with migraine with new onset digital RP while taking CGRP receptor antagonists (rimegepant, ubrogepant, atogepant) for acute and preventive treatment." | ( Ailani, J; Bedrin, K; Dougherty, C, 2022) |
| "Two cases are reported of people with migraine with new onset digital RP while taking CGRP receptor antagonists (rimegepant, ubrogepant, atogepant) for acute and preventive treatment." | ( Ailani, J; Bedrin, K; Dougherty, C, 2022) |
| "Two cases are reported of people with migraine with new onset digital RP while taking CGRP receptor antagonists (rimegepant, ubrogepant, atogepant) for acute and preventive treatment." | ( Ailani, J; Bedrin, K; Dougherty, C, 2022) |
| "Along with the development of novel migraine therapies as the monoclonal antibodies against calcitonin gene-related peptide (CGRP) and its receptor, the question arises if the treatment of chronic migraine (CM) and medication overuse headache (MOH) must be reconsidered." | ( Broessner, G; Gaul, C; Hamann, T; Kaltseis, K, 2022) |
| "Chronic migraine and medication overuse continues to be a difficult to treat condition." | ( Broessner, G; Gaul, C; Hamann, T; Kaltseis, K, 2022) |
| "Along with the development of novel migraine therapies as the monoclonal antibodies against calcitonin gene-related peptide (CGRP) and its receptor, the question arises if the treatment of chronic migraine (CM) and medication overuse headache (MOH) must be reconsidered." | ( Broessner, G; Gaul, C; Hamann, T; Kaltseis, K, 2022) |
| "Chronic migraine and medication overuse continues to be a difficult to treat condition." | ( Broessner, G; Gaul, C; Hamann, T; Kaltseis, K, 2022) |
| "Along with the development of novel migraine therapies as the monoclonal antibodies against calcitonin gene-related peptide (CGRP) and its receptor, the question arises if the treatment of chronic migraine (CM) and medication overuse headache (MOH) must be reconsidered." | ( Broessner, G; Gaul, C; Hamann, T; Kaltseis, K, 2022) |
| "Chronic migraine and medication overuse continues to be a difficult to treat condition." | ( Broessner, G; Gaul, C; Hamann, T; Kaltseis, K, 2022) |
| "Melatonin therapy in migraine was associated with a significantly higher responder rate when compared to both placebo and standard therapy (OR = 1." | ( Jena, M; Maiti, R; Mishra, A; Mishra, BR; Puliappadamb, HM, 2022) |
| "Melatonin therapy in migraine was associated with a significantly higher responder rate when compared to both placebo and standard therapy (OR = 1." | ( Jena, M; Maiti, R; Mishra, A; Mishra, BR; Puliappadamb, HM, 2022) |
| "In total, 154 patients reported migraine-associated symptoms, of which 119 (77%) improved after treatment, 18 (12%) did not improve, and 17 (11%) patients' data were missing." | ( Gordon, BJ; Kalayjian, LA; Mazza, GR; Solorio, C; Stek, AM; Wilson, ML, 2023) |
| "In total, 154 patients reported migraine-associated symptoms, of which 119 (77%) improved after treatment, 18 (12%) did not improve, and 17 (11%) patients' data were missing." | ( Gordon, BJ; Kalayjian, LA; Mazza, GR; Solorio, C; Stek, AM; Wilson, ML, 2023) |
| "We defined migraineurs as participants who reported a migraine diagnosis or use of a medication to treat migraine." | ( Crowe, HM; Hatch, EE; Jick, SS; Mikkelsen, EM; Rothman, KJ; Sørensen, HT; Wesselink, AK; Wise, LA, 2022) |
| "For patients with migraine who are prescribed atogepant for the preventive treatment of migraine, health care providers could prescribe ubrogepant for the acute treatment of breakthrough migraine attacks." | ( Ailani, J; Blumenfeld, AM; Boinpally, R; Dabruzzo, B; De Abreu Ferreira, R; Lipton, RB; Trugman, JM, 2023) |
| "Although migraine is one of the most common chronic diseases and is the subject of numerous studies, there is still a considerable proportion of patients who are not satisfied with their acute treatment." | ( Fumal, A; Timmermans, G, 2023) |
| "Medications for preventive treatment of migraine reduce migraine frequency, usually measured by a reduction in monthly migraine days (MMD), but generally do not eliminate the need for acute treatment." | ( Coric, V; Harris, L; L'Italien, G; Martin, T; Moren, JA; O'Connell, T; Woolley, JJ, 2023) |
| "In consideration of the migraine-specific acute medications used in FFS Medicaid 2020, for patients using CGRP mAbs for prevention, medication costs may vary significantly with the number of breakthrough attacks treated per month and the type of migraine-specific acute therapy used." | ( Coric, V; Harris, L; L'Italien, G; Martin, T; Moren, JA; O'Connell, T; Woolley, JJ, 2023) |
| "Female patients with migraine (n = 38) and age-matched HC (n = 35) underwent DBF measurement at baseline and after topical capsaicin administration using laser speckle imaging." | ( Basedau, H; Gundelwein Silva, E; May, A; Oppermann, T; Peng, KP, 2023) |
| "Patients with PFO-migraine may derive benefit from NBO treatment." | ( Dandu, C; Ding, Y; Ji, X; Lan, D; Meng, R; Wang, M, 2023) |
| "Treatment of migraine in the setting of either renal or hepatic disease can be daunting for clinicians." | ( Chiang, CC; Datta, S; Garza, I; Robertson, CE; Stern, JI; Vieira, DL, 2023) |
| "A large subgroup of people with migraine had an inadequate response to their usual acute OTC migraine treatment 2- and 24-h after dosing." | ( Ezzati, A; Fanning, KM; Lipton, RB; Reed, ML, 2023) |
| "Self-reported and "nosology-derived" migraine days during the baseline and treatment phases were strongly associated (r's = 0." | ( Chamberlin, LA; Coffey, CS; Ecklund, D; Gibler, RC; Hershey, AD; Kabbouche, M; Kacperski, J; Klingner, E; Korbee, LL; Peugh, JL; Porter, LL; Powers, SW; Reidy, BL; Yankey, J, 2023) |
| "Prophylactic treatments for migraine, such as topiramate or valproate, reduce the number of cortical spreading depression events in rodents." | ( Cormand, B; Cuenca-León, E; Fernàndez-Castillo, N; Kulis, M; Macaya, A; Martín-Subero, JI; Pozo-Rosich, P; Queirós, AC; Sintas, C; Vila-Pueyo, M, 2023) |
| "In this study we characterize an ED migraine pathway that uses IN sumatriptan as a first-line treatment." | ( Barry, D; Blume, H; Hartford, EA; Hauser Chatterjee, J; Law, E, 2023) |
| "Therefore, migraine treatment targeting prolactin should aim to block its effects using prolactin receptor antagonists or monoclonal antibodies specifically acting at migraine-pain related structures." | ( Aktürk, T; Al-Hassany, L; Börner, C; Cernigliaro, F; de Vries, T; Kodounis, M; Lo Cascio, S; Maassen Van Den Brink, A; Messlinger, K; Mikolajek, D; Onan, D; Ragaglini, C; Ratti, S; Rivera-Mancilla, E; Szewczyk, AK; Tsanoula, S; Ulutas, S; Villino, R, 2023) |
| "Ubrogepant is ratified for acute migraine treatment, atogepant is validated for preventive therapy, whereas rimegepant is ratified for both indications, all via oral administration and while zavegepant is administered intranasally for migraine attacks." | ( Csáti, A; Szok, D; Tajti, J; Vécsei, L, 2023) |
| "a female migraine patient who mistakenly administered supratherapeutic (three-fold higher) doses of erenumab leading to more efficacious clinical responses without any side-effects." | ( Al-Hassany, L; Goadsby, PJ; Karsan, N; Lampl, C; MaassenVanDenBrink, A, 2023) |
| "There are many available treatments for migraine, but some patients still need an option that works well for them, that is noninvasive, or does not need to be taken orally." | ( Aurora, SK; Mallick-Searle, T; Shrewsbury, SB; Starling, AJ, 2023) |
| "Among people with episodic migraine, a broader number of blood pressure-lowering medication classes and drugs reduce headache frequency than those currently included in treatment guidelines." | ( Anderson, CS; Atkins, E; Bai, Y; Balicki, G; Carcel, C; Clough, AJ; Cordato, D; Davies, L; Delcourt, C; Griffiths, LR; Haghdoost, F; Malavera, A; Nanda, P; Rodgers, A; Shen, J; Torii-Yoshimura, T; Vidyasagar, K; Wang, X; Zagami, AS, 2023) |
| "Menstrual migraine is a subtype of migraine disease that is typically more disabling, longer-lasting, and more challenging to treat." | ( Qi, JZ; Zhang, H; Zhang, ZH, 2023) |
| "The primary outcome measure was migraine days in weeks 5-8 of randomized treatment between melatonin (combined 6 mg + 3 mg) versus placebo." | ( Allen, IE; Gelfand, AA; Greene, K; Grimes, B; Irwin, S; Powers, SW; Qubty, W; Szperka, CL; Waung, M, 2023) |
| "Median (IQR) migraine/migrainous days in weeks 5-8 of double-blind treatment was 2 (1-7) in the placebo group versus 2 (1-12) in the melatonin groups combined; the difference in medians (95% CI for the difference) was 0 days (-9 to 3)." | ( Allen, IE; Gelfand, AA; Greene, K; Grimes, B; Irwin, S; Powers, SW; Qubty, W; Szperka, CL; Waung, M, 2023) |
| "The premonitory phase, or prodrome, of migraine, provides valuable opportunities to study attack initiation and for treating the attack before headache starts." | ( Goadsby, PJ; Karsan, N, 2023) |
| "Until a few years ago, preventive migraine treatments were based on molecules with pleiotropic targets, developed for other indications, and discovered by serendipity to be effective in migraine prevention, although often burdened by tolerability issues leading to low adherence." | ( Geppetti, P; Iannone, LF; Orologio, I; Russo, A; Silvestro, M; Tedeschi, G; Tessitore, A, 2023) |
| "However, in contrast to ordinary migraine, vestibular migraine patients have distinct characteristics, and the detailed treatment strategy for vestibular migraine is different and more challenging than ordinary migraine treatment." | ( Chen, JJ; Chen, TY; Chen, YW; Hsu, CW; Stubbs, B; Su, KP; Tseng, PT; Tu, YK; Wu, YC; Zeng, BS; Zeng, BY, 2023) |
| "New acute and preventive migraine medications are available, but data on current treatment patterns are limited." | ( Bensink, ME; Frerichs, L; Gill, K; Lu, J; Park, AS; Patel, LB; Urman, R; Vuvu, F; Wade, RL; Zhou, Z, 2023) |
| "Chronic migraine can be a profoundly disabling disorder that may be treated with preventive medications." | ( Aksentyte, A; Brown, A; Cooklin, A; Davies, N; Duncan, C; Grove, A; Madan, J; Matharu, M; Mistry, H; Naghdi, S; Rees, S; Underwood, M, 2023) |